POSTERIOR CAPSULAR OPACIFICATION

Incidence and Factors Influencing the Rate of Nd:YAG Capsulotomy in Diabetic and Uveitic Patients and after Multifocal Intraocular Lens Implantation

Submission to the University of London

By

Mostafa A. Elgohary

for the degree of Doctorate in Medicine (M.D.)

2005
I dedicate this work to my parents and my brother Ahmad, for their unrelenting support and unconditional love.
ABSTRACT

This thesis examined the incidence and factors affecting the rate of posterior capsular opacification (PCO), the most common complication of cataract surgery, in diabetic and uveitic patients and in patients with multifocal intraocular lenses (IOLs). These patients are particularly sensitive to PCO development because of the risks associated with Nd:YAG capsulotomy in the former two groups and the potential effect on visual function in the latter group. PCO rate was estimated both retrospectively, using Nd:YAG capsulotomy as a surrogate measure of clinically significant PCO, as well as prospectively using clinical and imaging methods.

Diabetic patients were found to have a lower incidence and risk of Nd:YAG capsulotomy than non-diabetic patients within 4 years after surgery. Young age, postoperative inflammation, pars plana vitrectomy and, in comparison to 3-piece silicone IOL, polymethylmethacrylate (PMMA) and plate-haptic silicone IOLs were associated with increased risk of Nd:YAG capsulotomy. In subgroup analysis, male gender was found to be a risk factor in the non-diabetic group and the duration and type of diabetes and diabetic retinopathy grade were not risk factors. In a prospective randomised trial, hydrophobic acrylic IOLs, while associated with a higher flare value within the early postoperative period, had a significantly lower rate of PCO development than plate-haptic silicone IOLs after 6 months and 1 year in diabetic patients. Optical coherence tomography revealed the development of a characteristic mid-peripheral apposition between the optic and the posterior capsule with hydrophobic acrylic IOLs both early and late after surgery, and the lack thereof with plate-haptic silicone IOLs, which is consistent with and explains the difference in PCO rate between the two IOLs.

In uveitic patients, the incidence of Nd:YAG capsulotomy was higher within the first two years after surgery than in non-uveitic patients, although the presence of uveitis was not an independent risk factor for an increased rate of Nd:YAG capsulotomy. The use of preoperative systemic steroids reduced the risk of Nd:YAG capsulotomy and, in comparison to PMMA IOLs, silicone IOLs reduced the risk of Nd:YAG capsulotomy while hydrophilic acrylic IOLs and young age increased it.

In patients with multifocal IOLs, within 4 years of follow-up the incidence of PCO and Nd:YAG capsulotomy were similar to those reported with monofocal implants.
and young age was a risk factor for the development of PCO. Patients with multifocal IOLs present for Nd:YAG capsulotomy with earlier loss of high and low-contrast acuity, which could increase the rate of Nd:YAG capsulotomy in these patients.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>3</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>17</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>17</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>19</td>
</tr>
<tr>
<td>Chapter 1</td>
<td>21</td>
</tr>
<tr>
<td>1  Introduction and review of the literature</td>
<td>22</td>
</tr>
<tr>
<td>1.1 Introduction</td>
<td>22</td>
</tr>
<tr>
<td>1.1.1 Cataract surgery and posterior capsular opacification: perspective and aims of the thesis</td>
<td>22</td>
</tr>
<tr>
<td>1.1.2 Embryology, anatomy and histology of the lens and its capsule</td>
<td>25</td>
</tr>
<tr>
<td>1.1.3 Cataract extraction techniques</td>
<td>27</td>
</tr>
<tr>
<td>1.1.4 Intraocular lenses used after cataract extraction: physical properties and clinical features</td>
<td>32</td>
</tr>
<tr>
<td>1.1.5 Anterior segment changes after cataract extraction</td>
<td>44</td>
</tr>
<tr>
<td>1.1.6 Changes in the capsular bag</td>
<td>45</td>
</tr>
<tr>
<td>1.2 Review of the literature</td>
<td>68</td>
</tr>
<tr>
<td>1.2.1 Incidence of PCO</td>
<td>68</td>
</tr>
<tr>
<td>1.2.2 Factors affecting the incidence of PCO</td>
<td>69</td>
</tr>
<tr>
<td>Chapter 2</td>
<td>79</td>
</tr>
<tr>
<td>2  Posterior capsular opacification in diabetic patients</td>
<td>80</td>
</tr>
<tr>
<td>2.1 Study of the incidence and risk factors of Nd:YAG capsulotomy</td>
<td>80</td>
</tr>
<tr>
<td>2.1.1 Introduction</td>
<td>80</td>
</tr>
<tr>
<td>2.1.2 Aims</td>
<td>81</td>
</tr>
<tr>
<td>2.1.3 Patients and methods</td>
<td>81</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>2.1.4 Results</td>
<td>83</td>
</tr>
<tr>
<td>2.1.5 Discussion</td>
<td>92</td>
</tr>
<tr>
<td>2.1.6 Limitations</td>
<td>96</td>
</tr>
<tr>
<td>2.1.7 Conclusion</td>
<td>97</td>
</tr>
<tr>
<td>2.2 Posterior Capsular Opacification after implantation of Plate Haptic Silicone and Hydrophobic Acrylic IntraOcular Lenses in Diabetic Patients: A Pilot random ised clinical trial</td>
<td>98</td>
</tr>
<tr>
<td>2.2.1 Introduction</td>
<td>98</td>
</tr>
<tr>
<td>2.2.2 Aims</td>
<td>99</td>
</tr>
<tr>
<td>2.2.3 Patients and methods</td>
<td>99</td>
</tr>
<tr>
<td>2.2.4 Results</td>
<td>102</td>
</tr>
<tr>
<td>2.2.5 Discussion</td>
<td>110</td>
</tr>
<tr>
<td>2.2.6 Conclusion</td>
<td>115</td>
</tr>
<tr>
<td>Chapter 3</td>
<td>116</td>
</tr>
<tr>
<td>3 Using the optical coherence tomography to compare the relationship of a plate haptic silicone and a hydrophobic acrylic intraocular lens to the posterior capsule: a pilot randomised clinical trial</td>
<td>117</td>
</tr>
<tr>
<td>3.1 Introduction</td>
<td>117</td>
</tr>
<tr>
<td>3.1.1 Optical coherence tomography</td>
<td>117</td>
</tr>
<tr>
<td>3.1.2 Light source in OCT</td>
<td>117</td>
</tr>
<tr>
<td>3.1.3 The beam splitter</td>
<td>119</td>
</tr>
<tr>
<td>3.1.4 Scanning and scan images</td>
<td>119</td>
</tr>
<tr>
<td>3.1.5 Use of the Optical coherence tomography for anterior segment examination</td>
<td>120</td>
</tr>
<tr>
<td>3.2 Aims</td>
<td>120</td>
</tr>
<tr>
<td>3.3 Patients and methods</td>
<td>121</td>
</tr>
<tr>
<td>3.3.1 Inclusion &amp; exclusion criteria</td>
<td>121</td>
</tr>
</tbody>
</table>
3.3.2 Surgical technique ................................................................. 121
3.3.3 OCT image acquisition .......................................................... 121
3.3.4 Outcome measures and statistical analysis .............................. 125

3.4 Results ...................................................................................... 125
3.4.1 Patient characteristics ............................................................ 125
3.4.2 Delineation of IOLs on the OCT scans ................................. 126
3.4.3 Appositional relationship between the intraocular lenses and the posterior capsule .................................................. 127
3.4.4 Follow-up scans ................................................................. 127
3.4.5 Posterior capsular opacification and IOL outline .................. 127

3.5 Discussion ................................................................................. 128
3.5.1 Delineation of the IOLs ........................................................ 128
3.5.2 Appositional relationship of the posterior capsule to the IOLs 131

3.6 Limitations ................................................................................ 137
3.7 Conclusion ................................................................................. 137

Chapter 4 ........................................................................................ 138

4 Incidence and risk factors of posterior capsular opacification in uveitis patients following phacoemulsification and extracapsular cataract extraction .............................. 139

4.1 Introduction ............................................................................... 139
4.2 Aims ......................................................................................... 139

4.3 Study of the incidence and risk factors of Nd:YAG capsulotomy after phacoemulsification in patients with uveitis ................................................................. 140
4.3.1 Material and Methods .......................................................... 140
4.3.2 Results ................................................................................ 145
4.3.3 Discussion .......................................................................... 156
4.3.4 Limitations ......................................................................... 160
4.3.5 Conclusion ......................................................................... 160
4.4 Study of the incidence and risk factors of Nd:YAG capsulotomy in uveitis patients: phacoemulsification versus extracapsular cataract extraction

4.4.1 Patients and methods

4.4.2 Results

4.4.3 Discussion

4.4.4 Limitations

4.4.5 Conclusion

Chapter 5

5 Posterior capsular opacification after multifocal intraocular lens implantation

5.1 Study of the incidence of posterior capsular opacification and Nd:YAG capsulotomy after implantation of multifocal Intraocular lens implantation

5.1.1 Introduction

5.1.2 Aims

5.1.3 Patients and methods

5.1.4 Results

5.1.5 Discussion

5.1.6 Limitations

5.1.7 Conclusion

5.2 Study of the effect of posterior capsular opacification on visual function in patients with monofocal and multifocal intraocular lenses

5.2.1 Introduction

5.2.2 Aim

5.2.3 Patients and method

5.2.4 Results

5.2.5 Discussion

5.2.6 Limitations
5.2.7 Conclusion...................................................................................................196

6 Summary and future directions ..............................................................................198

7 Publications and presentations generated from this thesis ..............................204

7.1 Publications .......................................................................................................204

7.2 Oral Presentations ............................................................................................205

7.3 Poster Presentations..........................................................................................205

8 References ............................................................................................................206
LIST OF FIGURES

Figure 1-1. A schematic diagram of the steps of extracapsular cataract extraction. Partial-thickness corneal section (a & b) of about 10-mm chord; can-opener capsulotomy (c) or continuous curvilinear capsulorhexis (d) performed through a small incision; hydrodissection and nuclear maneuvering to separate it from the cortex (e); enlargement of the corneal section (f); nuclear delivery by pressing on the superior edge of the wound by a vectis and counter-pressing at the opposite limbal area by a hook (g); irrigation-aspiration of the cortical matter (h); insertion of the IOL in the sulcus or capsular bag (i); closure of the wound with 10/0 nylon (j) (Lawrence, 2000) (with permission from Saunders Company) ................................................................. 28

Figure 1-2. A schematic diagram of the steps of phacoemulsification. Designing the incision: uniplanar, biplanar or triplanar (a), continuous curvilinear capsulorhexis by shearing (b) or traction using forceps (c), hydrodissection (d), initial grooving of the nucleus (e), dividing the nucleus into halves (f), dividing the nucleus into quadrants and removal of each quadrant in sequence (g), chopping (an alternate way of dividing the nucleus) (h), irrigation-aspiration of the cortical lens matter (i), insertion of a foldable IOL implants (Azar & Rumelt, 2000) (with permission from Saunders Company) ................................................................. 31

Figure 1-3. Design of Diffractive IOL ................................................................. 35

Figure 1-4. Plate-haptic IOL (C11UB, Bausch & Lomb) ................................. 38

Figure 1-5. STAAR toric one-piece silicone IOL. The mark on the optic shows the axis of additional power. (http://www.stlukeseye.com/news/items/ toric_lens.jpg) ................................................................. 38

Figure 1-6. SA40N AMO Array©: the five zonal progressive multifocal IOL in situ ........................................................................................................ 40

Figure 1-7. Diagrammatic representation of the different zones of AMO array multifocal IOL (Courtesy of Advanced Medical Optics, Inc.). ......................... 40

Figure 1-8. Ray diagram of the refractive multifocal IOL (Courtesy of Advanced Medical Optics, Inc.) ........................................................................... 41
Figure 1-9. Opacification of the anterior capsule (top left). Severe contraction of the anterior capsule (top, right). Closure of the capsular opening as a result of severe phimosis (bottom, left). PMMA IOL subluxation within a fibrotic capsular bag (bottom, left).

Figure 1-10. Clinical types of PCO: fibrotic type showing posterior capsule wrinkles (a) and grayish haze (b); and cellular type showing LEC pearls (c).

Figure 1-11. An example of the collateral damage in a silicone IOL (SI30NB; Advanced Medical Optic, Inc., AMO). It shows marks of laser strikes (pitting) and radial extensions of the marks presumably cuts (arrows) within the optic.

Figure 1-12. A schematic diagram of the twin-capsulorhexis and the IOL with the two perpendicularly orientated haptics (1 & 3). The side view shows the characteristic groove (2) that embraces the two capsular leaflets (Courtesy of Prof. Tassignon (Tassignon et al, 2002)).

Figure 1-13. A schematic diagram illustrating a comparison between the conventional in-the-bag IOL with the LECs covering the posterior capsule and the bag-in-the lens with the two flanges of the haptics embracing the capsular leaflets that in turn captures the LECs in between them. (Courtesy of Prof. Tassignon (Tassignon et al, 2002)).

Figure 2-1. Kaplan-Meier curves of the factors affecting the rate of Nd:YAG capsulotomy. An increased Nd:YAG capsulotomy rates is demonstrated in patients of 65 year or younger (a), in non-diabetic patients (b), in patients with plate-haptic silicone and PMMA implants compared to 3-piece silicone IOLs (c), in patients who developed postoperative inflammation (d) and in patients who underwent vitrectomy (e).

Figure 2-2. Anterior chamber flare (a) and cells (b) in the two groups of patients. Both flare and cells decreased significantly as the time went by, but there was only a borderline significant increase of flare in the Acrylic group in the early postoperative period.

Figure 2-3. The mask size (a) and the percentage of the area of opacified posterior capsule (b) in the two groups of patients. There was a decrease of the mask size in the plate-haptic silicone group and an increase in the area of PCO in the plate-haptic silicone IOL group. Only the latter was statistically significant.
Figure 2-4. Visual acuity (a) and contrast sensitivity (b) in the two groups of patients. Although both function showed some deterioration over time, the differences were not statistically significant.

Figure 2-5. An example of a patient with plate-haptic silicone IOL. The left panel show the contrast-enhanced images with the outlines of the masks and their sizes (in pixels). The right panel shows the software-processed images and the percentages of the area of PCO. MGO=the photo’s ID.

Figure 2-6 (A & B). Examples of patients with hydrophobic acrylic IOLs. The left panels show the contrast-enhanced images with the outline of the masks and their sizes (in pixels). The right panels show the software-processed images and the percentages of the area of PCO. They show relatively smaller increase in the area of PCO over the follow-up period (A) and even regression and reduction of the area of PCO that occurred in some cases (B). NCI & JHA=the Ids of the photos.

Figure 3-1. Optical coherence tomography: principle and components (Reproduced from Schmitt J. 1999 & Huang D. et al 1991).

Figure 3-2. Diagram showing the positions of the long scans across the pupillary area (interrupted lines) and short scans astride the pupillary margin (continuous lines).

Figure 3-3. An example of the video photographs and OCT scan images of a patient with a hydrophobic acrylic IOL. Top 2 panels: horizontal and vertical long scans, bottom 2 panels: short scans at 12 and 3 o’clock positions. Top panel OCT scan shows: pupillary margin (thin horizontal arrow), anterior capsule (thick horizontal arrows), anterior lens surface (thin vertical arrow), posterior lens surface (thick vertical arrow) and posterior capsule (curved arrow).

Figure 3-4. Video photograph and OCT scan of a patient with plate-haptic silicone IOL. Top 2 panels: vertical and horizontal long scans; bottom 2 panels: short scans at 6 and 9 o’clock positions. Top panel OCT scan shows: pupillary margin (thin horizontal arrow), anterior capsule (thick horizontal arrows), posterior lens surface (thin vertical arrow) and posterior capsule (thick vertical arrows).

Figure 3-5. Video photographs and OCT scan of two patients with hydrophobic acrylic IOLs within 2 days (top panel) and 9 months after surgery (bottom panel).
Note the clear delineation of the IOL outline. The OCT scans show the anterior capsular leaflet (thin vertical arrows), the haptic (thin horizontal arrows) and the posterior capsule (thick vertical arrow). The mid-peripheral part of the latter (thick horizontal arrows) is in close apposition to the optic.

Figure 3-6. Video photographs and OCT scans of two patients with plate-haptic silicone IOLs within 2 days (top panel) and 14 months after surgery (bottom panel). The OCT scan shows that the implant surfaces are poorly delineated in both panels. The peripheral part of the optics are visible though (horizontal arrows) and there is absence of the close apposition pattern demonstrated in 3-a. Instead there is an optically empty space between the optic (horizontal arrows) and the posterior capsule (vertical arrows).

Figure 3-7. Video photographs and OCT scans of a patient with a hydrophobic acrylic IOL. It shows a close mid-peripheral apposition between the posterior capsule and the optic 2 days (top panel: thin arrows) and total apposition 4 weeks after surgery (Bottom panel: thick arrow).

Figure 3-8. Video photographs and OCT scan of 2 patients with plate-haptic IOLs 2 years after surgery. There is lack of apposition between the implant and the mid-peripheral part of the capsule (thin arrows). A high-reflectance material is present between the capsule and the posterior lens surface (vertical arrows) (presumably of LECs and extracellular substance) and an optically similar substance underneath the anterior capsular leaflet (thick arrows), corresponding to the anterior capsular fibrosis showing in the video photograph.

Figure 3-9. A colour photograph and OCT scan of a patient with plate-haptic silicone IOL and PCO. The colour photograph shows abundant LECs forming Elshnig's pearls on the posterior capsule. The OCT scans shows better definition of the posterior surface of the optic (top panel: thin arrow), the central part of which became indiscernible after Nd:YAG capsulotomy (bottom panel: thick arrow), indicating that the reflections were predominantly from the posterior capsule rather than the optic of the implant.

Figure 3-10. A diagram of the proposed appositional patterns that develop between hydrophobic acrylic and plate-haptic silicone implants, and the posterior
capsule. Once in the capsule bag, early close apposition of the edge of the hydrophobic acrylic IOL optic to the posterior capsule occurs due to the posterior vaulting that result from their larger overall diameter (13mm vs. 10 mm) and the angulation between the optic and the haptic (10°) that supposedly increases as the capsular bag contracts. The square edge and the acrylic material create a tighter adherence force between the capsule and the IOL optic. This close apposition with the posterior capsule helps prevent LEC migration (straight arrows), whereas the lack of similar apposition with the plate-haptic silicone IOLs allows early migration and proliferation of the LECs on the posterior capsule (curved arrows).

Figure 4-1. Kaplan Meier curves of Nd:YAG capsulotomy. It shows that increased rate was associated with age of 55 or younger (a) and decreased rate with the use of prophylactic steroids (b). In comparison with PMMA IOL, plate-haptic and 3-piece silicone had lower capsulotomy rates whereas Hydrogel had higher capsulotomy rate (c). Censored data are that of patients whose follow-up ended before they need Nd:YAG capsulotomy.

Figure 4-2. Kaplan Meier curves of Nd:YAG capsulotomy. It shows no significant difference in the rate of Nd:YAG capsulotomy between non-uveitic and uveitic patients. Censored data are that of patients whose follow-up ended before they need Nd:YAG capsulotomy.

Figure 4-3. Kaplan-Meier curve of Nd:YAG capsulotomy rate of phacoemulsification and ECCE groups.

Figure 5-1. Kaplan-Meier survival curve of PCO (a) and Nd:YAG capsulotomy (b) over the follow-up period. It shows that the majority of cases occurred between 2 to 4 years after surgery.

Figure 6-1. Summary of the incidences of Nd:YAG laser capsulotomy in non-diabetic/non-uveitic patients, diabetic and uveitic. The incidences increased gradually over the 4 years (including in those with multifocal IOL). A drop in the incidence occurs after the third year in both diabetic and uveitic patients.
LIST OF TABLES

Table 1-1. General physical properties of the currently available generic types of IOLs (Seward, 1997; Cunanan et al, 1998; Doan et al, 2002; Tehrani et al, 2004) ...........................................................................................................................................33

Table 1-2. Published incidence of Nd:YAG capsulotomy after ECCE and implantation of IOLs with different materials and designs and a follow-up of at least one year (modified and updated with permission from Linnola) (Linnola R., 2001) ...........................................................................................................................................73

Table 1-3. Published incidence of Nd:YAG capsulotomy after phacoemulsification and implantation of IOLs with different materials and designs and a follow-up of at least one year (modified and updated with permission from Linnola) (Linnola R., 2001) ...........................................................................................................................................74

Table 2-1. Patient characteristics .........................................................................................84

Table 2-2. Incidences of Nd:YAG capsulotomy in diabetic and non-diabetic patients ...........................................................................................................................................85

Table 2-3. Multivariate Cox regression analysis of the factors associated with Nd:YAG Capsulotomy ...........................................................................................................................................87

Table 2-4. Multivariate Cox regression analysis of the factors associated with Nd:YAG capsulotomy in the two subgroups ...........................................................................................................................................88

Table 2-5. Clinical features of patients in the non-diabetic and diabetic groups .... 103

Table 2-6. Anterior chamber reaction and percentage of PCO at the different postoperative periods ...........................................................................................................................................105

Table 3-1. Patient characteristics .......................................................................................126

Table 4-1. Patient characteristics in the uveitis group ...................................................146

Table 4-2. Incidences of Nd:YAG capsulotomy in the uveitic group ...........................148

Table 4-3. Cox regression analysis of the factors affecting the rate of Nd:YAG capsulotomy ...........................................................................................................................................149

Table 4-4. Patient characteristic in the Non-uveitic and Uveitic group .......................153
Table 4-5. The incidence of Nd:YAG capsulotomy in the non-uveitic and uveitic group

Table 4-6. Demographic features and prevalence of PCO after phacoemulsification in uveitis patients in recent studies of similar follow-up.

Table 4-7. Comparison of the incidences of Nd:YAG capsulotomy in previous studies of non-uveitic and uveitic patients.

Table 4-8. Demographic and clinical features of patients in the phacoemulsification and ECCE groups.

Table 4-9. Incidences of Nd:YAG capsulotomy in phacoemulsification and ECCE groups.

Table 4-10. Cox regression analysis of the factors affecting the rate of Nd:YAG capsulotomy.

Table 5-1. Incidence of PCO and Nd:YAG capsulotomy.

Table 5-2. Clinical features of patients who developed PCO and those who underwent Nd:YAG capsulotomy.

Table 5-3. PCO grades.

Table 5-4. The questionnaires administered before and after Nd:YAG capsulotomy.

Table 5-5. Clinical features of patients in the two groups.

Table 5-6. Visual function in the two groups of patients.

Table 6-1. Risk factors for PCO/Nd:YAG capsulotomy identified in the different studies.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACC</td>
<td>Anterior capsular contraction</td>
</tr>
<tr>
<td>ACO</td>
<td>Anterior capsular opacification</td>
</tr>
<tr>
<td>AMO</td>
<td>Advanced Medical Optics</td>
</tr>
<tr>
<td>BAB</td>
<td>Blood-aqueous barrier</td>
</tr>
<tr>
<td>CCC</td>
<td>Continuous curvilinear capsulorhexis</td>
</tr>
<tr>
<td>CMO</td>
<td>Cystoid macular oedema</td>
</tr>
<tr>
<td>ECCE</td>
<td>Extracapsular cataract extraction</td>
</tr>
<tr>
<td>EPCO</td>
<td>Evaluation of Posterior Capsule Opacification</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HEMA</td>
<td>Hydroxyethylmethacrylate</td>
</tr>
<tr>
<td>HLA-B27</td>
<td>Human leukocyte antigen-B27</td>
</tr>
<tr>
<td>HPMC</td>
<td>Hydroxypropylmethylcellulose</td>
</tr>
<tr>
<td>IDDM</td>
<td>Insulin-dependent diabetes mellitus</td>
</tr>
<tr>
<td>IOL</td>
<td>Intraocular lens</td>
</tr>
<tr>
<td>IOP</td>
<td>Intraocular pressure</td>
</tr>
<tr>
<td>IQR</td>
<td>Interquartile range</td>
</tr>
<tr>
<td>LEC</td>
<td>Lens epithelial cell</td>
</tr>
<tr>
<td>logMAR</td>
<td>Logarithm of the minimum angle of resolution</td>
</tr>
<tr>
<td>mm</td>
<td>Millimeter</td>
</tr>
<tr>
<td>Nd:YAG</td>
<td>Neodymium:Yttrium-Aluminium-Garnet</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NIDDM</td>
<td>Non-insulin-dependent diabetes mellitus</td>
</tr>
<tr>
<td>NPDR</td>
<td>Non-proliferative diabetic retinopathy</td>
</tr>
<tr>
<td>ns</td>
<td>Nanosecond</td>
</tr>
<tr>
<td>OCT</td>
<td>Optical coherence tomography</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>PDR</td>
<td>Proliferative diabetic retinopathy</td>
</tr>
<tr>
<td>PCCC</td>
<td>Posterior continuous curvilinear capsulorhexis</td>
</tr>
<tr>
<td>PCO</td>
<td>Posterior capsular opacification</td>
</tr>
<tr>
<td>PE</td>
<td>Phacoemulsification</td>
</tr>
<tr>
<td>PH</td>
<td>Plate haptic</td>
</tr>
<tr>
<td>PMMA</td>
<td>Polymethylmethacrylate</td>
</tr>
<tr>
<td>ps</td>
<td>Picosecond</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming growth factor β</td>
</tr>
<tr>
<td>WESDR</td>
<td>Wisconsin Epidemiologic Study of Diabetic Retinopathy</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENT

My ultimate praise and gratitude is to Allah SWT for enabling me to finish this physically and mentally demanding work.

I was fortunate to have worked with and received help from several people to whom I will ever owe my sincere gratitude. First of all, I would like to thank my supervisor Professor Susan Lightman, Moorfields Eye Hospital, London, who has been a magnificent supervisor continuously motivating and encouraging me during the time I worked on this thesis. I learned tremendously from her comments and without her guidance, support and patience this work would have never been completed. I also would like to thank Mr. Jonathan Dowler, Consultant Ophthalmologist, Moorfields Eye Hospital, London, who taught me a great deal about research methods and statistics as well as about diabetes and diabetic retinopathy. He also helped me a great deal with the design, analysis and writing up of the diabetic studies. I also would like to thank Mr. Adrian Beckingsale, Consultant Ophthalmologist, Essex County Hospital, Colchester, who is one of the pioneers in using multifocal implants in the UK. He, in addition to teaching me all about these implants and their use, was an extremely supportive and inspiring mentor. I also would like to thank Miss Michelle Bradley, Department of Public Health and Primary Care, Cambridge University, for her help in reviewing the statistics of the diabetic, uveitis and multifocal intraocular lens studies. I also would like to thank Dr. Reijo Linnola, University of Oulu, Finland, Professor Tassignon, University Hospital Antwerp, Belgium, Karen Mills, Advanced Medical Optics (AMO), Dr Daniel Albert and Nicole McIntyre, Elsevier, and Tony Adams for the courtesy of the copyright permission. I also would like to thank my professors at Tanta Faculty of Medicine, Tanta University, Tanta, Egypt: Prof. Said Shalaby, Prof. Bothina Bondok and Prof. Samia El Ghabashi, for their support when I was applying to the University of Tanta for the scholarship grant, which was used to sponsor three projects of this thesis. I also would like to thank Alcon Inc. for providing the AcrySof lenses for the diabetic randomised trial and the limited grant for the patient transport expenses.
I also would like to thank the secretaries, nurses and the Medical Record staff at Moorfields Eye Hospital, London, and at Essex County Hospital, Colchester, for their help with the administrative work and patient recruitment.

Finally, my parents and all my family and my friends deserve my sincere and heartfelt gratitude and appreciation for their emotional support and for putting up with my extreme unsociability while working on this thesis.
CHAPTER 1

INTRODUCTION AND REVIEW OF THE LITERATURE
Chapter 1: Introduction and Review of the Literature

1 INTRODUCTION AND REVIEW OF THE LITERATURE

1.1 INTRODUCTION

1.1.1 Cataract surgery and posterior capsular opacification: perspective and aims of the thesis

Cataract, the leading cause of blindness all over the world, poses a significant challenge to the medical profession and health authorities. The increase in the population age and the modern enhancement of surgical techniques have led to lower threshold for surgical intervention and hence an increase in the cataract workload. Approximately 156,500 cataract operations were carried out under the National Health Service in England and Wales in 1995/6 (Minassian et al, 2000). This is now estimated to have risen to 270,000 in 2002/3, making it one of the most commonly performed elective procedures in the UK (Royal College of Ophthalmologists, 2004). Moreover, the number of cataract extraction procedures performed all over the world is predicted to increase under the auspices of Vision 2020 Global Initiative from the current annual rate of 8 millions to about 35 millions by 2020 (Taylor, 1999).

In diabetic and uveitic patients, cataract is more prevalent. In a review of two case-control studies, Harding et al, 1993 (Harding et al, 1993), found that diabetes was a highly significant risk factor for cataract development with a relative risk of 5.04. In the Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) (Klein et al, 1984), cataract was the most common cause of decreased vision in older-onset and the second commonest cause after proliferative retinopathy in younger-onset diabetics. The relative scarcity of uveitis patients led to the lack of epidemiological data on the prevalence of cataract in them. However, the incidence has been estimated to be between 10%, in HLA-B27 negative patients (Power et al, 1998), and 77.8%, in Fuchs' heterochromic cyclitis patients (Velilla et al, 2001).

Posterior capsular opacification (PCO) remains the most common complication of modern extracapsular cataract extraction and intraocular lens (IOL) implantation. It impairs the visual function (Magno et al, 1997; Hayashi et al, 2003) and obstructs the...
fundus view and, therefore, can interfere with early recognition and timely treatment of posterior segment diseases such as diabetic retinopathy in diabetic patients and macular oedema in diabetic and uveitic patients. In patients with multifocal IOLs, PCO can compromise visual function, in particular contrast sensitivity that is already compromised by the multifocal design of the implant optic.

Nd:YAG laser capsulotomy, the procedure of choice in treating patients with PCO, is a simple outpatient procedure that takes few minutes to perform and leads to significant improvement of visual function in the majority of patients (Magno et al, 1997; Hayashi et al, 2003). The procedure, however, is not without complications that include damage to the IOL, rise of intraocular pressure, anterior uveitis and potentially sight-threatening complications such as cystoid macular oedema and retinal breaks or detachment (Keates et al, 1984; Javitt et al, 1992; Johnson et al, 1984; Jahn et al, 2003; Ranta et al, 2004). Moreover, Nd:YAG capsulotomy incurs considerable costs and exhausts the resources of healthcare systems. In the United States, Nd:YAG capsulotomy is the second most commonly reimbursed procedure after cataract extraction and has been estimated to cost the Medicare program $250 million a year (Steinberg et al, 1993). The prohibitive cost of laser machines limits the availability of Nd:YAG capsulotomy to patients in the developing counties.

PCO has been estimated to occur in up to a third of the patients in 5 years (Schaumberg et al, 1998). While several studies have investigated PCO development in non-diabetic and non-uveitis patients and after monofocal IOL implantation, information about the incidence and factors affecting PCO rate in diabetic and uveitic patients and after multifocal IOL implantation are either conflicting or lacking.

Recent PCO studies often relied on the quantitative measurement of the density or extent of PCO using several imaging techniques for reporting PCO development and its incidence. While invaluable for research purposes, these imaging techniques and the reported PCO rates very often merely reflected early postoperative LEC activities and do not necessarily reflect what might be a clinically significant PCO i.e. one that reduces visual function or visibility of the posterior segment and thus requires treatment. Lens epithelial cell growth onto the posterior capsule can be variable in the short-term (Findl et al, 2004) and even show regression on the long-term (Hollick et al, 1998; Meacock et al, 2001; Findl et al, 2004).
On the other hand, Nd:YAG capsulotomy, which has been used before as a surrogate measure of clinically significant PCO (Knorz et al, 1991; Apple et al, 2001; Baratz et al, 2001; Ando et al, 2003), is a perfectly acceptable surrogate measure of PCO if our goal is to reduce the additional clinical and financial burdens the procedure imposes on patients as well as on the already exhausted health care resources, in addition to improving the overall outcome of cataract surgery. Although, it has been contended that the indications for Nd:YAG capsulotomy can be subject to variations in patients’ tolerance of PCO-induced symptoms and to clinician’s threshold for intervention, these indications are generally uniform within the same unit and universally fall into either of two main categories: (1) to improve the visual function or eliminate other PCO-induced symptoms e.g. glare or double vision, or (2) to improve the fundus visualisation.

In this thesis, the main aims were:

1. To estimate the incidence of PCO, using Nd:YAG capsulotomy as a surrogate measure of clinically significant PCO, in diabetic and uveitic patients and after multifocal intraocular lens implantation.

2. To examine the factors influencing Nd:YAG capsulotomy rates in the three patient groups with emphasis on the effect of different IOLs in diabetic and uveitic patients and functional changes in patients with multifocal IOLs.

Estimating the incidence and identifying the factors influencing the development of PCO and the need for Nd:YAG capsulotomy will help in peri-perative counselling of patients as well as in developing strategies to reduce or even prevent the development of PCO and the need for Nd:YAG capsulotomy in the above patient groups. That should help to reduce the demands on the healthcare system resources and improve the overall outcome of cataract surgery.
1.1.2 Embryology, anatomy and histology of the lens and its capsule

Crystalline lens development (Saha et al, 1989; Henry & Grainger, 1990; Kuszak et al, 2000) begins at the first month of gestation from the surface ectoderm overlying the optic vesicle. The ectodermal cells thicken to form the lens placode, which subsequently invaginates and eventually separates forming the lens vesicle. The basement membrane of the epithelial cells, lying now on the exterior of the lens vesicle, forms the lens capsule. The cuboidal epithelium lining the posterior half of the vesicle then begins to elongate and extend anteriorly, forming the primary lens fibres and obliterating the cavity of the lens vesicle. The anterior cuboidal cells, known later as the lens epithelial cells (LECs), also proliferate at the equator, forming the secondary lens fibres.

The lens (Saxby, 1999) is located behind the iris and pupil, held in place by means of zonular fibres that attach it to the ciliary body processes, with its anterior surface in contact with the aqueous humour and its posterior surface in contact with the vitreous. It has an asymmetric oblate spheroid shape and its equatorial axis lies perpendicular to the sagittal plane and its polar axis lies parallel to the sagittal plane. The anterior lens surface is 3.5 mm behind the cornea. The dimensions of the lens increase steadily throughout life, with the highest rate occurring during the early years. The equatorial diameter is about 5 mm at birth and steadily increases to reach 9 to 10 mm at the age of 20 years. The central thickness is about 3.5 to 4 mm at birth and can reach up to 4.75 to 5 mm.

The lens capsule (Saha et al, 1989; Henry & Grainger, 1990; Saxby, 1999; Kuszak et al, 2000) is a PAS-positive structure that is produced by the LECs. The anterior capsule is 14-21 μm while the posterior is 4 μm. The capsule increases in thickness until approximately 35 years of age when the equator and the posterior pole thin slightly while the anterior capsule remains stable (Kuszak, 1997; Kuszak et al, 2000). Immunohistochemical studies showed that the anterior capsule contains collagen types IV, V & VI, while the posterior capsule laminin and collagen type IV (Saika et al, 1998).
Chapter 1: Introduction and Review of the Literature

Two distinct types of LECs were described (Vargas et al., 2001; Kuszak et al., 2000). The first type is A-cells. These cells are located in the anterior central zone (corresponding to the zone of the anterior lens capsule) and have minimal mitotic activity. When disturbed, the primary type of response of A-cells is to proliferate in situ and form fibrous tissue by undergoing fibrous metaplasia (Font & Brownstein, 1974; Fagerholm, 1982). The anterior subcapsular plaques that form in a variety of disorders (e.g., inflammation, trauma or with certain types of posterior chamber or phakic IOLs) are typical examples of A-cell response. The second type is E-cells. These cells are the germinal cells located at the equator of the lens and normally contribute to the formation of the nucleus, epi-nucleus and cortex of the crystalline lens. They normally show mitotic activities, and continuously produce new lens fibres, accounting for a constant growth in size and weight of the lens throughout life. They are also rich in enzymes and have extensive protein metabolism. In pathological states, the E-cells tend to migrate posteriorly along the posterior capsule, forming large, balloon-like bladder cells (Wedl cells). E-cells are the primary source of classic secondary cataract, especially LEC pearls (Kappelhof et al., 1986; Fagerholm, 1982). They are also responsible for the formation of Soemmering's ring, an amalgam lesion composed of retained or regenerated cortex and LECs and is considered the basic prototype of classic PCO (Kappelhof et al., 1985).

The lens fibres (Kuszak, 1997; Saxby, 1999; Kuszak et al., 2000) form three distinct layers: the elongating fibres, the cortical fibres and the nuclear fibres. The elongating fibres consist of newly forming lens fibres that mature by losing their intracellular organelles, namely the nuclei, the Golgi apparatus and endoplasmic reticulum. The cortex is comprised of all mature secondary fibres. The nucleus consists also of mature secondary fibres but is divided according to developmental and growth criteria into: a) the embryonic nucleus consisting solely of primary lens fibres, b) the foetal nucleus consisting of the embryonic nucleus and all the added secondary fibres until parturition, d) the infantile nucleus consisting of the foetal nucleus and all the secondary fibres that are formed within the first 4 years of life, e) the juvenile nucleus consisting of the secondary fibres formed until sexual maturation and f) the adult nucleus, consisting of the juvenile nucleus and all the fibres added onto it until middle age.
Chapter 1: Introduction and Review of the Literature

1.1.3 Cataract extraction techniques

Couching is the first surgical procedure known to treat cataract surgically and is only of historic interest. Intracapsular cataract extraction is now obsolete. The most common techniques used nowadays for cataract extraction in adults are extracapsular cataract extraction (ECCE) and phacoemulsification, both are described below. The universal tendency is towards expanding the use of phacoemulsification as the primary technique of cataract extraction for the advantages that are discussed later (1.1.3.2.2). In the United States, phacoemulsification is now used in more than 90% of cataract surgeries (Masket et al., 2001; Leaming, 2002) and in the UK’s 1997/8 National Cataract Survey (Desai et al., 1999), phacoemulsification was performed on 77% of cases in the National Health Service (NHS), with proportions between 10% and 99%.

1.1.3.1 Extracapsular cataract extraction (Figure 1-1)

The technique of ECCE is shown in Figure 1-1. It involves a corneal or corneoscleral incision of about 10-mm chord (between 2 and 10 o’clock at the superior limbus). This is followed by the injection of a viscoelastic substance in the anterior chamber and the performance of a can-opener capsulotomy. The nucleus is then hydrodissected, to separate it from the cortex, and delivered through the wound using a vectis to apply gentle pressure at the superior limbal area, and a hook to assist that by counter-pressing at the inferior limbal area. The cortical lens matter is then removed using either a manual or an automated irrigation-aspiration system. Filling the anterior chamber with a viscoelastic substance precedes the implantation of an IOL and closure of the wound with 10/0 nylon sutures after washing out of the excess viscoelastic substance, which concludes the procedure.

Several modifications have been made to the above technique. The most important of these was the ‘endocapsular’ or ‘intercapsular cataract extraction’. In this technique, an incomplete capsulotomy is made by creating a semicircular flap of the anterior capsule. The nucleus and cortical matter are then removed as before, the IOL placed inside the capsular bag and the capsulotomy completed. The rest of the procedure is as above. The advantages were protection of corneal endothelial cells in addition to those advantages of in-the-bag placement of the IOL i.e. reduced incidence of IOL decentration and posterior synechiae (Naylor et al., 1989).
Figure 1-1. A schematic diagram of the steps of extracapsular cataract extraction. Partial-thickness corneal section (a & b) of about 10-mm chord; can-opener capsulotomy (c) or continuous curvilinear capsulorhexis (d) performed through a small incision; hydrodissection and nuclear maneuvering to separate it from the cortex (e); enlargement of the corneal section (f); nuclear delivery by pressing on the superior edge of the wound by a vectis and counter-pressing at the opposite limbal area by a hook (g); irrigation-aspiration of the cortical matter (h); insertion of the IOL in the sulcus or capsular bag (i); closure of the wound with 10/0 nylon (j) (Lawrence, 2000) (with permission from Saunders Company).
1.1.3.2 Phacoemulsification cataract extraction (Figure 1-2)

The introduction of the concept of phacoemulsification by Charles Kelman during the 60's decade (Kelman, 1967), marked a significant evolutionary stage of cataract surgery.

1.1.3.2.1 Surgical technique

The procedure of phacoemulsification is normally carried out under local anaesthesia, using anaesthetic eye drops or subtenon, retrobulbar or peribulbar injections. General anaesthesia is infrequently used in patients who refuse local anaesthesia and in those unable to cooperate such as children and mentally disabled adults.

The technique of phacoemulsification (Figure 1-2) includes a corneal or scleral tunnel incision, a continuous curvilinear capsulorhexis, ultrasound-assisted emulsification of the lens nucleus, irrigation-aspiration removal of the cortical lens matter and insertion of an IOL in the capsular bag after filling it with a viscoelastic substance. The development of foldable intraocular lenses, accompanied the increasing use of phacoemulsification and enabled the use of smaller incisions of 2.8 to 3.2mm.

1.1.3.2.2 Advantages of phacoemulsification

The technique of phacoemulsification has several advantages over ECCE. The smaller corneal incision used in phacoemulsification minimises postoperative surgically-induced astigmatism (el Maghraby et al, 1993; Zheng et al, 1997; Naus et al, 1995; Neumann et al, 1989). The tight seal of the small incision around the hand-piece allows better maintenance of the anterior chamber and intraocular pressure during the procedure and reduces the likelihood of vitreous prolapse in case of posterior capsular tear and suprachoroidal haemorrhage in predisposed patients. Also, phacoemulsification of the nucleus induces minimal trauma to the iris and results in less damage to the blood-aqueous barrier than after ECCE and hence less postoperative inflammation (Oshika et al, 1992). The latter contributes to reducing the incidence of postoperative cystoid macular oedema (Ursell et al, 1999; Mentes et al, 2003). These attributes have resulted in speedy postoperative functional recovery of the patients (Watson & Sunderraj, 1992; Naus et al, 1995). Also, when required,
posterior segment surgery such as vitrectomy or scleral buckling can be safely performed because of the small and more secure wound.

### 1.1.3.2.3 Disadvantages of phacoemulsification

Reliance on technology, the need for a longer period of training than with ECCE in addition to the excessive cost of the equipment and their maintenance are obvious disadvantages of phacoemulsification, with costs being the main limiting factor for its widespread use in the developing countries.

On balance, however, it is believed that the peri-operative complication rate during the learning period of phacoemulsification is comparable to that of ECCE (Seward et al, 1993; Thomas et al, 1997) and that overall the advantages outweigh the disadvantages.
Figure 1-2. A schematic diagram of the steps of phacoemulsification. Designing the incision: uniplanar, biplanar or triplanar (a), continuous curvilinear capsulorhexis by shearing (b) or traction using forceps (c), hydrodissection (d), initial grooving of the nucleus (e), dividing the nucleus into halves (f), dividing the nucleus into quadrants and removal of each quadrant in sequence (g), chopping (an alternate way of dividing the nucleus) (h), irrigation-aspiration of the cortical lens matter (i), insertion of a foldable IOL implants (Azar & Rumelt, 2000) (with permission from Saunders Company).
1.1.4 Intraocular lenses used after cataract extraction: physical properties and clinical features

Harold Ridley in 1949 (Ridley, 1952; Ridley, 1954) was the first to use IOLs. He conceived the idea after he observed that pilots who sustained Plexglas intraocular foreign bodies from aeroplane canopies, did not manifest significant intraocular inflammatory reaction.

Table 1-1 shows the general features of the three materials used for manufacturing IOL optics, namely polymethylmethacrylate, silicone and acrylate (or acrylic). IOLs (Seward, 1997; Dick et al, 2001; Daynes et al, 2002; Tehrani et al, 2004) vary widely in the physical properties of their material e.g. refractive indices, water contents and the water-contact angle. The latter is measured by the sessile drop method and characterises the material surface tension and negatively correlates with its hydrophilicity (Cunanan et al, 1998; Dick et al, 2001; Tehrani et al, 2004). Increased hydrophilicity was shown to enhance the implant uveal biocompatibility, leading to decreased surface cellular reaction and less damage to the blood-aqueous barrier (Amon & Menapace, 1992; Amon & Menapace, 1994; Mester et al, 1998; McCulley, 2003). Increased IOL hydrophilicity, however, was also shown to increase LECs proliferation and PCO development i.e. reduced capsular biocompatibility (Hollick et al, 1999b; Mullner-Eidenbock et al, 2001; Abela-Formanek et al, 2002c; Abela-Formanek et al, 2002b). IOLs also vary in their overall diameter, the optic size and shape, the haptic shape, angulation and material. Functionally, IOLs are classified depending on whether their design allows for a single focus (monofocal) or multiple foci (multifocal) formation on the retina.

1.1.4.1 Polymethylmethacrylate (PMMA) IOLs

PMMA IOLs are still considered the reference to which other IOLs are compared. The main features of PMMA IOLs are detailed in Table 1-1. These lenses are rigid, inert, light and relatively inexpensive. They has <1% water content. Because of their rigidity, they are introduced through large incisions (usually >5mm), which often require suturing.
Table 1-1. General physical properties of the currently available generic types of IOLs (Seward, 1997; Cunanan et al, 1998; Doan et al, 2002; Tehrani et al, 2004)

<table>
<thead>
<tr>
<th>Material</th>
<th>PMMA</th>
<th>Silicone</th>
<th>Hydrophobic Acrylic</th>
<th>Hydrophilic Acrylic (hydrogel)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rigidity</td>
<td>Rigid</td>
<td>Foldable</td>
<td>Foldable</td>
<td>Foldable</td>
</tr>
<tr>
<td>Contact angle</td>
<td>68.1-75.5</td>
<td>106-119</td>
<td>87.6-72.7</td>
<td>59.2-69.1</td>
</tr>
<tr>
<td>Water contents</td>
<td>&lt;1 %</td>
<td>&lt;1 %</td>
<td>&lt;2 %</td>
<td>18%-30%</td>
</tr>
<tr>
<td>Refractive index</td>
<td>1.49</td>
<td>1.41-1.47</td>
<td>1.44-1.55</td>
<td>1.47</td>
</tr>
</tbody>
</table>
PCO was found to occur at a higher rate with PMMA IOLs than with silicone and acrylic IOLs (Ursell et al., 1998; Hayashi et al., 1998c; Hollick et al., 1999c; Apple, 2000). Heaprin-coating of the PMMA IOL surface has led to reduced cellular reaction on their anterior surfaces (Amon et al., 1996) and less postoperative inflammatory reaction (Borgioli et al., 1992; Shah & Spalton, 1995a). Recently, 'snowflake opacification' of PMMA IOLs has been described by Apple et al (Apple et al., 2002). It was suggested to be due to direct destruction or molecular breakdown of the PMMA polymer by ultraviolet radiation and found to cause visual disturbance ranging from glare to severe blurring of vision.

1.1.4.1.1 Monofocal and diffractive multifocal PMMA IOLs (Figure 1-3)

Monofocal PMMA IOLs are the most commonly used type of PMMA implants. Diffractive multifocal PMMA IOLs (Davison, 2001) function by using the phenomenon of 'constructive and destructive interference'. As a result most of these implants are in effect bifocal. The lens has a spherical anterior surface and a grooved posterior surface (Figure 1-3) that splits the light and creates ripples of wave fronts 'interference patterns or fringes'. These wave fronts cross each other and create either 'constructive interference' if in-phase or 'destructive interference' if out-of-phase. Combining the spherical power of the anterior surface with the constructive or destructive interference patterns results in the formation of either a near or distance focus, respectively. Because the diffractive patterns are created throughout the optic of the implant, it is less dependent on the pupillary size than refractive IOLs (Discussed in 1.1.4.2.4). However, almost 18% of the incident light is lost because of interference. This is believed to explain the more profound reduction in contrast sensitivity that patients with these implants were shown to suffer from in comparison to patients with refractive implants (Pieh et al., 1998).
Figure 1-3. Design of Diffractive IOL
1.1.4.2 Silicone IOLs

The physical properties of the silicone IOLs are detailed in Table 1-1. These lenses were approved by the Food and Drug Administration (FDA) in 1990. The lenses are made of polymers of silicone and oxygen. The most common silicone IOLs are elastomers of polydiethylsiloxane backbone.

Silicone IOLs are inert, non-adherent to tissue and stable at a range of temperatures. They are also hydrophobic and difficult to handle when wet as they become slippery. The newer generation of silicone IOLs have higher refractive indices (1.46-1.47), and thus have thinner optics over a range of dioptric power, which enables implantation through a small wound size. One important feature of these lenses is their rapid unfolding action that can be hazardous especially in a patient with posterior capsular tear or zonular dialysis. After implantation, the rate of giant cell deposition was shown to be lower than with PMMA (Ravalico et al., 1997) and comparable to that with hydrophobic acrylic IOLs (Samuelson et al., 2000). The lenses also exhibit a lower threshold for Nd:YAG laser damage (Newland et al., 1999; Trinavarat et al., 2001) and were shown to adhere to silicone oil in patients who undergo vitrectomy and silicone oil tamponade (Apple et al., 1996; Dick et al., 1997; Apple et al., 1997). Senn, in an experimental study, showed that this could potentially affect its optical qualities (Senn et al., 1997). Recently case reports have been published of greyish to brownish opacification of some of these lenses including SI30NB (Parkin & Pitts-Crick, 2000), SI40NB (Hilgert et al., 2004; Tanaka et al., 2004b) and SA40N Array (Elgohary et al., 2005). The origin of this opacification is not clearly understood but was proposed to be the result of impurities, water incorporation into the IOL material or interaction with instruments or medications.

1.1.4.2.1 One-piece plate-haptic silicone IOLs (Figure 1-4)

These implants have a broad haptic and can be inserted through a small incision using an injector (Coombes et al., 2001). Hwang et al (Hwang et al., 1998) showed greater amount of decentration with 3-piece silicone IOLs than with plate-haptic silicone IOLs. Increasing the size of the positioning holes was suggested to have increased the stability of these implants in the capsular bag (Mamalis et al,
1996a; Kent et al, 1997; Whiteside et al, 1998) and several other studies have shown its favourable long-term outcome (Cumming, 1993; Maar et al, 2002).

The lenses, however, were shown to be associated with increased opacification and contraction of the anterior capsule (Werner et al, 2000b; Apple, 2000), which is attributed to the larger area of contact between the haptic and the anterior capsule and the hydrophobic nature of its material. The plate-haptic IOL design is also believed to be susceptible to forces of capsular contraction. There are reports of early decentration (Subramaniam & Tuft, 2001; Mackool, 1996), late subluxation and even posterior dislocation of the lens, either spontaneously (Agustin & Miller, 2000) or after Nd:YAG capsulotomy (Tuft & Talks, 1998; Petersen et al, 2000). Faucher and Rootman (Faucher & Rootman, 2001) reported anterior dislocation of the lens into the anterior chamber 4 months after an uneventful surgery.

1.1.4.2.2 Toric one-piece plate-haptic silicone IOLs

These lenses have a spherocylindrical anterior surface that is designed to correct corneal astigmatism of 1.5 to 3.5 dioptres. This is achieved by aligning the axis markings of the implant to the steep corneal meridian.

Although the lenses were found to effectively and stably correct the astigmatism in the majority of patients (Ruhswurm et al, 2000; Leyland et al, 2001), they are susceptible to the same postoperative positional changes as their spherical counterparts, namely decentration or dislocation, which can have a more dramatic effect on the visual function. Leyland et al (Leyland et al, 2001) reported 9% of the lenses undergoing rotation of more than 30 degrees both in the early and late postoperative periods.
Chapter 1: Introduction and Review of the Literature

1.4.2.3. Three-piece silicone IOLs

These are the most commonly implanted IOLs. All the lenses have squared edges except that of the Implantable Collamer Lens (ICL) in Athens, GA, USA) and Claris (AMO, Irvine, CA).

The first generation of the IOLs were similar to that associated with HOYA IOLs and higher than the subsequent IOLs. That has improved remarkably with the second generation. A second generation of IOLs has a PCO rate similar to that of hydrophobic acrylic IOLs. The first studies showed that square-edged silicone IOLs and hydrophobic acrylic IOLs have a similar incidence of PCO and development similar to that of hydrophobic acrylic IOLs.

Figure 1-4. Plate-haptic IOL (C11UB, Bausch & Lomb)

Figure 1-5. STAAR toric one-piece silicone IOL. The mark on the optic shows the axis of additional power.
1.1.4.2.3 Three-piece silicone IOLs

These are the most commonly used type of silicone IOLs. All the lenses have rounded edges except that of CeeOn-Edge 911 (Pharmacia Atlanta, GA, USA) and Clariflex (AMO, Irvine, CA, USA), which have sharp posterior edges.

The first generation of these lenses had a PCO rate similar to that associated with PMMA IOLs and higher than that with hydrophobic acrylic IOLs. That has improved remarkably with the second generation of implants. Daynes et al, 2002, found that SI40, a second generation 3-piece silicone IOL, had a PCO rate similar to hydrophobic acrylic IOLs (Daynes et al, 2002). Several studies also found that square-edged silicone IOLs had a preventative effect on LEC migration and PCO development similar to that of hydrophobic acrylic IOLs (Nishi et al, 2000; Schmack & Gerstmeyer, 2000). Mullner-Eidenbock et al (Mullner-Eidenbock et al, 2001) found that CeeOn Edge IOL had a low incidence of LEC growth and reduced non-specific foreign-body reactions in comparison to hydrophilic and hydrophobic acrylic IOLs.

1.1.4.2.4 Multifocal silicone IOL (Refractive type) (Figure 1-6)

The silicone multifocal design was developed in order to help patients overcome the accommodative loss associated with pseudophakia while enabling folding and implantating the IOL through a small incision. SA40N AMO Array (AMO) IOL (Figure 1-6) will be discussed in detail as it is the one studied in this thesis and is the most commonly used refractive multifocal implant.

1.1.4.2.4.1 Design and optics (Figures 1-6 to 1-8)

The Array IOL (Featherstone et al, 1999; Davison, 2001) is a 3-piece silicone IOL that has an overall diameter of 13mm, an optic diameter of 6mm and two PMMA haptics that make an angle of 10° with the optic. The optic has a biconvex surface, a spherical refractive posterior surface and an anterior surface that has 5 concentric refractive zones that give it a wavy-shape (Figure 1-6). The central zone of the optic is distance-dominant, as are the third and fifth zones. The second and fourth zones are near-dominant, each with 3.5 dioptres add (Figure 1-7). In each of the distance-dominant zones, the distance power is placed centrally and power gradually increases toward the periphery of the zone (zonal-progressive) to provide intermediate vision...
Chapter 1: Introduction and Review of the Literature

(Figure 1-8). The concentric zones are meant to make the IOL less sensitive to variation in pupil size and to provide stable vision under a variety of luminance conditions. At a pupillary size of 4mm, approximately 50% of available light is allocated to the distance focus, 37% to the near focus and 13% to the intermediate focus.

Figure 1-6. SA40N AMO Array©: the five zonal progressive multifocal IOL in situ

Figure 1-7. Diagrammatic representation of the different zones of AMO array multifocal IOL (Courtesy of Advanced Medical Optics, Inc.).
Multifocal intraocular lenses have proved to provide reasonably useful near and intermediate vision without spectacles and without adversely affecting distance vision (Brydon et al, 2000; Javitt et al, 2000; Steinert, 2000; Vaquero-Ruano et al, 1998; Leyland et al, 2002). These implants, however, are known to reduce contrast sensitivity, especially under low contrast (Steinert et al, 1999; Schmitz et al, 2000) and mesopic conditions (Williamson et al, 1994). They also cause dysphotopic phenomena such as glare and haloes with bright light (Steinert et al, 1999).

Increasing age, variation of pupil size and the degree of corneal astigmatism were found to affect the degree of contrast sensitivity loss as well as patients’ satisfaction with these lenses. Schmitz et al, 2000 (Schmitz et al, 2000), found that, with and without glare disability, patients over 70 years have reduced contrast sensitivity. In a study by Hayashi et al (Hayashi et al, 2001), a pupil size of less than 4.5 mm was found to reduce near vision ability. Using an experimental optical model consisting of a helium-neon laser, a triangular optical bench with a precision collimator, a micropositionable immersion stage to support the IOL and a digital image-processing system, Ravalico et al (Ravalico et al, 1999) found that correcting astigmatism of more than 1 dioptre reduces light intensity by about 20%. Also, Hayashi et al (Hayashi et al, 2000) found that up to 1.5 dioptres, astigmatism reduced distance and
Chapter 1: Introduction and Review of the Literature

intermediate vision but that all degrees of astigmatism up to 2.5 dioptres favoured near vision. On the other hand, Schmitz et al (Schmitz et al, 2000) found that there was no clinically significant difference between monofocal and multifocal IOL groups with and without > 1 dioptre of astigmatism.

1.1.4.3 Hydrophobic acrylic IOLs

Hydrophobic acrylic IOLs are relatively new lenses, with FDA approval obtained only in December 1994. Three-piece with PMMA haptics or one-piece design are available and in common use. These lenses are made of copolymers of acrylate and methacrylate. They have a contact angle of 73° and are thinner, because of their higher refractive index, and lighter than silicone IOLs (Table 1-1). They have lower elasticity and increased stiffness and thus require larger incisions to be introduced into the eye. The implant feels like PMMA at low temperature and it needs to be warmed to facilitate its folding. These features, however, make its unfolding in the capsular bag slower and more controlled but also make it fragile and more liable to scratches and dents.

Hydrophobic acrylic IOLs are less likely to cause problems of adherence when silicone oil tamponade is used than silicone IOLs (Apple et al, 1997). The square-edged design of some of these implants creates a capsular bend preventing migration of LECs onto the posterior capsule and PCO formation (Nishi et al, 1998c; Nishi & Nishi, 1999; Nishi et al, 2000). The square edge, however, causes internal reflection of the incident light leading to positive dysphotopic complaints such as glare, streaks or flashes of lights; or negative dysphotopic symptoms such as dark shadows (Farbowitz et al, 2000; Davison, 2000). New implant designs with a frosted edge (SA60, Alcon) or rounded anterior edge (Sensar, Allergan) have been developed to minimise these symptoms. These lenses are also more resistant to damage by Nd:YAG laser than PMMA and silicone IOLs (Newland et al, 1999; Trinavarat et al, 2001).

Several reports have shown the development of ‘glistenings’ within hydrophobic acrylic (Alcon) IOLs (Gunenc et al, 2001; Christiansen et al, 2001; Tognetto et al, 2002). These were proved to be water vacuoles and the phenomenon was related to a change in the equilibrium of water content caused by temperature changes (Miyata & Yaguchi, 2004; Shiba et al, 2003; Tognetto et al, 2002). Recent reports have shown no
effect (Gunenc et al, 2001) or only a mild effect (Christiansen et al, 2001) on visual acuity in cases with severe ‘glistenings’.

1.1.4.4 Hydrophilic acrylic (hydrogel) IOLs

Hydrophilic acrylic (hydrogel) IOLs are composed of a mixture of a hydroxyethylmethacrylate (poly-HEMA) backbone and a hydrophilic acrylic monomer. The water content varies between 18-30%. Because of their water content, they must be kept hydrated until implantation. The lenses are soft and resist scratches and surface damage from folding because of their high water content and flexible surfaces. They fold and unfold faster than hydrophobic acrylic but still are more controllable than silicone IOLs. They are also resistant to damage by Nd:YAG laser and have minimal adherence to silicone oil.

Several studies reported an excellent uveal biocompatibility profile for these implants i.e. less flare in the early postoperative period and a low incidence of non-specific foreign body reaction, i.e. less deposition of small and giant cells on its surface, than with silicone and hydrophobic acrylic IOLs (Schauersberger et al, 1999; Hollick et al, 1999b; Mullner-Eidenbock et al, 2001; Abela-Formanek et al, 2002c). However, the lens was found to be associated with a high rate of LEC proliferation and high PCO and Nd:YAG capsulotomy rates i.e. it has a low capsular biocompatibility (Hollick et al, 1999b; Abela-Formanek et al, 2002c; Abela-Formanek et al, 2002d; McCulley, 2003).

MemoryLens (Ciba Vision) is a pre-rolled 3-piece implant hydrophilic acrylic implant. It slowly unfolds within the eye in a controlled fashion. This lens was reported to be associated with a late-onset of toxic anterior segment syndrome (Jehan et al, 2000), which was attributed by the manufacturer to residual polishing compounds in the lens.

Hydroview (Bausch & Lomb) is a three-piece IOL that lens has been reported to develop late opacification due to calcium phosphate deposition within the optic (Werner et al, 2000a), a phenomenon which is still under investigation. These proved to be visually significant and required IOL explantation in many patients (Fernando & Crayford, 2000; Mamalis et al, 2004). The origin of this phenomenon was blamed on the silicone packaging of the IOL (Dorey et al, 2003).
1.1.5 Anterior segment changes after cataract extraction

1.1.5.1 Breakdown of the blood-aqueous barrier

Surgical trauma, the presence of an IOL, which attracts a foreign body reaction, and the release of inflammatory mediators synthesized by LECs are the main factors responsible for the breakdown of the blood-aqueous barrier (BAB) after cataract extraction (Miyake et al, 1996; Nishi et al, 1995b; Nishi et al, 1996c). This is mediated by prostaglandin E$_2$ and various other cytokines, such as interleukin-1 and interleukin-6 that can be produced by LECs. Clinically this gives rise to flare (protein) and cells in the anterior chamber, which can be quantified by laser flare-cell photometry (Shah & Spalton, 1994).

Several factors seem to affect the degree of breakdown of the BAB and hence the anterior chamber flare value or cell count. Increased BAB breakdown was found to be associated with larger corneal incisions such as those used for ECCE as compared to small incisions used in phacoemulsification (Oshika et al, 1992; Pande et al, 1996b; Chee et al, 1999), sclero-corneal as compared to pure corneal incisions (Dick et al, 2000), sulcus as compared to in-the-bag placement of the IOL (Alio et al, 1997), torn capsulorhexis as compared to intact ones (Pande et al, 1996a) and hydrophobic as compared to hydrophilic IOLs (Miyake et al, 1996; Schauersberger et al, 1999).

1.1.5.2 Cellular reaction on IOL surface

Immunohistochemical staining has been used to study the cellular deposits on the surface of IOLs (Saika et al, 1998). Specular microscopy, using high magnification and intense illumination on the slit lamp, enables us to clinically identify these cellular elements in vivo (Wenzel M et al, 1988; Shah et al, 1993; Shah & Spalton, 1995b). These include blood-derived monocytes, which give rise to histiocytes and its different forms including macrophages, spindle-shaped or fibroblast-like cells, epitheloid and giant cells (Wolter & Kunkel, 1983a; Wolter, 1985; Wolter & Kleberger, 1985), capsule-derived LECs (Wolter, 1993; Ibaraki et al, 1995; Saika et al, 1998; Hollick et al, 1999b) and iris-derived melanocytes (Tanner et al, 1998).

These cellular deposits can produce a clear membrane on the IOL composed of a film of extracellular matrix (Wolter & Kunkel, 1983c; Wolter et al, 1985; Saika et al,
Chapter 1: Introduction and Review of the Literature

1998). Experimental and postmortem studies have shown this membrane to be produced in the early postoperative period (within few hours to few days) (Wolter & Kunkel, 1983b; Wolter & Kleberger, 1985). They also showed that it contained proteins such as fibronectin (Kanagawa et al, 1990; Saika et al, 1992; Saika et al, 1995), collagen types I, III and IV (Saika et al, 1995; Saika et al, 1997), vitronectin and laminin (Linnola et al, 1999b; Linnola et al, 2000a; Linnola et al, 2000b).

The IOL material has an effect on the number of cells attached to the IOL surface. Fewer epitheloid and giant cells were found attached to hydrophilic IOLs: HSM-PMMA in comparison to PMMA IOLs (Larsson et al, 1989; Amon et al, 1996; Fagerholm et al, 1989; Shah & Spalton, 1995a), and hydrophilic acrylic (Hydroview) in comparison to hydrophobic acrylic (AcrySof) and silicone IOLs (CeeOn 920) (Mullner-Eidenbock et al, 2001).

1.1.6 Changes in the capsular bag

The changes in the capsular bag after IOL implantation are the most important changes as they lead to more lasting and clinically significant effects.

1.1.6.1.1 Anterior capsular opacification and contraction (Figure 1-9)

Anterior capsular opacification (ACO) is probably the earliest and most common pathological development in the capsular bag. It may occur as soon as one month and variably in almost all the patients. A clinically more important change is anterior capsular contraction (ACC) or phimosis, which is usually associated with and often consequential upon ACO. Davison (Davison, 1993) suggested that ACC occurs as a result of an imbalance between centrifugal and centripetal forces of the contracting fibrous tissue on the capsular bag. ACC was shown to occur maximally within the first 3 months after surgery (Hayashi et al, 1997; Zambarakji et al, 1997) and, on average, amounts to about 22% of the original CCC size (Sugimoto et al, 1998). Both ACO and ACC have common pathological features and have similar predisposing factors.
Chapter 1: Introduction and Review of the Literature

Figure 1-9. Opacification of the anterior capsule (top left). Severe contraction of the anterior capsule (top, right). Closure of the capsular opening as a result of severe phimosis (bottom, left). PMMA IOL subluxation within a fibrotic capsular bag (bottom, left).

[Images of opacified and contracted anterior capsules, and subluxated PMMA IOL within a fibrotic capsular bag]

The pathology changes leading to the development of ACD occur mainly underneath the capsule, which is why it has been found that a more hydrophilic IOL and the material used in the IOL were found to be associated with a lower rate of ACD than those of PMMA and acrylic IOLs.
Chapter 1: Introduction and Review of the Literature

1.1.6.1.1 Pathology of ACO and ACC

The pathological changes leading to the development of ACO occur mainly underneath the capsule. Macky et al (Macky et al, 2001) indicated that a more accurate term is ‘anterior subcapsular opacification’ but the term is maintained as it is well established in the literature and in clinical practice. These pathological changes include LEC proliferation and trans-differentiation, and extracellular matrix formation (Ishibashi et al, 1993). Human anterior capsule fibrosis samples were found to have dense fibrous tissue and numerous activated fibroblasts with contractile capacity, because of the presence of α-smooth muscle actin in the cell cytoplasm (Tanaka et al, 2004a). Collagen, fibronectin, osteoporin and glycosaminoglycans such as chondroitin, keratan, and dermatan sulphate, are among the extracellular matrix substances that were found in histological specimens (Ishibashi et al, 1993; Azuma et al, 1998). Azuma et al (Azuma et al, 1998) suggested that the substances found in ACO resemble those found in wound healing.

1.1.6.1.2 Factors associated with ACO and ACC and clinical features

Three major factors have been postulated to affect the degree of ACO and consequently the development of ACC: the initial size of the capsulorhexis, the IOL material and design and pre-existing diseases. It is proposed that the larger the remaining anterior capsular leaflet, the more anterior subcapsular epithelial cells there are and, therefore, the greater the potential for capsular opacification and contraction (Davison, 1993; Arshinoff, 1994; Packard, 1998). Miyake et al (Miyake et al, 1996) found a negative correlation between the hydrophilicity of an IOL and the severity of postoperative inflammation and the speed of ACO, with hydrophobic silicone of 99° water contact angle having greater postoperative inflammation and anterior capsular opacification. On the other hand, Werner et al (Werner et al, 2001) found that 3-piece, hydrophobic acrylic optic, PMMA-haptic IOLs (AcrySof) had a lower ACO score than small- and large-hole, single-piece, plate-haptic silicone IOLs. This was also confirmed in several other histopathological studies (Apple, 2000; Werner et al, 2000b; Werner et al, 2001; Werner et al, 2000b) that showed plate-haptic silicone IOLs to be associated with a higher rate of ACO than PMMA and acrylic IOLs.
The amount of ACC was shown to be significantly greater with silicone than with PMMA IOLs (Zambarakji et al, 1997; Cochener et al, 1999; Hayashi et al, 1997) and acrylic IOLs (Ursell et al, 1997). The haptic material (polypropylene versus polymethylmethacrylate in two otherwise similar silicone IOLs) did not affect the amount of ACC (Gallagher & Pavilack, 1999). Dahlhauser et al (Dahlhauser et al, 1998) reported that 14% of patients who had plate-haptic silicone IOLs developed clinically significant ACC and needed Nd:YAG anterior capsulotomy. Other factors found to be associated with increased ACC are increased anterior chamber flare, older age (Sugimoto et al, 1998; Kato et al, 2002), smaller capsulorhexis (Sugimoto et al, 1998), diabetes mellitus and the presence of diabetic retinopathy (Hayashi et al, 1998b; Kato et al, 2001). The risk of anterior capsular contraction was found to be greater in eyes with zonular weakness such as those with pseudoexfoliation syndrome (Davison, 1993; Gallagher & Pavilack, 1999; Moreno-Montanes et al, 2002). Also, patients with retinitis pigmentosa (Nishi & Nishi, 1993; Jackson et al, 2001; Lee et al, 2004), uveitis (Davison, 1993), and myotonic dystrophy (Newman, 1998; Hansen et al, 1993) were found to have a greater tendency to develop ACC.

1.1.6.1.3 Treatment

Polishing the anterior capsule to remove the subcapsular lens epithelium is a useful technique to reduce the incidence of ACO (Davison, 1993; Nishi, 1987), using large CCC (> 5.5 mm diameter) and implantation of large PMMA IOLs or intracapsular PMMA rings should be considered in high risk patients (Spang et al, 1999; Hayashi et al, 1998a).

As soon as ACC is noted in high-risk patients or those who have already had ACC-related problems in the other eye, relaxing radial anterior capsular incisions can be performed using Nd:YAG laser (Davison, 1993; Scorolli et al, 1996; Chawla & Shaikh, 1999). These incisions will help to reduce traction on the equator of the capsular bag and hence pre-empt the development of complications such as lens decentration, subluxation and dislocation. Surgical anterior capsulotomy may be required in patients with severe degrees of ACC that can not be treated with laser (Yeh et al, 2002).
1.1.6.1.2 Posterior capsular opacification (PCO)

1.1.6.1.2.1 Pathology of PCO

Schmidbauer et al (Schmidbauer et al., 2001b) and Aslam et al, 2003 (Aslam et al., 2003b), pointed out that the term ‘posterior capsular opacification’ is a misnomer as the changes are sub-capsular. However, similar to ‘anterior capsular opacification’, the term is maintained because it is commonly accepted and widely used.

1.1.6.1.2.1.1 Methods of studying PCO development

Several methods have been used to study PCO (Wormstone, 2002). These include cell culture, in vivo animal studies, capsular bag models, in vivo clinical studies and analysis of post-mortem material. Cell culture studies have provided information on certain aspects of LECs such as factors affecting their growth. Capsular bag cultures and in vivo animal studies have been used to establish the effect of surgical techniques and IOLs design and material on the development of PCO. Different posterior capsule imaging and image analysis systems have enabled in vivo monitoring of PCO development and progression. Post-mortem examination, using electron microscopy, immunohistochemistry and ELISA techniques has provided information about the different molecules that exist in the capsular bag and the possible effect they have on PCO development and progression.

1.1.6.1.2.1.2 Anatomical considerations

As discussed before (in 1.1.2), there are two anatomical classes of LECs: A-cells and E-cells. While A and E-cells are capable of contributing to all forms of capsular opacification, A-cells are primarily responsible for the development of anterior capsular opacification and the fibrotic changes of PCO and E-cells for the cellular element of PCO and inter-lenticular opacification in patients with piggyback IOLs (Schmidbauer et al., 2001b).

E-cell proliferation and migration onto the posterior capsule lead to the formation of large, balloon-like bladder cells (Wedl cells) of Elshnig’s pearls. Metaplastic transformation (transdifferentiation) of LECs into spindle-shaped or myofibroblast-like cells and residual lens fibres lead to fibrotic changes, including greyish
discolouration and wrinkling of the posterior capsule, and Sommering's ring formation at the equator.

1.1.6.1.2.1.3 Pathogenesis of PCO

McDonell et al (McDonnell et al, 1983; McDonnell et al, 1984; McDonnell et al, 1985; Green & McDonnell, 1985) have shown that LECs in both rabbits and humans initially undergo hyperplasia and transdifferentiation into myofibroblast-like cells within 4 days of surgery. The proliferation of LECs has been shown to be under control of paracrine and autocrine pathways (Wormstone et al, 2002). Paracrine control is related to increased aqueous protein content, including serum growth factors, induced by the breakdown of the BAB and the inflammatory response to surgery (Wallentin et al, 1998; Pande et al, 1996b). These were shown to increase LEC proliferation and collagen formation (Nishi et al, 1996a). The autocrine mechanism is conceivable in patients who develop PCO several years after surgery when the aqueous protein levels would have subsided to preoperative levels. This is evidenced by the ability of LECs to survive under minimal cultural conditions and to produce de novo proteins (Wormstone et al, 1997; Wormstone et al, 2001).

Both the autocrine and paracrine mechanisms were found to be influenced by several cytokines. Nishi O et al (Nishi et al, 1996a) found that cytokines such as interleukin (IL)1 and basic fibroblast growth factor (b-FGF) increased LECs mitosis and collagen synthesis. Wallentin et al (Wallentin et al, 1998) found that LEC proliferation positively correlated with protein concentration and with leukocyte count but negatively with TGF-β concentration. The latter finding was consistent with the findings by Kurosaka et al (Kurosaka & Nagamoto, 1994; Kurosaka et al, 1995).

Myofibroblastic transdifferentiation of LECs leads clinically to the formation of wrinkles and contraction of the capsule. Kurosaka et al (Kurosaka et al, 1996) showed the presence of alpha smooth muscle actin in LECs after experimental cataract extraction. They also showed that adding TGF-β2 to a culture of LECs on a collagen gel increased the shrinkage of the collagen gel as well as the expression of alpha smooth muscle actin from these cells in a dose dependent manner (Kurosaka et al, 2000).
LEC migration onto the posterior capsule was shown to be facilitated by the presence of collagen type IV, laminin and fibronectin (Olivero & Furcht, 1993). Also, metalloproteinases (gelatinases), which are proteolytic enzymes that were found to be stimulated by sham cataract surgery (Tamiya et al., 2000), were suggested to play an important role in the regulation of LEC migration onto the posterior capsule (Kawashima et al., 2000; Wong et al., 2004).

Extracellular matrix (ECM) formation by LECs is the result of capsular bag wound-healing response after extracapsular cataract surgery. The cells become surrounded by multiple layers of ECM consisting predominantly of dermatan, chondroitin and heparan sulphates, and collagen types I, III, IV, V, VI (Ishibashi et al., 1994; Azuma et al., 1998; Nishi et al., 1995c), XII and XIV (Saika et al., 2001). Other substances found are laminin (Zhang et al., 2001) and osteopontin (Saika et al., 2003).

1.1.6.1.2.2 Clinical types of PCO (Figure 1-10)

Clinically there are two main morphological types of PCO: fibrotic and cellular. The fibrotic type is the result of collagen deposition and myofibroblastic transdifferentiation of LECs. This type leads to greyish-white discoloration and often wrinkling of the posterior capsule. The cellular type is associated with the formation of lens epithelial cell clumps (Elshnig’s pearls) as a result of growth factor and cytokine stimulation of LEC proliferation. In the majority of cases, the two forms normally coexist, although a predominant feature can often be identified.

In a series of patients who had a square-edged hydrophobic acrylic IOLs (AcrySof), Wolken and Oetting (Wolken & Oetting, 2001) described a linear form of PCO that developed along the posterior capsular striae. These striae, which are often seen both during surgery and in the early postoperative period with these implants as well as with other 3-piece IOLs, were believed to have provided tunnels for the LECs to migrate through and onto the posterior capsule.

Following Nd:YAG capsulotomy, LEC pearls were found to form around the margin of the capsular opening (Kato et al., 1997a; Kurosaka et al., 2002). The cumulative probability of that occurrence was estimated to be 70% in 2 years, but according to Kurosaka et al (Kurosaka et al., 2002) only 20% of these pearls were progressive and required a second capsulotomy procedure.
Figure 1-10. Clinical types of PCO: fibrotic type showing posterior capsule wrinkles (a) and grayish haze (b); and cellular type showing LEC pearls (c).
Posterior capsular and anterior hyaloid opacification or closure of the capsular opening after Nd:YAG capsulotomy was reported before in patients younger than 50 years (McPherson & Govan, 1995) and was found to be significantly more frequent in diabetic patients (Kumagai et al, 1999) and with hydrogel IOLs (Georgopoulos et al, 2003).

1.1.6.1.2.3 Methods of assessment of PCO

1.1.6.1.2.3.1 Subjective methods: visual function tests

Centripetal migration of the LECs, fibrosis and wrinkling of the posterior capsule leads to scattering of the light entering the eye (forward scatter) and hence compromises visual function. The two main visual functions that are commonly tested and that were shown to be compromised by PCO are visual acuity and contrast sensitivity (Hayashi et al, 2003; Tan et al, 1998; Aslam & Patton, 2004; Meacock et al, 2003). In addition, glare disability (Hayashi et al, 2003; Tan et al, 1998; Aslam & Patton, 2004) and forward light scatter (Meacock et al, 2003) have been linked to PCO development.

Using Scheimpflug videophotography and measurements of visual acuity and contrast sensitivity with and without glare, Hayashi et al, 2003 (Hayashi et al, 2003), found that the degree of PCO correlated with both these visual functions, although most strongly with visual acuity. Tan et al (Tan et al, 1999) reported that high spatial frequency contrast sensitivity loss (3 cycles/degree) provided a more sensitive measure than other spatial frequencies in the early stages of PCO formation. Sunderraj et al (Sunderraj et al, 1992) found that glare disability is more prominent in some patients who still had good visual acuity.

Meacock et al (Meacock et al, 2003) estimated that the percentage of PCO required for a decline in visual acuity to occur was 78% but was 38% to 46% for a decline in contrast sensitivity and less than 1% for a decline in forward light-scatter. The authors thus concluded that the latter is the most sensitive test to assess the influence of PCO on visual function.
Chapter 1: Introduction and Review of the Literature

1.1.6.1.2.3.2 Objective methods

1.1.6.1.2.3.2.1 Slit lamp grading

Many authors have used different systems that rely on slit lamp grading of PCO. Kruger et al (Kruger et al, 2000) used a system that graded capsular opacification within the central 3mm into: 0=absent, 1=very mild, 2=moderate, and 3=dense white. Sellman and Lindstrom (Sellman & Lindstrom, 1988) graded fibrosis and Elshnig’s pearls on a similar four-point scale, which was used by other studies (Oner et al, 2000; Winther-Nielson et al, 1998). They used diagrams to illustrate the various grades of both fibrosis and cell pearls: 1= no or slight PCO without reduced red reflex and no pearls to the IOL edge; 2 = mild PCO reducing the red reflex, Elshnig’s pearls to the IOL edge; 3 = moderate fibrosis or Elshnig pearls inside IOL edge but with a clear visual axis; 4 = severe fibrosis or Elshnig’s pearls covering the visual axis and severely reducing red reflex. Legler et al (Legler et al, 1993) used ease of visibility of posterior segment structures, including the optic nerve head, retinal blood vessels and retinal nerve fibre layer, with the indirect ophthalmoscope. Prajna et al (Prajna et al, 2000) combined this method with the slit lamp grading system. According to Prajna’s system, in grades II and III the capsular opacity is visible through an undilated pupil and grade II is characterised by clearly seen optic nerve head but hazy retinal nerve fibre layer and blood vessels, whereas in grade III, even the optic nerve head is not visible.

These methods are easy to apply clinically and their reproducibility is expected to be high for an experienced observer but they are still subject to inherent interobserver variability. Also, although they can be considered to be semi-quantitative, they lack precise quantification.

1.1.6.1.2.3.2.2 Imaging systems

1.1.6.1.2.3.2.2.1 Scheimpflug system

Scheimpflug system was introduced by Lasa et al in 1995 (Lasa et al, 1995) then further developed by Hayashi in 1998 (Hayashi et al, 1998d; Hayashi et al, 1998e) to enable quantification of the density of the PCO. The system is called Anterior Eye Segment Analysis (EAS-1000; Nidek, Japan) and has been used in several studies.
Chapter 1: Introduction and Review of the Literature

(Klos et al, 1999; Zaczk & Zetterstrom, 1999; Hayashi et al, 2001; Hayashi et al, 2002; Tsuchiya et al, 2003; Hayashi et al, 2003; Hayashi & Hayashi, 2004; Hayashi et al, 2004). The central 3-mm position of the posterior capsule is quantified by means of area densitometry that measures the scattering light intensity. Slit images of the implanted IOL are taken at 0, 45, 90 and 135 meridians after full pupillary dilatation. The highest quality image of each meridian is selected and then transferred to a computer. The axial densitometry is used to calculate the scattered light density of the central 3-mm area of the posterior capsule. The density value of one section is determined by subtracting the scatter light density value of the IOL from that of the posterior capsule. The averaged density of the 4 meridians then determines the PCO density value. Hayashi et al (Hayashi et al, 1998e) found intraobserver and interobserver correlation coefficient of 0.95 and 0.976, respectively, that indicated high reproducibility. However, in a recent study by Tantaka et al (Tanaka et al, 2004c), IOL material was found to significantly influence the scattered light density measurements of Scheimpflug system, and thus the density of PCO quantified by this system cannot be directly compared with different optic materials.

1.1.6.1.2.3.2.2.2 Digital photography

Digital photography or digital image acquisition of the posterior capsule (Aslam et al, 2002) includes a group of computer-based systems, each adopts a specific principle to quantify PCO.

Brightness-based analysis system relies on the image pixel grey value (light intensity of the pixel) to classify it into either PCO area or not according to a given light intensity threshold. The percentage of classified pixels is then calculated by a computer to give the percentage of PCO. Wang et al (Wang & Woung, 2000) used digital images with the EAS anterior segment analysis system and graded brightness within the central and peripheral zones of the optic area from 0 to 255. A predefined threshold of transparency is 167 and the percentage level of transparency is estimated by mean of a computer program. Because the system requires that each pixel be defined individually as opaque or clear, problems of image analysis and interpretation arise due to the inherently variable background illumination intensity. This can be due to variations in patient fixation, head posture, pupillary size, fundus
Chapter 1: Introduction and Review of the Literature

pigmentation and IOL centration or refractive index (Pande et al, 1997; Barman et al, 2000).

Density map system is another imaging system that was developed by Friedman et al (Friedman et al, 1999). In that method, a polarised light is incorporated in the illumination and viewing systems of the camera to suppress much of the corneal reflex. The image illumination is evened out by an image analysis technique that produces an illumination-compensated image. The grading of PCO assesses both average area density (grey level of opacification), which is converted to a scale (0 to 4), and percentage coverage of PCO. Validation studies showed that the image analysis system identifies the percentage coverage and the density of PCO similar to subjective assessment by an ophthalmologist. The system, however, seems to lack ability to identify progression of PCO. Because the system uses the average density, when more area is covered with less dense PCO the overall average decreases. Therefore, it was suggested that using the standard deviation (rather than the mean) of the density for the specified area, regionalising areas of different opacities and assessing texture of the capsule would improve the assessment scheme.

Evaluation of the Posterior Capsule Opacification (EPCO) system was developed by Heidelberg and uses retro-illumination colour photographs taken with a Zeiss photo slit lamp to score PCO. This system was first described by Tetz et in 1997 (Tetz et al, 1997). The area of opacification of the posterior capsule is encircled and graded 0-4 according to perceived density. The overall opacity is then calculated by multiplying the density of the opacification by the fraction of the area behind the IOL optic that is involved. The system is cheap and is claimed to be one of the best systems for evaluating PCO. Inter-observer and intra-observer variability were assessed by estimating the standard deviation of the PCO grade and was found to be low. The system, however, was not assessed for its ability to identify progression and is limited by not being fully objective as it relies on the observer to define the PCO level d in different areas.

Texture segmentation system has been described by Pande et al (Pande et al, 1997) and recently by Barman et al (Barman et al, 2000). It has been used in several studies by the research group at St Thomas Hospital, London since 1997. It depends on specialised photographic equipment that produces a high-resolution, evenly illuminated image of the posterior capsule. The image analysis software is based on
TRACEE, an image analysis computer program that is enhanced with dedicated modules written for the purpose of PCO analysis. The system analyses the area behind the optic of the IOL and not obscured by the anterior capsule 'the mask'. All images undergo processing steps including removal of Purkinje images, contrast-enhancement, filtering to enhance the texture of areas of opacity that look like clear capsule and texture segmentation to classify the mask area into areas of opacity and transparency. This binary classification is dependent on the texture (structural details), with increased texture indicating opacity. The final result is calculated in percentage area of opacification based on the number of opaque pixels in the mask area compared with the total number of pixels within the mask. A colour-coded form of the software has been developed with the intention of simplifying interpretation.

The system has been validated by comparing the computer-derived percentages of PCO to clinical assessment of PCO percentage on the slit lamp by experienced clinicians and intra-observer variability was found to be less than 10% (Barman et al, 2000).

1.1.6.1.2.4 Treatment of PCO

1.1.6.1.2.4.1 Nd:YAG capsulotomy

Nd:YAG laser capsulotomy was introduced as a method of treating PCO in the 1980s by Aron-Rosa (Aron-Rosa et al, 1980) and Fankhauser (Fankhauser et al, 1981) and proved to be both effective and safe.

1.1.6.1.2.4.1.1 Principles of Nd:YAG laser

Nd:YAG laser (Murrill et al, 1995; Thall, 1999) is a CO₂ infrared laser of 1,064nm wavelength that works on the principle of photodisruption. When amplified, focused and applied to tissues, Nd:YAG laser light strips the electrons away from their nuclei and produces plasma. The reuniting of the electrons and nuclei creates an acoustic shock wave that damages the tissues.

Commonly used Nd:YAG lasers are either Q-switched or mode-locked or both. In Q-switching, a shutter in front of one of the mirrors prevents any significant laser emission until a large population inversion of electrons has been achieved. The shutter is then opened and the energy exits in a very short pulse (~10-20ns). In mode-
locking, an interferometer inside the cavity of the laser tube synchronises the modes of the emitted light in a train of 7 to 10 shorter pulses than that of a Q-switched pulse (~30ps). Q-switched lasers are more commonly used since they are less expensive.

1.1.6.1.2.4.1.2 Technique of Nd:YAG capsulotomy

Since Nd:YAG laser is an invisible infrared light, an ancillary helium-neon (He-Ne) aiming system is used. A slight discrepancy of the foci of both lasers results from chromatic aberration, with the shorter wavelength of the He-Ne focusing in front of the infrared light of the Nd:YAG (Thall, 1999). Also, although photodisruption occurs at the focus of the laser, impurities of the laser or lens material may produce damage to the lens implant before the focusing point (Thall, 1999). Slightly defocusing the laser behind the point of intended delivery helps avoid damaging the implants. Also, using a contact lens to converge the light at a steeper angle makes the impact at an area remote from the focus point less likely (Downing & Alberhasky, 1990).

Capsular opening made with the laser should be at least 1.5mm. Hu et al (Hu et al, 2001) found that the size of the opening tended to increase in size up to 1 month and then stabilises. Decentration of the capsular opening by up to 1mm was not found to affect visual function as long as the opening was clear (Aslam & Dhillon, 2002).

1.1.6.1.2.4.1.3 Complications of Nd:YAG capsulotomy

Nd:YAG capsulotomy can lead to several complications, some of which can be sight threatening.

1.1.6.1.2.4.1.3.1 Rise of IOP

The incidence of this complication varies between 25% and 90%. An increase of IOP up to 30mmHg was found to occur in 5.7% (Keates et al, 1984) to 28.6% in the early reports of the procedure (Terry et al, 1983; Stark et al, 1985). The maximal increase in IOP occurs within 3-4 hours after capsulotomy (Richter et al, 1985). Keates et al (Keates et al, 1984) found that the increase in IOP returned to its pre-treatment level in 89% of patients after 1 week. A persistent elevation of IOP was reported to occur in about 1% of patients (Stark et al, 1985). The authors also found the ratio of the IOP in the treated eye to that in the other eye to be significantly higher than in the group with intact capsule. A late-onset elevation of IOP after a mean follow-up of
Chapter 1: Introduction and Review of the Literature

2.7 years was found in 5.9% of patients (Fourman & Apisson, 1991). Recently Hu et al (Hu et al, 2000) and Ge et al (Ge et al, 2000) reported conflicting evidence on the effect of Nd:YAG capsulotomy on the IOP. Hu’s study showed no significant rise in IOP up to 3 months after Nd:YAG capsulotomy. Ge’s study, on the other hand, showed a long-term rise of IOP in patients who developed an increase of IOP within an hour of the procedure and in patients with glaucoma.

The mechanisms of this complication include obstruction of the trabecular meshwork by inflammatory cells, capsular (Stark et al, 1985; Lynch et al, 1986) and dialyzable proteins of a small molecular weight from the disrupted anterior vitreous face (Schubert et al, 1985). Shock-wave damage to the trabecular endothelial cells (Lynch et al, 1986), and release of inflammatory mediators (Stjernschantz et al, 1986) have also been suggested to be involved in producing IOP rise following Nd:YAG capsulotomy.

Risk factors for IOP rise following Nd:YAG capsulotomy include larger size of the capsular opening (Channell & Beckman, 1984) aphakia (Richter et al, 1985; Javitt et al, 1992), glaucoma (Ge et al, 2000) and myopia (Schubert, 1987). Similarly, although some authors found that increased total laser energy was associated with increased IOP (Channell & Beckman, 1984; Richter et al, 1985), Slomovic et al (Slomovic & Parrish, 1985) was unable to find a significant correlation between them.

Apraclonidine 1% or Timolol 0.5% drops and oral acetazolamide are among the most commonly used medications to prevent and control IOP spikes following Nd:YAG capsulotomy. To date, there is no evidence for a long-lasting visual damage as a result of IOP rise following Nd:YAG capsulotomy.

1.1.6.1.2.4.1.3.2 Retinal breaks and detachment

In patients who underwent ECCE, the incidence of retinal detachment following Nd:YAG capsulotomy has been estimated to be between 0.4% (Keates et al, 1984) and 3.6% (Rickman-Barger et al, 1989). More recently, Jahn et al (Jahn et al, 2003) found the incidence of retinal detachment to be 0.5% within 24 months after phacoemulsification and subsequent Nd:YAG capsulotomy.

Javitt et al (Javitt et al, 1992) found almost fourfold increase in the incidence of retinal tears or detachment following Nd:YAG capsulotomy. Also, Nd:YAG
capsulotomy was identified as an independent risk factor for the development of retinal detachment in a case-control study (Tielsch et al, 1996). Powell et al (Powell & Olson, 1995), however, found no significant difference in the incidence of retinal detachment between patients who underwent phacoemulsification alone and those who underwent Nd:YAG capsulotomy following phacoemulsification.

The risk factors of developing retinal detachment after Nd:YAG capsulotomy include high myopia, lattice degeneration with associated holes, greater laser energy and larger capsulotomy size (Koch et al, 1989; MacEwen & Baines, 1989). Dardenne et al (Dardenne et al, 1989) and Steinert et al (Steinert et al, 1991), however, were unable to establish a relationship between the laser parameters and the incidence of retinal detachment.

1.1.6.1.2.4.1.3.3 Cystoid macular oedema (CMO)

The incidence of CMO following Nd:YAG capsulotomy ranges between 0.68 to 1.23% (Shah et al, 1986; Steinert et al, 1991). The exact mechanism leading to the development of CMO is not known. However, it is postulated to be a non-specific response to any intraocular surgical procedures. The disruption of the anterior hyaloid face, movement of the vitreous and possibly vitreoretinal traction are believed to contribute to its development. It was also postulated to be the result of an inflammatory response to the release of capsular fragments that involves the release of prostaglandins and leukotrienes (Murrill et al, 1995).

The majority of cases of CMO following Nd:YAG capsulotomy are asymptomatic and in only a small percentage is there a drop in vision. Fluorescein angiography can demonstrate the leakage from the peri-foveal capillaries. The low incidence and difficulty in quantifying CMO rendered the assessment of the effectiveness of its treatment difficult. A common therapeutic regimen includes applying either non-steroidal antiinflammatory or steroidal eye drops 4 times a day for 4 weeks (Murrill et al, 1995). The use of the non-invasive technique of optical coherence tomography to measure the changes in macular thickness after cataract surgery (Sourdille & Santiago, 1999; Grewing & Becker, 2000) offers an effective and safe means to further investigate this complication and its treatment following Nd:YAG capsulotomy.
Chapter 1: Introduction and Review of the Literature

1.1.6.1.2.4.1.3.4 IOL damage

The most common occurrence during Nd:YAG capsulotomy is ‘striking’ or ‘pitting’ of the IOL by the laser, with rates between 4% to 40% (Stark et al, 1985; Weiblinger, 1986). Silicone IOLs were found to have a lower threshold of damage by the laser in comparison to acrylic and PMMA IOLs (Trinavarat et al, 2001). The threshold for damage of these implants was estimated to be 0.37mJ, 0.52 to 0.66mJ and 0.68mJ, respectively. Mainster et al (Mainster et al, 1983) indicated that the threshold of damage to an implant decreases with repeated striking by the laser.

The Nd:YAG laser optical breakdown was shown to occur up to 2mm anterior to its focal plane (Clayman & Jaffe, 1988). Fallor et al (Fallor & Hoft, 1985) showed that an IOL with a theoretical separation of 0.25mm or more between the lens and the posterior capsule sustains no damage. Also using a contact lens to focus the laser beam just behind the posterior capsule minimises the damage to the IOL (Downing & Alberhasky, 1990).

Newland et al (Newland et al, 1999) showed that silicone implants, in addition to having the lowest threshold for laser-induced damage, exhibit collateral damage in the form of a greater linear extension of damage (Figure 1-11) than PMMA and acrylic implants. They also showed that PMMA and silicone polymers could eject particulate matters adjacent to the entry site. One study showed cytotoxicity to cultured choroidal and retinal pigment epithelial cells by compounds released from experimentally damaged PMMA IOLs at energy levels of 10mJ or higher but not at 2-5mJ (Terry et al, 1985). There is, however, no clinical evidence of any toxic effect to the corneal endothelium or other intraocular tissues from striking the IOLs.

Generally, IOL ‘strikes’ or ‘pits’, unless excessive, are of no clinical significance (Keates et al, 1984). Rarely, however, they may cause glare, blurring or even distortion of vision (Gardner et al, 1985; Nirankari & Richards, 1985; Mamalis et al, 1990) that might at times require removal of the IOL (Mamalis et al, 1990).
Figure 1-11. An example of the collateral damage in a silicone IOL (SI30NB; Advanced Medical Optic, Inc., AMO). It shows marks of laser strikes (pitting) and radial extensions of the marks presumably cuts (arrows) within the optic.

1.1.6.1.2.4.1.3.5 IOL displacement

Findl et al (Findl et al, 1999), using dual beam partial coherence interferometry, showed that a small but measurable backward movement of the IOL occurs after Nd:YAG capsulotomy. The backward movement was more pronounced in patients with plate-haptic IOLs than with one-piece PMMA or 3-piece foldable IOLs and its magnitude was related to the size of the capsular opening.

Several case reports have been published of spontaneously dislocated IOLs following Nd:YAG capsulotomy that included hydrogel (Levy et al, 1990), PMMA (Framme et al, 1998) and plate-haptic silicone IOLs (Tuft & Talks, 1998; Dick et al, 1998; Akerele et al, 1999; Petersen et al, 2000). In one of the patients, this led to pupillary block glaucoma (Shankar & Halliwell, 2003).
1.1.6.1.2.4.1.3.6 Other rare complications

Anterior uveitis (0.4%-1.4%) (Keates et al, 1984; Chambless, 1985), persistent vitritis after 6 months (0.6%) (Keates et al, 1984), spread of low-grade infective endophthalmitis (Carlson & Koch, 1988; Neuteboom & Vries-Knoppert, 1988; Hollander et al, 2004), iris haemorrhage (Gardner et al, 1985), secondary closure of capsular aperture (Oshika et al, 2001) and corneal oedema (Wasserman et al, 1985) were rarely reported following Nd:YAG capsulotomy.

1.1.6.1.2.4.2 Surgical discision

Surgical discision (Murrill et al, 1995) either at the time of surgery or later on was the treatment of choice of PCO before the development of Nd:YAG laser capsulotomy. The procedure was associated with numerous serious complications such as corneal endothelial damage, IOL dislocation, vitreous loss, endophthalmitis and retinal detachment (Weiblinger, 1986; Flohr et al, 1985).

1.1.6.1.2.5 Prevention of PCO

1.1.6.1.2.5.1 Surgical technique

In a review by Apple et al (Apple et al, 1992), two major principles have been proposed to apply to the prevention of PCO. These included minimising the number of residual LECs, especially the equatorial cells, and creating a secondary barrier to block migration of LECs from the equatorial region toward the visual axis. They identified six factors, three of them are surgery-related and three are IOL-related, that play crucial roles in preventing or delaying the development of this complication (Ram et al, 1999; Apple et al, 2000; Peng et al, 2000; Apple et al, 2001). The surgery-related factors are hydrodissection-enhanced cortical removal, a smaller continuous capsulorhexis than the optic and in the bag placement of the IOL. The IOL-related factors are the biocompatibility of the IOL material to reduce stimulation of cellular proliferation, square-optic geometry of the IOL and maximal optic-capsule contact.
A PMMA square-edged capsular bag tension ring was used by Hara (Hara et al., 1995), Hashizoe (Hashizoe et al., 1998), and Nishi (Nishi et al., 1998b; Nishi et al., 1998a), who showed a significant reduction in PCO development. Nishi et al (Nishi et al., 1998a) concluded that a discontinuous bend in the capsule significantly inhibits LEC migration. The subsequent development of the square-edged IOLs and the establishment of their beneficial effect have made this technique redundant, however.

Posterior continuous curvilinear capsulorhexis (PCCC) and the optic capture technique with or without vitrectomy is another method that was primarily used in children and was reported by many authors to successfully prevent posterior capsular opacification (Gimbel, 1996; Vasavada et al., 2001; Raina et al., 2002). The procedure, however, did not prevent the growth of LECs on the anterior hyaloid face and Vasavada et al (Vasavada et al., 2004) reported up to almost 40% of anterior hyaloid opacification. Secondary surgical procedure was required after a mean follow-up of 2.3 years in 13.6% to clear the visual axis.

Tassignon et al (Tassignon et al., 2002) recently described the 'bag-in-the-lens' technique (Figure 1-12 & 1-13), where two identical continuous curvilinear capsulorhexes are created in both the anterior and posterior capsules and the capsular leaflets are inserted between the flanges of an IOL especially designed for that technique 'twin-capsulorhexis IOL'. The authors reported no PCO or rather any similar retro-lenticular opacification in adults (Tassignon et al., 2002); (Tassignon, 2004b) and children (Tassignon, 2004a). They advocated the technique as the most effective surgical technique to prevent the development of PCO in high-risk patients such as children, uveitic patients and following vitrectomy. The procedure, however, is technically demanding but the authors report no increased risk of vitreous loss or increased incidence of cystoid macular oedema.
Figure 1-12. A schematic diagram of the twin-capsulorhexis and the IOL with the two perpendicularly orientated haptics (1 & 3). The side view shows the characteristic groove (2) that embraces the two capsular leaflets (Courtesy of Prof. Tassignon (Tassignon et al, 2002))

Figure 1-13. A schematic diagram illustrating a comparison between the conventional in-the-bag IOL with the LECs covering the posterior capsule and the bag-in-the lens with the two flanges of the haptics embracing the capsular leaflets that in turn captures the LECs in between them. (Courtesy of Prof. Tassignon (Tassignon et al, 2002))
1.1.6.1.2.5.2 Surface modification of IOLs

Coating the IOL surfaces is generally meant to change their surface tension, which determines their relative hydrophilicity. The latter affects the attraction of the cells and their growth onto the IOL surfaces and is inversely related to their surface tension and to their contact angles (section 1.1.4).

Heparin-coating of PMMA IOLs renders their surfaces hydrophilic, with a contact angle of 33° to 56.5° (Cunanan et al., 1998; Dick et al., 2001; Tehrani et al., 2004). Although the lens was shown to have higher uveal biocompatibility i.e. less anterior chamber inflammation (Fagerholm et al., 1989; Percival & Pai, 1993) and cellular deposits (Shah & Spalton, 1995a), Umezawa et al showed that it increased the incidence of PCO (Umezawa & Shimizu, 1993).

Surface-passivation of PMMA IOLs changes their surface energy and hence renders them more hydrophobic with a contact angle of 90° (Umezawa & Shimizu, 1993). Kochounia et al (Kochounian et al., 1991) found that surface-passivated PMMA IOLs activated complement to the same degree of regular PMMA and no significant effect was found on lowering the incidence of PCO (Umezawa & Shimizu, 1993).

1.1.6.1.2.5.3 Inhibiting lens epithelial cell proliferation

The main classes of medications that have been used to inhibit LEC proliferation are:

a) Antiproliferative drugs such as 5-fluorouracil (Ruiz et al., 1990; Ismail et al., 1996), daunorubicin (Tetz et al., 1996), colchicines (Legler et al., 1993) and mitomicin C (Ismail et al., 1996; Chung et al., 2000);

b) Immunotoxins such as 4197X-ricin A immunoconjugate (Tarsio et al., 1997), lens epithelial cell adhesion molecule blocking agent (Nishi et al., 1997) and immunotoxin MDX-RA (Clark et al., 1998) and
c) Antiinflammatory drugs such as indomethacin (Nishi et al., 1996b; Tetz et al., 1996) and diclofenac sodium (Nishi et al., 1995a; Cortina et al., 1997) and cyclosporin A (Cortina et al., 1997). These medications are applied either intraoperatively, through a long-acting delivery system or postoperatively. None of these medications, however, have been proved clinically useful yet.
1.1.6.1.2.5.4 Other methods

Experimental use of heparin-mixed anterior chamber irrigating solution during cataract extraction (Zaturinsky et al, 1990) and implantation of an anterior chamber heparin drug-delivery system (Xie et al, 2003) were found to be useful in reducing the postoperative inflammatory reaction and the incidence of PCO. Also, in a case-controlled trial, heparin eye drops have been shown to reduce the incidence of PCO after 4 years (Mastropasqua et al, 1997). The long-term effectiveness of these methods has not been yet established.


Chapter 1: Introduction and Review of the Literature

1.2 REVIEW OF THE LITERATURE

1.2.1 Incidence of PCO

PCO is the most common postoperative complication after modern cataract extraction surgery. Published estimates that are based on the need for Nd:YAG capsulotomy have shown a gradually increasing incidence of PCO after surgery. Within the first postoperative year, the incidence was found to be up to 12% (Sudhakar et al, 1989; Schaumberg et al, 1998; Baratz et al, 2001; Ando et al, 2003) and that increases to about 50% in 5 years (Moisseiev et al, 1989; Apple et al, 1992; Baratz et al, 2001; Ando et al, 2003). Sundelin (Sundelin & Sjostrand, 1999) found that, 5 years after surgery, there was a ‘hidden’ untreated group of approximately 9% of patients that had clinically significant PCO and would benefit from Nd:YAG capsulotomy.

Table 1-2 and 1-3 details the incidence rate of PCO, as indicated by the need for Nd:YAG capsulotomy, reported in the most recent studies with a follow-up of at least 1 year after ECCE and phacoemulsification. Incidence of Nd:YAG capsulotomy has mainly been used in retrospective (Mamalis et al, 1996b; Ninn-Pedersen & Bauer, 1997; Dana et al, 1997; Baratz et al, 2001; Beltrame et al, 2002; Ando et al, 2003; Abhilakh Missier et al, 2003) and post-mortem studies (Apple et al, 2001; Schmidbauer et al, 2001a). The method is criticised for its subjectivity as it relies on patients’ complaints and surgeons’ threshold for intervention. However, the method derives validity from the fact that it reflects ‘clinically significant’ PCO i.e. PCO that affects visual function or obscures the fundus view.

Several factors related either to the patient or the surgical technique have been suggested to affect the incidence and rate of PCO.
1.2.2 Factors affecting the incidence of PCO

1.2.2.1 Surgery related factors

1.2.2.1.1 Surgical technique

Although, a meta-analysis by Powe et al (Powe et al, 1994) was unable to show a significant difference between ECCE and phacoemulsification techniques in the incidence of PCO, a decline in PCO and Nd:YAG capsulotomy rates has recently been documented in a large post-mortem study of Nd:YAG capsulotomy rate (Apple et al, 2001). Reports of the 5-year incidence following ECCE indicated that PCO occurred in up to 50% (Moisseiev et al, 1989; Apple et al, 1992), while after phacoemulsification the incidence was only up to 33% (Baratz et al, 2001; Ando et al, 2003). In a study by Ram et al (Ram et al, 2001) ECCE was found to have a higher rate of visually significant PCO than phacoemulsification (42.5% vs. 19.2%). The lower incidence with phacoemulsification is believed to be related to the improvement in the surgical techniques, the use of smaller incisions, better cortical clean-up and the use of modern foldable intraocular lenses with better design profiles. Also, the reduced postoperative inflammatory reaction shown to occur after phacoemulsification (Oshika et al, 1992; Ursell et al, 1999; Mentes et al, 2003) seem to have a role in lowering the incidence of PCO.

The type and size of capsulorhexis affects the incidence of PCO. The performance of continuous curvilinear capsulorhexis was found to be associated with less PCO than ‘envelope’ capsulectomy (Birinci et al, 1999). Hollick et al, 1999 (Hollick et al, 1999a), and Aykan et al, 2003 (Aykan et al, 2003), reported an increase in the percentage of area of opacified posterior capsule after phacoemulsification and implantation of PMMA IOLs in patients with larger capsulorhexis (6-7mm in comparison to 4.5-5mm). Also, Wejde et al (Wejde et al, 2004) found that a small central CCC that totally covers the optic edge was associated with significantly less PCO than that that lies partially or completely off-the-optic.
1.2.2.1.2 Intraocular lens

1.2.2.1.2.1 IOL and its position

Implantation of an IOL following cataract surgery was shown to decrease the incidence of PCO and Nd:YAG capsulotomy in comparison to aphakia (Nishi, 1986; Badr et al, 1995). Also, bag-fixated IOLs were found to decrease the incidence of PCO (Laurell et al, 1998) and Nd:YAG capsulotomy (Ram et al, 1999; Ram et al, 2001).

1.2.2.1.2.2 Design of the IOL

Angulation of the haptic and the overall size of an implant or its optic can have an effect on the rate of PCO. Patients implanted with PMMA IOLs with angled haptics were found to have a lower capsular discission rate than uniplanar PMMA IOLs (7.9% vs. 15%) (Downing, 1986). In a later study by Shmidbauer et al (Schmidbauer et al, 2002) this was not found to be the case, however. Mamalis et al (Mamalis et al, 1995) found less PCO requiring Nd:YAG capsulotomies in a PMMA IOL group with an overall lens diameter less than 13.5 mm, than in a PMMA IOL group with an overall diameter of 13.5mm or larger. Nishi and Nishi (Nishi & Nishi, 2003) found that acrylic IOLs with larger optics (7 mm) had a higher rate of PCO development than those with smaller optics (5.5 mm).

Similarly, the configuration of the posterior surface of the IOL has been found to affect the rate of PCO as well as the type of opacification that develops. Intraocular lenses with a convex posterior surface were found to have a lower capsulotomy rate (up to 17.6%) than those with a plane posterior surface (up to 29.3%) (Sterling & Wood, 1986). Following a continuous capsulorhexis and phacoemulsification, Yamada et al (Yamada et al, 1995) found that Nd:YAG capsulotomy rates were 5.9% and 32.5% after plano-convex and biconvex IOL implantation, respectively.

A laser-created ridge on the posterior surface of the implant was found in earlier studies to lower the PCO rate (Maltzman et al, 1989). Born et al (Born & Ryan, 1990) found that implants of biconvex or plano-convex design that had broader posterior surface contact with the posterior capsule had a lower cumulative
capsulotomy rates than implants with a convex-plano optic or those with laser ridges (5.9% versus 40%).

Plate-haptic silicone IOLs was shown to have less PCO requiring Nd:YAG capsulotomy in comparison to 3-piece silicone IOLs (Cumming, 1993). Mamalis et al (Mamalis et al, 1996b) found the same results but the difference between the capsulotomy rates in their study was not statistically significant (30.2% and 39.1%). In a recent study by Abhilakh Missier (Abhilakh Missier et al, 2003), plate-haptic silicone IOL had more PCO and Nd:YAG capsulotomy rate than hydrophobic acrylic IOLs.

A square-edge profile of an IOL has been shown to reduce or even prevent migration of LECs onto the posterior capsule and hence the development of PCO through either a contact inhibition mechanism (Nishi et al, 1998c) or a mechanical barrier effect (Boyce et al, 2002). Nishi et al has shown that to be the case in experimental and clinical settings (Nishi et al, 1998a;Nishi et al, 1998c;Nishi & Nishi, 1999;Nishi et al, 2000). Peng et al (Peng et al, 2000), in a study of 150 autopsy eyes with 3 types of IOLs: PMMA, silicone and hydrophobic acrylic, noticed that there was an abrupt termination of cells at the peripheral edge of the truncated or square-edged optic. In a study by Kruger et al (Kruger et al, 2000), after 2 years of follow-up, silicone implants with square edges had less PCO and Nd:YAG capsulotomy rates than those with rounded edges.

The optic edge profile was shown to be more relevant in preventing PCO development than the optic material. Nishi et al (Nishi et al, 2000;Nishi & Nishi, 2002) found the speed of capsular bend-formation at the optic edge was comparable and that there was no difference in PCO between two square-edged 3 piece IOLs made of silicone and hydrophobic acrylic material. Nishi also found that hydrophobic acrylic implants with rounded edge lost their PCO preventative effect (Nishi et al, 2001).

1.2.2.1.2.3 IOL material

Several studies have shown that PMMA IOLs have a higher Nd:YAG capsulotomy rate than silicone and acrylic implants. Hollick et al (Hollick et al, 1999c) reported
26%, 14% and 0% Nd:YAG capsulotomy after 3 years for PMMA, silicone and hydrophobic acrylic IOLs, respectively.

Nagata et al and Oshika et al found that the adhesion force of a type I collagen sheet and of the posterior capsule to intraocular lenses made of acrylate was greater than with PMMA (Nagata et al, 1998; Oshika et al, 1998b) or silicone IOLs (Oshika et al, 1998b). Linnola et al (Linnola et al, 1999a) suggested that acrylate is a bioactive material that adheres to the biological tissues better than silicone and PMMA. They suggested that this is due to better adhesion of fibronectin to acrylate than to silicone and PMMA IOLs. This was postulated to explain the stronger adhesion between the posterior capsule and acrylic IOLs than PMMA and silicone IOLs and hence the preventative effect on LEC migration and PCO development (Linnola et al, 1999b; Linnola et al, 2000a; Linnola et al, 2000b). They also proposed that a single layer of lens epithelial cell binds both to the IOL and to the posterior capsule, which produces a sandwich-like structure, including the IOL, the cell monolayer, and the posterior capsule; and that this sealed sandwich-like structure prevents further epithelial ingrowth and PCO development (The sandwich theory) (Linnola, 1997; Linnola et al, 1999b; Linnola et al, 2000b; Linnola et al, 2000a).
Table 1-2. Published incidence of Nd:YAG capsulotomy after ECCE and implantation of IOLs with different materials and designs and a follow-up of at least one year (modified and updated with permission from Linnola) (Linnola R., 2001).

<table>
<thead>
<tr>
<th>Study &amp; Year</th>
<th>IOL model</th>
<th>Haptic material</th>
<th>No.</th>
<th>Follow-up (months)</th>
<th>Nd:YAG %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PMMA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Winther-Nielsen et al, 1998)</td>
<td>Pharmacia 725b</td>
<td>PMMA</td>
<td>60</td>
<td>36</td>
<td>43</td>
</tr>
<tr>
<td>(Winther-Nielsen et al, 1998)</td>
<td>Pharmacia 700b</td>
<td>PMMA</td>
<td>62</td>
<td>36</td>
<td>43.5</td>
</tr>
<tr>
<td>(Khan &amp; Percival, 1999)</td>
<td>Cilco JF1LRU</td>
<td>PMMA</td>
<td>40</td>
<td>144</td>
<td>50</td>
</tr>
<tr>
<td>(Hollick et al, 1999c)</td>
<td>Alcon MC60BM</td>
<td>PMMA</td>
<td>23</td>
<td>36</td>
<td>26</td>
</tr>
<tr>
<td><strong>Hydrophilic acrylic (HSM-PMMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Winther-Nielsen et al, 1998)</td>
<td>Pharmacia HSM-725b</td>
<td>PMMA</td>
<td>70</td>
<td>36</td>
<td>44</td>
</tr>
<tr>
<td>(Khan &amp; Percival, 1999)</td>
<td>Iolab L14IU</td>
<td>Single-piece</td>
<td>35</td>
<td>144</td>
<td>20</td>
</tr>
<tr>
<td><strong>Silicone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Hollick et al, 1999c)</td>
<td>Iolab L14IU</td>
<td>PMMA</td>
<td>22</td>
<td>36</td>
<td>14</td>
</tr>
<tr>
<td><strong>Hydrophobic Acrylic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Oshika et al, 1996)</td>
<td>Alcon AcrySof MA60BM</td>
<td>PMMA</td>
<td>64</td>
<td>24</td>
<td>11.1</td>
</tr>
<tr>
<td>(Hollick et al, 1999c)</td>
<td>Alcon AcrySof MA60BM</td>
<td>PMMA</td>
<td>19</td>
<td>36</td>
<td>0</td>
</tr>
</tbody>
</table>
### Chapter 1: Introduction and Review of the Literature

#### Table 1-3. Published incidence of Nd:YAG capsulotomy after phacoemulsification and implantation of IOLs with different materials and designs and a follow-up of at least one year (modified and updated with permission from Linnola) (Linnola R., 2001).

<table>
<thead>
<tr>
<th>Study &amp; Year</th>
<th>IOL model</th>
<th>Material</th>
<th>No.</th>
<th>Follow-up (months)</th>
<th>Nd:YAG %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PMMA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Hayashi et al, 1998c)</td>
<td>Alcon MZ60BD</td>
<td>PMMA</td>
<td>69</td>
<td>24</td>
<td>30.4</td>
</tr>
<tr>
<td>(Olson &amp; Crandall, 1998)</td>
<td>*</td>
<td>PMMA</td>
<td>59</td>
<td>36</td>
<td>33</td>
</tr>
<tr>
<td>(Erie et al, 1998)</td>
<td>Pharmacia 805/Storz 359</td>
<td>PMMA</td>
<td>171</td>
<td>41</td>
<td>23.5</td>
</tr>
<tr>
<td>(Oner et al, 2000)</td>
<td>Opsia-Agena 550</td>
<td>PMMA</td>
<td>77</td>
<td>17.8+1.7</td>
<td>26.3</td>
</tr>
<tr>
<td><strong>Silicone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Cumming, 1993)</td>
<td>*</td>
<td>Plate-haptic</td>
<td>503</td>
<td>30</td>
<td>2.3</td>
</tr>
<tr>
<td>(Mamalis et al, 1996b)</td>
<td>Starr AA-4203</td>
<td>Plate-haptic</td>
<td>139</td>
<td>21</td>
<td>30.2</td>
</tr>
<tr>
<td>(Mamalis et al, 1996b)</td>
<td>AMO S118NB/S130NB</td>
<td>Polypropylene</td>
<td>349</td>
<td>23.3</td>
<td>39.1</td>
</tr>
<tr>
<td>(Hayashi et al, 1998c)</td>
<td>AMO S130NB</td>
<td>Polypropylene</td>
<td>70</td>
<td>24</td>
<td>5.7</td>
</tr>
<tr>
<td>(Linnola &amp; Holst, 1998)</td>
<td>Pharmacia CeeOn 920</td>
<td>PMMA</td>
<td>45</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>(Olson &amp; Crandall, 1998)</td>
<td>AMO S130NB</td>
<td>Polypropylene</td>
<td>60</td>
<td>36</td>
<td>24</td>
</tr>
<tr>
<td>(Abhilakh Missier et al, 2003)</td>
<td>Starr AA4-203</td>
<td>Plate-haptic</td>
<td>107</td>
<td>36</td>
<td>23.1</td>
</tr>
<tr>
<td><strong>Hydrophiliaic acrylic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Brown et al, 1998)</td>
<td>Starr Collamer</td>
<td>Plate-haptic</td>
<td>125</td>
<td>65</td>
<td>4.7</td>
</tr>
<tr>
<td>(Stordahl &amp; Drolsum, 2003)</td>
<td>Ioltech Stabibag</td>
<td>Hydroge</td>
<td>370</td>
<td>23.7 (3.1)</td>
<td>7.6</td>
</tr>
<tr>
<td><strong>Hydrophobic Acrylic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Hayashi et al, 1998c)</td>
<td>Alcon AcrySof MA60B</td>
<td>PMMA</td>
<td>73</td>
<td>24</td>
<td>2.7</td>
</tr>
<tr>
<td>(Oner et al, 2000)</td>
<td>Alcon AcrySof MA30BA</td>
<td>PMMA</td>
<td>80</td>
<td>17.8+1.7</td>
<td>14.34</td>
</tr>
<tr>
<td>(Abhilakh Missier et al, 2003)</td>
<td>Alcon AcrySof MA30BA/60B</td>
<td>PMMA</td>
<td>107</td>
<td>9 (2-23)/5.5(5-6)</td>
<td>0.34/0.64</td>
</tr>
<tr>
<td>(Stordahl &amp; Drolsum, 2003)</td>
<td>Alcon AcrySof MA30BA</td>
<td>PMMA</td>
<td>335</td>
<td>23.3 (3.3)</td>
<td>2.7</td>
</tr>
</tbody>
</table>

ECCE=Extracapsular cataract extraction; AMO= Advanced Medical Optics. * = data not available.
1.2.2.2 Patient-related factors

1.2.2.2.1 Ocular factors

1.2.2.2.1.1 Uveitis

Several studies have reported the incidence or prevalence of PCO in uveitis patients after ECCE or phacoemulsification cataract extraction. After extracapsular cataract extraction, Krishna et al (Krishna et al, 1998) reported a prevalence of 58% after a mean follow-up period of 81.4 months. In a case-controlled retrospective study of patients who underwent either ECCE or phacoemulsification, Dana et al (Dana et al, 1997) reported 45% of PCO rate after a mean follow-up of 4.3 years. In that study, the rate was compared to a contemporary group of non-uveitic patients who had a mean follow-up of 3.9 years and a PCO rate of 40%. Although the difference was statistically significant, the difference became no longer significant after adjusting for the younger age of the uveitis patients.

After phacoemulsification in uveitis patients, Estafanous et al (Estafanous et al, 2001) reported PCO in 62% of patients after a mean follow-up of 20 months. Also, Suresh et al (Suresh & Jones, 2001), reported 42% of PCO and 21% of Nd:YAG capsulotomy among their patients after a mean follow-up of 2 years.

Berker et al (Berker et al, 2004) indicated that PCO was the most frequent complication, occurring in 37.5% of 40 eyes of patients with uveitis and Behçet’s disease after phacoemulsification and IOL implantation. In a recent study by Rahman et al (Rahman & Jones, 2004), the long-term incidence of PCO in uveitis patients (after a mean follow-up of 7.5 years) was 96%.

1.2.2.2.1.2 Myopia

After phacoemulsification, patients with myopia and increased axial length were found to have an increased incidence of PCO. In a series of 109 highly myopic eyes (axial length over 26 mm) with a mean postoperative follow-up of 27 months, Lyle et al (Lyle & Jin, 1996), found an incidence of 50% of PCO, 95% of whom needed Nd:YAG capsulotomy. In another retrospective study of 32 eyes of 27 highly myopic patients (axial length=31mm to more than 35 mm) who had cataract surgery and
negative power_posterior chamber IOL implantation (-1.0 to -8.0 dioptres), PCO occurred in 44% after a follow-up of 6 to 36 months (Kohnen & Brauweiler, 1996).

1.2.2.2.1.3 Retinitis pigmentosa

Auffarath et al (Auffarth et al, 1996) found that, after phacoemulsification, patients with retinitis pigmentosa had an incidence of PCO of about 70.7% after 1 to 4 years. That was found to be significantly higher than an age and follow-up matched control group. Ando et al found that retinitis pigmentosa was an independent risk factor for the development of PCO (Ando et al, 2003).

1.2.2.2.1.4 Pseudoexfoliation

In a retrospective study of 197 patients, 99 of whom had pseudoexfoliation syndrome, Kuchle et al (Kuchle et al, 1997) reported an incidence of 45% of PCO in comparison to 9% in the control group.

1.2.2.2.1.5 Glaucoma and phaco-trabeculectomy

The relationship between glaucoma and the incidence of PCO appears to be related mainly to the surgical technique performed or to coexistent diseases. Phaco-trabeculectomy was found to have a decreased incidence of early PCO than combined ECCE and trabeculectomy (Anand et al, 1997). Shin et al (Shin et al, 2002) found that the incidence of PCO did not particularly increase after phaco-trabeculectomy when compared to phacoemulsification. They found, however, that the use of mitomycin C and the presence of diabetes mellitus significantly decreased the rate of PCO. An increased rate of PCO, on the other hand, was reported in eyes having a combined procedure and a limbal-based conjunctival flap when compared to those with a combined procedure and a fornix-based flap (Tezel et al, 1997). Ober et al (Ober et al, 2000) found no difference between silicone and acrylic IOLs in the incidence of PCO after phaco-trabeculectomy.
1.2.2.2.2 Systemic factors

1.2.2.2.2.1 Age

Both experimental and clinical studies have shown the effect of age on the development of PCO. Wormstone and coauthors (Wormstone et al, 1997) found that lens epithelial cell growth rate was age-dependent. They found that LEC count was significantly higher in the capsular bags of children in comparison to adults with senile cataract. Majima (Majima, 1995) showed a higher growth potential of LECs in patients with congenital cataract compared to those with senile cataract. Also, Jamal (Jamal & Solomon, 1993) found that an increased risk of developing epithelial pearls onto the posterior capsular associated with younger age and Stager (Stager, Jr. et al, 2002) reported an incidence of PCO up to 100% in children under 4 years after 2.75 years of follow-up.

1.2.2.2.2 Sex

In an epidemiological study, Ninn-Pedersen et al (Ninn-Pedersen & Bauer, 1997) showed that after about 4 to 5 years, the percentage of patients not having had a Nd:YAG capsulotomy was reduced to around 50% for women and 60% for men. Also, Ando, et al (Ando et al, 2003) found that female sex was an independent risk factor for increased rate of Nd:YAG capsulotomy.

1.2.2.2.3 Diabetes mellitus

Conflicting reports exist regarding the effect of diabetes mellitus on PCO. A lower PCO rate in diabetic patients was reported by Knorz et al (Knorz et al, 1991) in a retrospective study of 939 eyes with an average follow-up of 26.3 months following ECCE and in a prospective study by Zaczek and Zetterstrom (Zaczek & Zetterstrom, 1999) following phacoemulsification and implantation of heparin-coated intraocular lenses. A lower incidence in diabetics was also reported in other studies of PCO in glaucoma (Shin et al, 1998; Shin et al, 2002) and pseudoexfoliation syndrome patients (Kuchle et al, 1997). In a recent prospective randomised clinical trial, Hayashi et al, 2002 (Hayashi et al, 2002), found that both PCO density and the incidence of Nd:YAG capsulotomy were significantly higher in diabetic patients up
to 3 years after surgery. The differences in these studies design, patient populations and method of PCO assessment could explain the differences in their conclusions.
CHAPTER 2

POSTERIOR CAPSULAR OPACIFICATION IN DIABETIC PATIENTS
2 POSTERIOR CAPSULAR OPAQUIFICATION IN DIABETIC PATIENTS

2.1 STUDY OF THE INCIDENCE AND RISK FACTORS OF ND:YAG CAPSULOTOMY IN NON-DIABETIC AND DIABETIC PATIENTS

2.1.1 Introduction

Posterior capsular opacification, in addition to impairing vision, can obscure fundus visualisation and potentially compromise the surveillance and timely treatment of posterior segment pathology such as diabetic retinopathy and macular oedema. Nd:YAG laser capsulotomy, the treatment of choice, is not without complications, some of which can be sight-threatening such as retinal oedema and detachment (Keates et al, 1984), which are particularly important in diabetic patients.

The long-term incidence of PCO in diabetic patients after phacoemulsification has not been separately examined before. Also, although factors such as young age, female gender, extra-capsular cataract extraction (ECCE), retinitis pigmentosa, better preoperative acuity and polymethylmethacrylate (PMMA) IOLs have been identified as risk factors for increased rate of PCO development and/or Nd:YAG capsulotomy (Baratz et al, 2001; Ando et al, 2003), the effect of diabetes mellitus remains uncertain. Some studies have shown an increased (Ionides et al, 1994; Hayashi et al, 2002), and others a decreased risk of PCO development and Nd:YAG capsulotomy in diabetic patients (Zaczek & Zetterstrom, 1999; Knorz et al, 1991). Moreover, none of the studies have investigated the influence of factors such as ethnic origin, postoperative inflammation and diabetes type and duration.

Many recent studies of PCO relied on the quantitative measurement of the density or extent of capsular opacification. While invaluable as an indicator of early lens epithelial cell (LEC) proliferative activity, the reported PCO rates in these studies do not necessarily reflect what might be a clinically significant opacification i.e. one that reduces visual functions or visibility of the posterior segment and thus requires treatment. Moreover, LEC proliferation and migration onto the posterior capsule can
be variable and even show regression at the short- and long-terms (Hollick et al., 1998; Meacock et al., 2001; Findl et al., 2004).

2.1.2 Aims

We undertook this retrospective study to examine the incidence and factors that affect Nd:YAG capsulotomy rate, which was used as a surrogate measure of PCO rate, in a cohort of non-diabetic and diabetic patients in a single medical retina unit at a tertiary referral hospital.

2.1.3 Patients and methods

2.1.3.1 Inclusion & exclusion criteria

After obtaining ethical approval for the study, we reviewed 1223 medical records of a continuous series of patients who underwent phacoemulsification cataract extraction in the medical retina service at Moorfields Eye Hospital between 1994 and 2000. Only one eye was randomly included for patients who had bilateral surgery (n=216). Patients who underwent other anterior segment surgery (e.g. trabeculectomy or keratoplasty) (n=156) and those with unavailable records at the time of the study (n=45) were excluded. Four patients (0.5%) were included who had diagnoses of uveitis (Behcet’s, multifocal choroiditis, sympathetic ophthalmia and Eales disease). The number of included patients was 806, 327 (40.6%) of whom were diabetic.

2.1.3.2 Surgery

The number of included patients was 806, 327 (40.6%) of whom were diabetic. All patients underwent a standard phacoemulsification and implantation of an IOL. Surgery was performed by a consultant or a fellow (306; 38%); or a senior resident (420, 52.1%) attached to the medical retina service. In 80 patients (9.9%), it was not possible to identify the surgeon’s grade at the time of surgery. A corneal incision of 2.8 to 3.2mm was performed on all patients except those who were given PMMA implants where a 5.5mm to 6mm incision and corneal sutures were needed. A circular continuous capsulorhexis was fashioned, the size of which was aimed to just overlap the optic edge. This was typically 5 to 5.5mm, although details of the exact size and position of the lens in relation to the capsule was not routinely recorded.
Hydrodissection was then performed followed by phacoemulsification of the nucleus and manual irrigation-aspiration of cortical lens matter. Intraocular lenses used were either polymethylmethacrylate (PMMA) \( n = 114, 14.2\% \) (MC550, Iolab, \( n = 82 \) or 6840U, Chiron Vision-Iolab, \( n = 32 \)), plate-haptic silicone \( n = 647, 80.3\% \) (Chiron CI0UB, \( n = 100 \); or Chiron Vision CI1UB, \( n = 547 \)) or 3-piece-silicone (LI41U, Iolab) \( n = 45, 5.6\% \). All IOLs were implanted inside the capsular bag except in 9 patients \( (1\%) \), in whom posterior capsular tear necessitated sulcus-fixation.

At the conclusion of the procedure, subconjunctival Betamethasone \((4mg)\) and Cefuroxime \((125mg)\) or Gentamicin were given. After surgery, patients were prescribed Guttae Dexamethasone \(0.1\%\) and Guttae Chloramphenicol \(0.5\%\) QDS for 2 weeks followed by Guttae Dexamethasone \(0.1\%\) BID for 2 weeks. Postoperative evaluation was performed immediately after surgery, within two weeks and at regular intervals thereafter depending on the clinical need.

### 2.1.3.3 Outcome measure and data collection

The principal outcome variable was the performance of Nd:YAG capsulotomy, taken as a surrogate measure for clinically significant PCO. Indications for this procedure were the presence of significant PCO that is: (1) causing visual symptoms such as reduced acuity or glare; or (2) interfering with the visualisation of the posterior segment.

A database file was used for entering all the relevant data including age at surgery, ethnic origin, the medical and surgical history, operative and postoperative details, the surgeon’s grade (resident or fellow/consultant), the duration between surgery and the performance of Nd:YAG capsulotomy and the follow-up time. Information about diabetes mellitus included diabetes type: non-insulin dependent or insulin-dependent, duration (in years) and grade of retinopathy: none, non-proliferative or proliferative. Also, the presence of uveitis and the occurrence of clinically significant postoperative inflammation, i.e. documented inflammatory signs that required additional topical or systemic steroid treatment within 3 months of surgery, was recorded.

### 2.1.3.4 Statistical analysis

The Statistical Package for Social Science (SPSS, v.9; Chicago, Ill.) for Windows software was used for statistical analysis. The median and inter-quartile range were
used for description of continuous data. Survival tables and Kaplan-Meier curves, which accounts for censored data i.e. patients that did not have Nd:YAG laser treatment by the end of their follow-up, were used to derive the cumulative incidence and compare rates of Nd:YAG capsulotomy between patient subgroups. The cumulative incidence was calculated as the number of events (i.e. Nd:YAG capsulotomy) divided by the number of patients at risk at each of the time intervals (No. of patients entering the period less 50% of those lost to follow-up). Confidence intervals for the incidences were calculated using the Wilson score method.

A log rank test was used for bivariate analysis and a backward step-wise Cox-proportional hazard regression for multivariate analysis. A variable qualified for inclusion in the Cox-proportional hazard model if they had a \( p \) value of 0.2 or less or if believed from previous studies to affect the rate of PCO. Post hoc assessment showed that the study sample size had a power of 90% to detect a hazard ratio of 10% to 30% between the two subgroups for variables such as diabetes mellitus, postoperative inflammation, IOL type and vitrectomy over an accrual period of 48 months. The sample size allowed for up to 95% censored data (loss of follow-up or no capsulotomy by the time patients were discharged) in either of the two subgroups and 10% conversion rate (from non-diabetic to diabetic) during the follow-up period. A \( p \) value of <0.05 was considered statistically significant.

**2.1.4 Results**

**2.1.4.1 Patient characteristics**

The demographic and clinical features of the patients are listed in Table 2-1. The median age of the patients was 69.7 years (range=20.2 to 99.3) and the median length of follow-up was 16.6 months (range=1.8 to 74).

**2.1.4.2 Incidences of PCO**

Survival table analysis (Table 2-2) revealed that the incidences of Nd:YAG capsulotomy were 9.9%, 12.3%, 18% and 15.4% after 1,2,3 and 4 years respectively. In non-diabetic patients the incidences were 10.6%, 14.8%, 21.2% and 28.6% and in diabetic patients they were 9%, 9.4%, 15.3% and 5.4% after the same follow-up periods.
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

Table 2-1. Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Non-diabetic</th>
<th>Diabetic</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No.</strong></td>
<td>806</td>
<td>479(59.4%)</td>
<td>327(40.6%)</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>337</td>
<td>189(59.4%)</td>
<td>148(45.3%)</td>
<td>0.12</td>
</tr>
<tr>
<td>Female</td>
<td>469</td>
<td>290(61.8%)</td>
<td>179(54.7%)</td>
<td></td>
</tr>
<tr>
<td><strong>Ethnic origin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>311</td>
<td>229(73.1%)</td>
<td>82(25.1%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asian</td>
<td>99</td>
<td>38(38.4%)</td>
<td>61(61.6%)</td>
<td></td>
</tr>
<tr>
<td>Afro-Caribbean</td>
<td>59</td>
<td>19(32.8%)</td>
<td>40(67.2%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>72</td>
<td>41(57.1%)</td>
<td>31(42.9%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>265</td>
<td>152(57.3%)</td>
<td>113(42.7%)</td>
<td></td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>70</td>
<td>72</td>
<td>67</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IQR</td>
<td>63-77</td>
<td>64-79</td>
<td>61-74</td>
<td></td>
</tr>
<tr>
<td>&lt;= 65 years</td>
<td>283(35.1%)</td>
<td>144(46.8%)</td>
<td>139(42.5%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&gt; 65 years</td>
<td>523(64.9%)</td>
<td>335(53.5%)</td>
<td>188(57.5%)</td>
<td></td>
</tr>
<tr>
<td><strong>Follow-up (months)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>13.8</td>
<td>12.9</td>
<td>14.97</td>
<td>0.001</td>
</tr>
<tr>
<td>IQR</td>
<td>7.3-22.8</td>
<td>6.7-20.07</td>
<td>7.8-26.43</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDDM</td>
<td>-</td>
<td>-</td>
<td>37(11.3%)</td>
<td></td>
</tr>
<tr>
<td>NIDDM</td>
<td>-</td>
<td>-</td>
<td>290(88.7%)</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetic retinopathy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>-</td>
<td>-</td>
<td>104(31.8%)</td>
<td></td>
</tr>
<tr>
<td>NPDR</td>
<td>-</td>
<td>-</td>
<td>137(41.9%)</td>
<td></td>
</tr>
<tr>
<td>PDR</td>
<td>-</td>
<td>-</td>
<td>86(26.3%)</td>
<td></td>
</tr>
<tr>
<td><strong>Retinitis pigmentosa</strong></td>
<td>12(1.5%)</td>
<td>11(2.3%)</td>
<td>1(0.3%)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Surgeon's grade</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resident</td>
<td>420</td>
<td>262(62.1%)</td>
<td>158(48.3%)</td>
<td>0.04</td>
</tr>
<tr>
<td>Fellow/Consultant</td>
<td>306</td>
<td>179(58.4%)</td>
<td>127(39.6%)</td>
<td></td>
</tr>
<tr>
<td>Unknown grade</td>
<td>80</td>
<td>38(47.5%)</td>
<td>42(52.5%)</td>
<td></td>
</tr>
<tr>
<td><strong>IOL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA</td>
<td>114</td>
<td>62(54.6%)</td>
<td>52(45.4%)</td>
<td>0.04</td>
</tr>
<tr>
<td>PH silicone</td>
<td>647</td>
<td>397(60.7%)</td>
<td>250(39.3%)</td>
<td></td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>45</td>
<td>20(44.4%)</td>
<td>25(55.6%)</td>
<td></td>
</tr>
<tr>
<td>Postop inflammation</td>
<td>62</td>
<td>43(68.7%)</td>
<td>19(31.3%)</td>
<td>0.10</td>
</tr>
<tr>
<td>Vitrectomy</td>
<td>114</td>
<td>82(71.4%)</td>
<td>32(28.6%)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

IDDM=insulin-dependent diabetes mellitus; NIDDM=non-insulin dependent diabetes mellitus, NPDR=non-proliferative diabetic retinopathy; PDR=proliferative diabetic retinopathy, PMMA=polymethylmethacrylate; PH=plate-haptic
# Chapter 2: Posterior Capsular Opacification in Diabetic Patients

Table 2-2. Incidences of Nd:YAG capsulotomy in diabetic and non-diabetic patients

<table>
<thead>
<tr>
<th>Time Interval</th>
<th>Non-Diabetic (n=479)</th>
<th>Diabetic (n=327)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of patients :</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No. lost to follow-up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No. of capsulotomy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>% incidence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>95% Confidence interval</td>
<td></td>
</tr>
<tr>
<td>Up to 1 year</td>
<td>479:200</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>10.6</td>
</tr>
<tr>
<td></td>
<td>7.9, 14.1</td>
<td></td>
</tr>
<tr>
<td>&gt;1 year-2 years</td>
<td>239:140</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>14.8</td>
</tr>
<tr>
<td></td>
<td>10.2, 20.9</td>
<td></td>
</tr>
<tr>
<td>&gt;2 years-3 years</td>
<td>74:44</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>21.2</td>
</tr>
<tr>
<td></td>
<td>12.2, 34</td>
<td></td>
</tr>
<tr>
<td>&gt;3 years-4 years</td>
<td>19:10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>28.6</td>
</tr>
<tr>
<td></td>
<td>11.7, 54.7</td>
<td></td>
</tr>
<tr>
<td>&gt;4 years-5 years</td>
<td>5:4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0.56, 2</td>
<td></td>
</tr>
<tr>
<td>No. of patients :</td>
<td>327:118</td>
<td></td>
</tr>
<tr>
<td>No. lost to follow-up</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>No. of capsulotomy</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>% incidence</td>
<td>6.1, 13</td>
<td></td>
</tr>
<tr>
<td>95% Confidence interval</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2.1.4.3 Risk factors for Nd:YAG capsulotomy

We constructed a Cox proportional hazard regression model (Table 2-3) that included gender, age (<65 or ≥ 65), ethnic origin, diabetes mellitus, pars plana vitrectomy, surgeon's grade, IOL type, postoperative inflammation and retinitis pigmentosa as potential risk factors. The model revealed that a decreased risk of Nd:YAG capsulotomy was associated with diabetes mellitus, [HR= 0.69; 95% CI (0.47, 0.99)] and with the use of 3-piece silicone IOLs [HR= 0.25; 95% CI (0.10, 0.63)] while an increased risk was associated with patient age of 65 years or younger [HR=1.58; 95% CI (1.09, 2.27)], postoperative inflammation [HR=2.63; 95% CI (1.56, 4.42)] and vitrectomy surgery [HR=1.85; 95% CI (1.20, 2.83)] (Figures 2-1 a to e).

In the non-diabetic subgroup (Table 2-4), a Cox proportional hazard model that included the same variables (except diabetes mellitus) showed that male gender [HR=1.63; 95% CI (1.04, 2.57); p=0.03], vitrectomy [HR=1.90; 95% CI (1.09, 3.33); p=0.02], postoperative inflammation [HR=2.78; 95% CI (1.51, 5.12); p=0.001] were associated with an increased risk while 3-piece silicone IOL with a reduced risk for Nd:YAG capsulotomy [HR=0.18; 95% CI (0.04, 0.82); p=0.03]. In the diabetic subgroup (Table 2-4), a model that included, instead of diabetes mellitus, diabetes type (IDDM vs. NIDDM), duration, and diabetic retinopathy grade (None, NPDR and PDR), only vitrectomy was significantly associated with an increased risk of Nd:YAG capsulotomy [HR=2.47; 95% CI (1.26, 4.83); p=0.008].
Table 2-3. Multivariate Cox regression analysis of the factors associated with Nd:YAG Capsulotomy

<table>
<thead>
<tr>
<th></th>
<th>Hazard ratio</th>
<th>95% Confidence interval</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diabetes mellitus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.69</td>
<td>0.47, 0.99</td>
<td>0.047</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;65</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;=65</td>
<td>1.58</td>
<td>1.09, 2.27</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Postop inflammation (within 3 months)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2.63</td>
<td>1.56, 4.42</td>
<td>0.0003</td>
</tr>
<tr>
<td><strong>IOL type</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PH silicone</td>
<td>0.94</td>
<td>0.59, 1.49</td>
<td>0.79</td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>0.25</td>
<td>0.10, 0.63</td>
<td>0.003</td>
</tr>
<tr>
<td><strong>Vitrectomy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.85</td>
<td>1.20, 2.83</td>
<td>0.005</td>
</tr>
</tbody>
</table>
Table 2-4. Multivariate Cox regression analysis of the factors associated with Nd:YAG capsulotomy in the two subgroups

<table>
<thead>
<tr>
<th></th>
<th>Non-diabetic subgroup</th>
<th></th>
<th></th>
<th>Diabetic subgroup</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hazard ratio</td>
<td>95% Confidence interval</td>
<td>p</td>
<td>Hazard ratio</td>
<td>95% Confidence interval</td>
<td>p</td>
</tr>
<tr>
<td>Surgeon grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resident</td>
<td>0.86</td>
<td>0.45, 2.10</td>
<td>0.74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultant</td>
<td>1.98</td>
<td>0.85, 4.57</td>
<td>0.11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>Reference</td>
<td></td>
<td></td>
<td>0.86</td>
<td>0.45, 2.10</td>
<td>0.74</td>
</tr>
<tr>
<td>Male</td>
<td>1.63</td>
<td>1.04, 2.57</td>
<td>0.03</td>
<td>1.98</td>
<td>0.85, 4.57</td>
<td>0.11</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;65</td>
<td>Reference</td>
<td></td>
<td></td>
<td>0.86</td>
<td>0.45, 2.10</td>
<td>0.74</td>
</tr>
<tr>
<td>&lt;=65</td>
<td>1.49</td>
<td>0.94, 2.36</td>
<td>0.09</td>
<td>1.98</td>
<td>0.85, 4.57</td>
<td>0.11</td>
</tr>
<tr>
<td>IOL type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>Reference</td>
<td></td>
<td></td>
<td>0.86</td>
<td>0.45, 2.10</td>
<td>0.74</td>
</tr>
<tr>
<td>PH silicone</td>
<td>6.98</td>
<td>1.65, 29.46</td>
<td>0.008</td>
<td>1.98</td>
<td>0.85, 4.57</td>
<td>0.11</td>
</tr>
<tr>
<td>PMMA</td>
<td>5.48</td>
<td>1.22, 24.68</td>
<td>0.03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postop inflammation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
<td>0.86</td>
<td>0.45, 2.10</td>
<td>0.74</td>
</tr>
<tr>
<td>Yes</td>
<td>2.78</td>
<td>1.51, 5.12</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitrectomy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
<td>0.86</td>
<td>0.45, 2.10</td>
<td>0.74</td>
</tr>
<tr>
<td>Yes</td>
<td>1.90</td>
<td>1.09, 3.33</td>
<td>0.03</td>
<td>2.47</td>
<td>1.26, 4.83</td>
<td>0.008</td>
</tr>
</tbody>
</table>
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

a. The effect of age on the rate of Nd:YAG capsulotomy

b. The effect of diabetes mellitus on the rate of Nd:YAG capsulotomy
c. The effect of IOL type on the rate of Nd:YAG capsulotomy

![Graph showing the effect of IOL type on the rate of Nd:YAG capsulotomy.]

- 3-piece silicone
- 3-piece silicone-censored
- PH silicone
- PH silicone-censored
- PMMA
- PMMA-censored

d. The effect of developing postoperative uveitis on the rate of Nd:YAG capsulotomy

![Graph showing the effect of postoperative uveitis on the rate of Nd:YAG capsulotomy.]

- Yes
- Yes-censored
- No
- No-censored
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

2.1.5 Discussion

2.1.5.1 Incidence of Nd:YAG capsulotomy

In this study, we estimated the annual incidence rates of Nd:YAG capsulotomy were 9.5%, 6.6%, 5.3%, and 3.6% after 3, 5, 7, and 10 years of follow-up, respectively. While the incidence rates were consistent over the first 5 years, they decreased to 2.2% in the sixth year and dropped to 0.3% in the eighth year (Table 2.1). The numbers of patients analyzed and the conclusion about the incidence in each year are shown in Table 2.1.

![Figure 2-1. Kaplan-Meier curves of the factors affecting the rate of Nd:YAG capsulotomy. An increased Nd:YAG capsulotomy rates is demonstrated in patients of 65 year or younger (a), in non-diabetic patients (b), in patients with plate-haptic silicone and PMMA implants compared to 3-piece silicone IOLs (c), in patients who developed postoperative inflammation (d) and in patients who underwent vitrectomy (e).](image)

**Figure 2-1.** Kaplan-Meier curves of the factors affecting the rate of Nd:YAG capsulotomy. An increased Nd:YAG capsulotomy rates is demonstrated in patients of 65 year or younger (a), in non-diabetic patients (b), in patients with plate-haptic silicone and PMMA implants compared to 3-piece silicone IOLs (c), in patients who developed postoperative inflammation (d) and in patients who underwent vitrectomy (e).

The effect of vitrectomy operation on the rate of Nd:YAG capsulotomy

It is well known that vitrectomy operation can significantly reduce the incidence of Nd:YAG capsulotomy in diabetic patients. In our study, we found that the incidence of Nd:YAG capsulotomy in patients who underwent vitrectomy was significantly lower than in those who did not undergo vitrectomy. The results are shown in Figure 2-1(e).

The effect of age on the rate of Nd:YAG capsulotomy

We observed, as suggested by several studies (Gentile et al., 2004; Chen et al., 2003), that the incidence of Nd:YAG capsulotomy did not increase with age. While this can be attributed to the improvement in surgical techniques, especially with the use of small incision and foldable IOLs, we also noted a possible natural variation in the rate of Nd:YAG capsulotomy in elderly patients. This finding is supported by several studies (McCarthy et al., 1993; Matarica et al., 2002), which showed that the incidence of Nd:YAG capsulotomy was lower in older patients.

The effect of diabetes complications on the rate of Nd:YAG capsulotomy

Our results, as well as those from other studies, suggest that diabetes complications can increase the risk of Nd:YAG capsulotomy. This finding is supported by the results from our study, which showed that patients with diabetes had a significantly higher risk of Nd:YAG capsulotomy compared to non-diabetic patients.

The effect of IOL type on the rate of Nd:YAG capsulotomy

We found that the incidence of Nd:YAG capsulotomy was significantly lower in patients with plate-haptic silicone and PMMA implants compared to those with 3-piece silicone IOLs. This finding is consistent with several studies that have shown a lower incidence of Nd:YAG capsulotomy in patients with plate-haptic implants.

The effect of postoperative inflammation on the rate of Nd:YAG capsulotomy

Our study, as well as others, has shown that postoperative inflammation can increase the risk of Nd:YAG capsulotomy. In our study, we found that patients who developed postoperative inflammation had a significantly higher risk of Nd:YAG capsulotomy compared to those who did not develop inflammation.

91
2.1.5 Discussion

2.1.5.1 Incidences of Nd:YAG capsulotomy

In this study, we estimated that the incidences of Nd:YAG capsulotomy were 9.9%, 12.3%, 18% and 15.4% after 1, 2, 3 and 4 years of follow-up, respectively. While the incidences progressively increased within the first 3 postoperative years in the two subgroups (from 10.6% to 22.2% and from 9% to 15.3%), they were consistently lower in the diabetic subgroup. During the fourth year, the incidence increased to 28.6% in the non-diabetic and dropped to 5.3% in the diabetic group (Table 2-3). The numbers of patients afterwards were too small to draw any useful conclusions about the incidences in either group.

These incidences are generally similar to those reported by Baratz et al (Baratz et al, 2001) and Ando et al (Ando et al, 2003). They estimated cumulative probabilities of 15 to 18.5% and 32.7 to 33% after 3 and 5 years of follow-up, respectively. Both studies, however, reported lower probabilities within one year of follow-up (6% & 1.95%). This could be related to the inclusion in their studies of patients who had hydrophobic acrylic implants (1.2% and 12.6%). These implants were proved to have a lower PCO rate than PMMA and silicone implants (Ingram et al, 1980; Ursell et al, 1998; Hollick et al, 1999c) and the patients must have been entered late in their studies and hence perhaps comprised a significant proportion of those followed up within the first year.

2.1.5.2 Effect of DM on the rate of PCO

We noticed, as suggested by Baratz study (Baratz et al, 2001), that the steady increase of capsulotomy rate did not appear to continue. While this can be attributed to the improvement in the surgical technique, especially with the use of small incisions and foldable IOLs, or even to a possible natural decline in LEC survival suggested in experimental studies (Kato et al, 1997b; Saika et al, 2002), our findings (the lower incidence of Nd:YAG capsulotomy, the sharp drop after the third year and the lower risk of Nd:YAG capsulotomy in diabetic patients) suggest a role for the presence of diabetes mellitus in lowering the long-term incidence of Nd:YAG capsulotomy and possibly PCO.
While neither of the above studies found a difference between diabetic and non-diabetic patients, conflicting reports exist regarding the rate of PCO in the two groups. Lower PCO rates in diabetic patients were reported by Knorz and coauthor (Knorz et al, 1991) in a retrospective study of 939 eyes following ECCE and an average follow-up of 26.3 months and by Zaczek and Zetterstrom (Zaczek & Zetterstrom, 1999) in a prospective study following phacoemulsification and implantation of heparin-coated IOLs. In a prospective randomised trial, Hayashi et al (Hayashi et al, 2002) found that both PCO density and Nd:YAG capsulotomy rate were significantly higher in diabetic patients after 3 years of follow-up.

The conflict of reported PCO rates between studies could be related to variation in the clinical features of their patients, the threshold for performing Nd:YAG capsulotomy or the duration of follow-up. The progression of retinopathy reported to occur after cataract extraction (Liao & Ku, 2003; Hauser et al, 2004) could increase the clinician's threshold to perform Nd:YAG capsulotomy for fear of inducing macular oedema or because the decline in visual acuity could be attributed to the retinopathy when in fact PCO could, at least partly, be contributory to causing the poor vision. However, a plausible biological explanation for the lower PCO rate in diabetics can be related to the detrimental effect of accumulating intracellular sorbitol (Kinoshita, 1974; Lin et al, 1991; Takamura et al, 2003; Ramana et al, 2003) and that of free radicals and oxidative stress (Hothersall et al, 1988; Kubo et al, 2004) on proliferation and survival of LECs and their decreased density in the diabetic capsular bag (Saitoh et al, 1990; Struck et al, 2000). These effects, presumably reinforced by the longer postoperative duration, perhaps explain the drop in PCO rate in diabetics that manifested after the third year in our series (Table 2-2).

2.1.5.3 Other risk factors of PCO in non-diabetic and diabetic patients

We also found that Nd:YAG capsulotomy was more likely in patients who were 65 years or younger, those who underwent pars plana vitrectomy or developed postoperative inflammation within 3 months and with implantation of PMMA or plate-haptic silicone IOLs (Figures 2-1 a to e). While, in addition, male sex increased the risk of Nd:YAG capsulotomy and age had a non-significant effect in non-diabetic patients, only vitrectomy increased the risk in diabetic patients. The disturbance of LEC metabolism induced by the presence of diabetes or, perhaps, the relatively
smaller sample sizes might have effaced the effect of some of the risk factors in the subgroups.

2.1.5.3.1 Age

The increased Nd:YAG capsulotomy rate in younger individuals has been attributed to the increased proliferative capacity of the LECs in younger patients demonstrated in experimental studies (Liu et al, 1996; Wormstone et al, 1997). This can also conceivably be due to the increased visual demands in younger patients.

2.1.5.3.2 Pars plana vitrectomy

The increased Nd:YAG capsulotomy rate in patients who underwent pars plana vitrectomy concurs with the findings by Helbig et al (Helbig et al, 1996), and Pinter and Sugar (Pinter & Sugar, 1999). This could be related to increased LEC proliferation or collagen formation as a result of surgical trauma. The development of posterior capsular plaques commonly described during cataract extraction after pars plana vitrectomy indirectly supports this hypothesis (Grusha et al, 1998; Pinter & Sugar, 1999; Chang et al, 2002). Another explanation is the possible increased exposure to retina-derived growth factors that could stimulate LEC proliferation (Jacob et al, 1988). This was suggested by Jones et al (Jones et al, 1995), who described massive LEC proliferation at the edge of the capsulotomy in 6 of 8 eyes, all of which had posterior segment pathology.

2.1.5.3.3 Diabetic retinopathy

In our study, as in the study by Hayashi et al, 2002 (Hayashi et al, 2002), although retinopathy had no significant effect on Nd:YAG capsulotomy rate, a possible effect could not be completely ruled out. The forward diffusion of retina-derived growth factors into the anterior segment (Aiello et al, 1994), which can be enhanced by vitrectomy (Noma et al, 2002), could provide a stimulatory drive for LEC proliferation. This was also suggested in Jones’ study (Jones et al, 1995) as 4 of their patients had proliferative diabetic retinopathy.
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

2.1.5.3.4 IOLs: Polymethylmethacrylate (PMMA) and plate-haptic silicone versus 3-piece silicone

PMMA and plate-haptic silicone IOLs were associated with a higher risk for Nd:YAG capsulotomy in comparison with 3-piece-silicone IOLs. This is in agreement with other studies that have shown a higher PCO rate with PMMA when compared to 3-piece silicone IOLs (Hayashi et al, 1998c; Olson & Crandall, 1998). In earlier studies by Mamalis et al (Mamalis et al, 1996b) and Cumming et al (Cumming, 1993) a lower rate of PCO with plate-haptic silicone IOLs than with 3-piece silicone IOLs was reported. In a postmortem analysis of the Nd:YAG rates with different IOLs, Apple et al (Apple et al, 2001) found that foldable IOLs had a lower rate than rigid PMMA IOLs (14.1% vs. 31.1%). Schmidbauer et al (Schmidbauer et al, 2001b) later reported that 3-piece silicone IOLs had Nd:YAG capsulotomy rates between 14.5% to 23.3% and plate-haptic silicone 15.3% to 25%. The rates vary between small-hole and large-hole implants (possibly due to the advances in surgical technique rather than to the hole size).

2.1.5.3.5 Postoperative inflammation

Our study also suggests an independent risk associated with the occurrence of postoperative inflammation for the development of PCO. This relationship, which is consistent with the clinical impression of many surgeons, has not been suggested in a clinical study before. The interaction between the presence of residual LECs, their proliferation and the development of postoperative inflammation seem to pose a clinical conundrum, similar to the evolutionary ones, of ‘which came first?’ Clinical and experimental studies have demonstrated that cytokine release from residual LECs after cataract extraction can excite postoperative inflammation (Nishi & Nishi, 1992; Nishi et al, 1992; Nishi et al, 1999). On the other hand, the rate of LEC proliferation has been shown to increase in a protein rich environment (Quinlan et al, 1997; Davidson et al, 2000; Wallentin et al, 1998; Wormstone et al, 1997), which would be similar to that resulting from inflammation due to the influx of growth factors through the damaged blood-aqueous barrier and the consequent decreased concentration of aqueous transforming growth factor-beta (TGF-β) that would normally inhibit LEC proliferation (Wormstone et al, 2002; de Boer et al, 1994). It is most likely that these two mechanisms, as intimately consequential as they may look,
are independent of each other as several other factors are associated with postoperative inflammation, such as incision size (Oshika et al, 1994; Oshika et al, 1998a) and surgical technique (Pande et al, 1996b). In addition LECs can grow independently of external growth factors (Wormstone et al, 1997).

This finding raises the question of whether prophylactic or more aggressive treatment of postoperative inflammation would be a worthwhile strategy in patients at risk of developing postoperative inflammation and in the presence of other risk factors e.g. young age. The inhibitory effect of steroids and other antiinflammatory medications on the LECs proliferation and extracellular matrix formation has been suggested in experimental studies (Mansfield et al, 2004; Cortina et al, 1997) but remains to be established clinically.

2.1.5.3.6 Gender

The relationship between gender and Nd:YAG capsulotomy is not clear and is difficult to explain. In this study we found that, in contrast to that by Ando et al (Ando et al, 2003), in the non-diabetic group, men were more likely to have Nd:YAG capsulotomy than women. Ando et al explained the excess of PCO in the female patients by the gender difference in attitude towards health problems, with more women seeking medical advice and reporting symptoms more readily than men. This, however, varies across different cultures and the presence of more ethnically diverse population in our study might have reversed that effect. Moreover, in women, the protective effect of oestrogen against TGF-β (Hales et al, 1997; Chen et al, 2004), implicated in cellular trans-differentiation and extracellular matrix formation for PCO (Davidson et al, 2000; Wormstone et al, 2002), provides a possible hormonal explanation in favour of our finding.

2.1.6 Limitations

The retrospective nature is an apparent limitation of this study because of the inability to account for all potential confounders. Attempts to avoid bias because of the retrospective design of this study included: the large sample size, the continuous nature of the series, drawing the sample from a single service in the hospital to ensure as much as possible homogeneity of the indications for Nd:YAG capsulotomy and the random inclusion of one eye in patients with bilateral surgeries. Also, we
used multivariate analysis to identify the independent risk factors after accounting for all possible clinical and surgery-related confounders.

2.1.7 Conclusion

Despite its limitations, this study is an addition to other large-scale studies that aimed to identify the potential risk factors of developing clinically significant PCO, which is the preliminary step towards developing strategies of preventing its development and planning for the review and treatment of predisposed patients. It suggests that diabetic patients have a lower long-term incidence and risk of PCO and an increased risk of PCO in association with younger age, postoperative inflammation, vitrectomy surgery and PMMA or plate-haptic silicone implants in comparison to 3-piece silicone implants. Future studies should perhaps aim at further exploring the long-term effect of diabetes and of prophylactic control of postoperative inflammation in predisposed patients on the incidence and risk of developing PCO.
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

2.2 POSTERIOR CAPSULAR OPAQUE ACCESSION AFTER IMPLANTATION OF PLATE HAPTIC SILICONE AND HYDROPHOBIC ACRYLIC INTRAOCULAR LENSES IN DIABETIC PATIENTS: A PILOT RANDOMIZED CLINICAL TRIAL

2.2.1 Introduction

The IOL physical properties, including the optic material and design were shown to be important determinants of the rate of PCO development (Ursell et al, 1998; Hollick et al, 1999). Also, postoperative breakdown of the blood-aqueous barrier was related to the type of IOL (Abela-Formanek et al, 2002; Miyake et al, 1996; Schauersberger et al, 1999) and could potentially affect the rate of PCO development.

Chiron Cl1UB (Bausch & Lomb) and AcrySof MA 60 BM (Alcon Inc.) are two of the commonly used implants that are made of different materials and have different designs. The former is a single-piece second-generation silicone implant that has a 6-mm biconvex optic, plate-haptics and an overall diameter of 10.5 mm (Figure 1-4). The latter is a 3-piece hydrophobic acrylic implant that has a 6-mm biconvex optic and a polymethylmethacrylate haptics that make 10° angles with the optic and an overall diameter of 12.5 mm. Chiron Cl1UB IOL is normally implanted using an injector, which allows introduction of the IOL through a relatively small corneal incision (3.2 to 3.5 mm). Acrysof hydrophobic acrylic IOL, on the other hand, is inserted using lens forceps and needs corneal incision enlargement. This, in addition to increasing the incidence of wound-related complications (Kumar et al, 2001), was found to increase blood-aqueous barrier breakdown and postoperative inflammatory reaction (Oshika et al, 1992; Pande et al, 1996; Chee et al, 1999). Moreover, some studies have established a greater inflammatory response and blood-aqueous barrier breakdown after hydrophobic acrylic IOL implantation (Abela-Formanek et al, 2002; Miyake et al, 1996). In the meantime, previous studies of plate-haptic silicone IOLs have established favourable results (Maar et al, 2002; Kent et al, 1997) and
suggested a lower PCO rate than with 3-piece silicone IOLs (Cumming, 1993; Mamalis et al, 1996b).

In diabetic patients, posterior capsular opacification obstructs the posterior segment view and can interfere with timely diagnosis and treatment of sight-threatening retinopathy and postoperative inflammation was shown to occur more frequently in diabetic patients, especially those with diabetic retinopathy (Zaczek & Zetterstrom, 1998). Comparison of the above two implants in diabetic patients has not been previously published.

### 2.2.2 Aims

In this pilot randomised clinical trial, we aimed to compare the magnitude of inflammation and extent of PCO up to one year after surgery in a group of diabetic patients who were randomised to be given one the above two IOLs.

### 2.2.3 Patients and methods

After approval of the study protocol by Moorfields ethical committee, patients were recruited consecutively from those who had diabetes mellitus and were listed for phacoemulsification cataract extraction. The study was performed in accordance with the tenets of Helsinki treaty.

#### 2.2.3.1 Inclusion and exclusion criteria

Recruitment was carried out between March 2001 and February 2002. Patients were considered eligible for inclusion if they were diagnosed with diabetes mellitus (according to the World Health Organization and American Diabetic Association criteria), had cataract sufficient to either cause visual disturbance or impair the fundus view and gave consent to be included in the study. Both type I and type II diabetic patients were eligible.

Exclusion criteria included patients on oral steroids or medications for glaucoma, coexistent ocular disease unrelated to diabetes that were likely to reduce visual acuity, e.g. age-related macular degeneration, amblyopia or retinal venous occlusion. Also, patients with iris neovascularisation or those who had had prior intraocular
surgery, e.g. trabeculectomy or vitrectomy, were excluded. Also, capsular complication lead to the patient being excluded and replaced.

2.2.3.2 Randomisation

Patients were randomised when in the operating theatre using a computer-generated random number to have either an injectable plate-haptic silicone (Chiron, C11UB, Bausch and Lomb) or a hydrophobic acrylic (AcrySof, MA60BM, Alcon) IOL. The C11UB plate-haptic silicone IOL has a 6-mm biconvex surface optic and an overall diameter of 10.5 mm (Figure 1-4). The hydrophobic acrylic IOL, also, has a 6-mm biconvex optic but polymethylmethacrylate haptics that make an angle of 10° and an overall diameter of 12.5 mm.

2.2.3.3 Preoperative management

Before surgery, mydriasis was achieved using G. Phenylepherine 5% and G. Cyclopentolate 1% six times within an hour and a half prior to surgery. Topical anaesthesia was used on all patients using G. Amethocaine and that was coupled with a single quadrant subtenon injection of 3 ml of Lignocaine in 2 patients. Preoperative assessment included measuring the best-corrected visual acuity (BCVA) using the logarithm of the minimum angle of resolution (logMAR) chart at 4 meters in addition to routine anterior and posterior segment examination.

2.2.3.4 Surgery

A standard phacoemulsification was carried out by a single surgeon (JGD) through a 3.2 mm self-sealing clear corneal section. Hydroxypropylmethylcellulose (HPMC) viscoelastic was used to fill the anterior chamber and a continuous curvilinear capsulorhexis was performed followed by hydrodissection of the nucleus and divide-and-conquer removal of the nucleus. Manual aspiration of cortical lens matter was conducted using a Simcoe irrigation-aspiration cannula and a balanced salt solution containing 1 ml of 1:1000 adrenaline per 500 ml. No attempt was made to remove the subcapsular LECs. The viscoelastic was then used to fill in the capsular bag before placement of the IOL. The occurrence of a posterior capsular tear or radial extension of the capsulorhexis edge led to the patient being excluded.
2.2.3.5 Postoperative management

Patients were routinely examined immediately after surgery and prescribed G. Dexamethasone 0.1% four times a day for two weeks then twice a day for two weeks, and G. Chloramphenicol four times a day for two weeks. Acetazolamide (Diamox) 250mg QDS for 2 days was prescribed for any elevation of intraocular pressure above 21 mmHg. For the purpose of the study, patients were reviewed at 2-3 weeks, 6 months and 12 months and additional visits were arranged, if needed, for assessment and treatment of postoperative inflammation and/or diabetic retinopathy (Dowler et al, 1999; Dowler & Hykin, 2001).

At each of the postoperative visit, assessment was made of anterior capsular opening and posterior capsular opacification as well as of the anterior chamber flare and cells using Kowa FC 1000 laser flare-cell meter. Seven consecutive readings were taken and after discarding the highest and lowest values, the average of the remaining readings was taken. The flare was expressed as photons/millisecond and the cells as number/0.075 mm³. Also, logMAR BCVA at 4 meters and Pelli-Robson contrast sensitivity at 1 meter were measured at each visit.

2.2.3.6 Posterior capsule imaging system

Standardized retro-illumination photographs were taken at each of the 3 visits using St Thomas’ digital retro-illumination camera system, described in more details elsewhere (1.1.5.2.3.2.3.2. Digital photography). The system is based on a Zeiss 120 slit lamp frame with specially adapted optics to provide axial illumination to the camera light path from a flash pack through a fibre-optic cable and the images are acquired through a 420 digital camera (Eastman-Kodak, Rochester, NY). The system produces high definition, evenly illuminated images of the posterior capsule that are accessed directly by computer. The reproducibility of the system was assessed before and its short-term variability was estimated to be less than 10% (Hollick et al, 1999c).

Only one observer carried out the analysis for the PCO pictures. Because of the distinctive shapes of the IOLs, the observer could not be masked to the IOL type. The area of the posterior capsule assessed was that not obscured by the anterior capsular rim (the mask). That area, which corresponds to that of the anterior capsular opening, was measured in pixels after being defined manually on a 21-inch monitor.
screen using a mouse. Dedicated software was used to calculate the area of opacity using a technique known as image segmentation. The software allows separation of the pixels into binary classes of opaque and clear areas. The areas of opacified posterior capsule are characterized by having an increased texture of the corresponding area of the image, whereas clear areas have little or no texture. From the binary values the area of PCO is calculated and expressed as percentage of the mask area.

2.2.3.7 Statistical analysis

The primary outcome of interest was the percentage of the area of opacified posterior capsule. Other outcome measures were anterior chamber flare value and cell count, anterior capsular opening size, logMAR BCVA and Pelli-Robson contrast sensitivity.

For the purpose of description, the mean and standard deviation (SD) were used. Categorical data were compared using the Chi-squared test. Between-group comparison of the percentage of the area of PCO, flare value, cell count and the size of the anterior capsular opening (in pixels) at the different visits between the two groups was carried out using either independent Student-t or Mann-Whitney test after checking the data for normality of distribution. Within-group analysis of the changes in the above measurements over the follow-up period in each group was carried out using Friedman within-group analysis. A $p$ value of $<0.05$ was considered statistically significant. A post hoc analysis showed that the study had between 97.9% and 99% power for 2-sided and 1-sided tests, respectively, to detect the difference in the area of PCO.

2.2.4 Results

2.2.4.1 Patient characteristics

We recruited 43 patients between March 2001 and February 2002, three of whom opted out. Four patients were excluded because two of those randomised to acrylic and one randomised to plate-haptic silicone IOL had posterior capsular tears. Another patient, who was randomised to a plate-haptic silicone IOL, had a radial extension of the capsulorhexis and was excluded, which left 35 patients. During the study 2 patients died and the overall follow-up rate was 60% after 1 year. The
recruitment was terminated in February 2002 after the results suggested increased PCO in patients with plate-haptic silicone IOLs.

Demographic data of the two groups of patients are detailed in Table 2-5. There was no significant difference in the mean age, preoperative logMAR BCVA, the gender distribution or grade of diabetic retinopathy between the two groups.

Table 2-5. Clinical features of patients in the non-diabetic and diabetic groups

<table>
<thead>
<tr>
<th></th>
<th>PH Silicone (N=15)</th>
<th>Hydrophobic Acrylic (No=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>72.5(9.6)</td>
<td>68.6(12.1)</td>
</tr>
<tr>
<td>Median</td>
<td>71</td>
<td>69.3</td>
</tr>
<tr>
<td>IQR</td>
<td>65.2-80.3</td>
<td>62.2-75.8</td>
</tr>
<tr>
<td>M:F</td>
<td>8:7</td>
<td>9:11</td>
</tr>
<tr>
<td><strong>IDDM: NIDDM</strong></td>
<td>2:13</td>
<td>2:18</td>
</tr>
<tr>
<td><strong>Diabetic retinopathy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>NPDR</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>PDR</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td><strong>Preop logMAR BCVA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>0.66(0.8)</td>
<td>0.62(0.7)</td>
</tr>
<tr>
<td>Median</td>
<td>.38</td>
<td>0.51</td>
</tr>
<tr>
<td>IQR</td>
<td>0.38 to 0.80</td>
<td>0.51 to 0.96</td>
</tr>
</tbody>
</table>

SD=standard deviation; IQR=interquartile range, PH=plate-haptic; SD=standard deviation; M=male; F=female; IDDM=insulin-dependent diabetes mellitus; NIDDM=non-insulin-dependent diabetes mellitus.
2.2.4.2 Between-group analysis: inflammatory indices, ACO and PCO difference between the two groups

Between-group analysis (Table 2-6 & Figures 2-2, 2-3 & 2-4) showed that at 2-3 weeks, there was a higher flare value in the hydrophobic acrylic than in the PH silicone group but the difference was only of borderline significance ($p=0.08$). No significant difference was found in cell count, size of the anterior capsular opening (the mask size) or the percentage of PCO between the two groups. Within the first month, 5 patients developed clinically significant inflammation that required additional topical steroid treatment, 3 in the PH silicone IOL group (20%) and 2 in the hydrophobic acrylic group (10%). This difference was not statistically significant.

At 6 and 12 months, there was no significant difference in flare value or cell count between the two groups. At 6 months, the anterior capsular opening size was significantly smaller in the PH silicone group ($p=0.04$) but the difference was not statistically significant at 12 months ($p=0.08$). The average percentage area of PCO was significantly greater in patients with PH silicone than in those with hydrophobic acrylic IOLs ($p=0.002 & p=0.002$; at 6 and 12 months, respectively). LogMAR visual acuity and Pelli-Robson contrast sensitivity scores were not significantly different between the two groups at any postoperative visit.
### Table 2-6. Anterior chamber reaction and percentage of PCO at the different postoperative periods

<table>
<thead>
<tr>
<th></th>
<th>PH silicone</th>
<th>Hydrophobic acrylic</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>2-3 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AC Flare</td>
<td>15.3 (7.3)</td>
<td>26.9 (18.1)</td>
<td>0.08</td>
</tr>
<tr>
<td>AC cells</td>
<td>2.9 (2.5)</td>
<td>6.3 (7.9)</td>
<td>0.2</td>
</tr>
<tr>
<td>Mask size in pixels†</td>
<td>431941.3 (82675.9)</td>
<td>411965.5 (77615.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>% of PCO</td>
<td>10 (13.2)</td>
<td>10.3 (8.3)</td>
<td>0.9</td>
</tr>
<tr>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AC Flare</td>
<td>11.1 (4.3)</td>
<td>11.2 (5.4)</td>
<td>0.9</td>
</tr>
<tr>
<td>AC cells</td>
<td>0.03 (0.08)</td>
<td>0.10 (0.2)</td>
<td>0.5‡</td>
</tr>
<tr>
<td>Mask size in pixels†</td>
<td>371652.1 (93355.7)</td>
<td>440504.2 (56537.8)</td>
<td>0.04</td>
</tr>
<tr>
<td>% of PCO</td>
<td>27.2 (13.9)</td>
<td>10.9 (8.7)</td>
<td>0.002</td>
</tr>
<tr>
<td>12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AC Flare</td>
<td>9.5 (3.2)</td>
<td>11.5 (7.5)</td>
<td>0.5</td>
</tr>
<tr>
<td>AC cells</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0.9</td>
</tr>
<tr>
<td>Mask size in pixels†</td>
<td>383974.1 (104230.7)</td>
<td>443102.3 (61838.5)</td>
<td>0.08</td>
</tr>
<tr>
<td>% of PCO</td>
<td>57.7 (41.1)</td>
<td>13.9 (11.1)</td>
<td>0.002‡</td>
</tr>
</tbody>
</table>

PH=plate-haptic, SD=standard deviation; AC=anterior chamber

* Between-group analysis.

† Corresponds to the size of the anterior capsular opening.

‡ Mann-Whitney test used for comparison
2.2.4.3 Within-group analysis: the inflammatory indices, ACO and PCO in each group over the follow-up period

Within group analysis (Figures 2-2, 2-3 & 2-4) showed a significant reduction in anterior chamber flare value in the hydrophobic acrylic group ($p=0.01$) but not in the PH silicone group ($p=0.47$). Cell count did not change significantly in the two groups over the period of follow-up. The mask size decreased over the follow-up period in both groups but the difference was of borderline significance only in the PH silicone group ($p=0.09$ & 0.9). There was a statistically significant increase in the area of opacified posterior capsule in the PH group ($p=0.003$) but the difference was not significant in the hydrophobic acrylic group ($p=0.4$) (Figure 2-5).

One of the patients in the PH silicone IOL group required Nd:YAG capsulotomy after one year and 4 patients in the hydrophobic acrylic group had less area of PCO at 1 year than at 6 months (Figure 2-6). There was no significant difference in logMAR BCVA or Pelli-Robson CS scores between the three visits in either of the two groups.
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

Figure 2-2. Anterior chamber flare (a) and cells (b) in the two groups of patients. Both flare and cells decreased significantly as the time went by, but there was only a borderline significant increase of flare in the Acrylic group in the early postoperative period.
Figure 2-3. The mask size (a) and the percentage of the area of opacified posterior capsule (b) in the two groups of patients. There was a decrease of the mask size in the plate-haptic silicone group and an increase in the area of PCO in the plate-haptic silicone IOL group. Only the latter was statistically significant.
2.2.6 Discussion

2.2.6.1 Postoperative inflammation

The hydrophilic acrylic IOL was associated with increased inflammation. Although differences were not statistically significant, they are not uncommon in patients with phakic type of cataract or cataract surgery with hydrophilic acrylic IOLs (Schaumberger et al., 1997). The mechanical stress induced by the inelastic cohesive silicone hydrogel acrylic IOLs (Cahill et al., 1998) or the hydrophilic acrylic IOLs (Olitsky et al., 1997) could all have contributed to increasing the iris neovascular and cell count in these patients. Notably, however, these changes were not significantly different between the two groups in the absence of clinically significant postoperative inflammation that would require additional medical intervention or surgical intervention.

In our study we observed that patients with hydrophilic acrylic IOLs had better visual acuity at 6 months and 1 year, although the difference was not statistically significant. Although this may reflect the relative paucity of inflammatory cells in these eyes, it is likely that postoperative inflammation was a mild influence on the study outcome since both groups were comparable with respect to the relatively similar baseline characteristics.

2.2.6.2 Anterior capsular contraction

We found that anterior capsular contraction was significantly smaller in the posterior silicone group but there was no statistically significant difference between the two groups. The hydrophilic acrylic IOLs were associated with higher anterior capsular opacification rates in addition to increased incidence of posterior capsular fibrosis in comparison to hydrophilic acrylic IOLs.

Figure 2-4. Visual acuity (a) and contrast sensitivity (b) in the two groups of patients. Although both function showed some deterioration over time, the differences were not statistically significant.
2.2.5 Discussion

2.2.5.1 Postoperative inflammation

The hydrophobic acrylic IOL was associated with increased flare and cells within the first 2-3 weeks after surgery. Although the differences were not statistically significant, they are in agreement with other studies, which showed increased flare in the early postoperative period with this type of implant in comparison with hydrophilic acrylic and silicone IOLs (Schauersberger et al, 1999).

The mechanical trauma induced by the use of forceps to introduce the hydrophobic acrylic implant, the need for a larger incision (Oshika et al, 1994; Oshika et al, 1998a) or the hydrophobic nature (Miyake et al, 1996) could all have contributed to increasing the flare intensity and cell count in these patients. Notably, however, these changes were not clinically significant as there was no difference between the two groups in the incidence of clinically significant postoperative inflammation (i.e. requiring additional steroid treatment) at any time in the postoperative period.

In a study by Zaczek and Zetterstrom, 1998 (Zaczek & Zetterstrom, 1998), flare intensity was associated with the severity of retinopathy in diabetic patients. Although our patients were matched as regards their postoperative retinopathy grade, a mild influence due to the retinopathy could not be completely ruled out because of the relatively small sample size.

2.2.5.2 Anterior capsular contraction

We found that at 6 months the anterior capsular opening as indicated by the mask size was significantly smaller in the plate-haptic silicone group but there was no significant difference at 1 year. Also the mask size got significantly smaller over the follow-up period in the plate-haptic silicone group. Hayashi et al (Hayashi et al, 1997) and Zambrakji et al (Zambrakji et al, 1997) found that anterior capsular opacification occurs mostly within the first 3 months after surgery.

This finding is consistent with that by Werner et al, 2001 (Werner et al, 2001), who, in an autopsy series, found that plate-haptic silicone IOLs were associated with higher anterior capsular opacification scoring in addition to increased incidence of anterior capsular phimosis in comparison with hydrophobic acrylic IOL.
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

The relatively smaller overall diameter of the IOL as well as its ability to easily yield under pressure form the contracting capsule make this complication more likely with these implants.

2.2.5.3 Posterior capsular opacification

Recent research seems to underscore the role of IOLs as the most important factor in preventing its development of PCO. This role is further emphasised in diabetic patients, where prevention of PCO development is essential for maintenance of clear fundus view. Our findings established a significantly increased rate of PCO development with plate-haptic silicone IOLs after 6 months and 1 year when compared to hydrophobic acrylic IOLs in diabetic patients, which is in agreement with the findings of a recent study that compared the two lenses in non-diabetic patients (Abhilakh Missier et al, 2003).

Figures 2-5 and 2-6 (A & B) show examples of the changes in PCO over the follow-up time with the two implants. Four cases in the hydrophobic acrylic group showed reduction of the PCO area at 1 year in comparison with 6 months. Although the number was too small to be statistically tested, the finding is consistent with that of Hollick et al (Hollick et al, 1998; Meacock et al, 2001; Findl et al, 2004), who found regression of LEC in 83% of patients with that implant after 2 years of follow-up.
Figure 2-5. An example of a patient with plate-haptic silicone IOL. The left panel show the contrast-enhanced images with the outlines of the masks and their sizes (in pixels). The right panel shows the software-processed images and the percentages of the area of PCO. MGO=the photo’s ID
Chapter 2: Posterior Capsular Opacification in Diabetic Patients

NCI at 4 days

591899  11.3%

NCI at 185 days

589056  18.7%

NCI at 367 days

614731  24.1%

(A)
Figure 2-6 (A & B). Examples of patients with hydrophobic acrylic IOLs. The left panels show the contrast-enhanced images with the outline of the masks and their sizes (in pixels). The right panels show the software-processed images and the percentages of the area of PCO. They show relatively smaller increase in the area of PCO over the follow-up period (A) and even regression and reduction of the area of PCO that occurred in some cases (B). NCI & JHA = the Ids of the photos.
Although the two implants have biconvex surfaces and similar optic size, the difference in the rate of PCO development between the two implants can be attributed mainly to other differences in design and to their material. The most important of these features seem to be the square-edge of the acrylic IOLs. This has been shown in experimental research and clinical studies of non-diabetic patients to inhibit migration of the LECs onto the posterior capsule and hence the development of PCO (Nishi & Nishi, 1999; Nishi et al., 2000; Nishi & Nishi, 2002; Wejde et al., 2003; Nishi et al., 2002). This was suggested to be due to either a contact inhibition mechanism (Nishi et al., 1998c) or a mechanical barrier effect (Boyce et al., 2002).

The haptic angulation (10° in the acrylic and 0° in the plate-haptic silicone IOL) together with the larger overall diameter of the acrylic implant are other features that could play an important role in preventing migration of the LECs by creating and increasing posterior vaulting of the optic upon capsular contraction. This further reinforces the barrier effect of the square edge by increasing the force of mechanical apposition between the IOL optic and the posterior capsule.

Also, Oshika et al., 1998 (Oshika et al., 1998b), found that acrylic IOLs adhered more strongly to the posterior capsule than polymethylmethacrylate and silicone IOLs and proposed that this strong adhesion prevents lens epithelial cell migration and PCO formation. Linnola et al., 2000 (Linnola et al., 2000b), suggested that to be due to fibronectin and vitronectin adhering better to hydrophobic acrylic IOLs than to silicone IOLs.

2.2.6 Conclusion

In diabetic patients, PCO and anterior capsular contraction occurs at a higher rate with plate-haptic silicone than with hydrophobic acrylic IOLs. Although the latter may cause more early postoperative flare, this was not associated with increased clinically significant postoperative inflammation. This suggests that hydrophobic acrylic implants are more favourable than plate-haptic silicone implants in these patients.
CHAPTER 3

IN VIVO ASSESSMENT OF THE RELATIONSHIP BETWEEN THE INTRAOCULAR LENS AND THE POSTERIOR CAPSULE
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

3 USING THE OPTICAL COHERENCE TOMOGRAPHY TO COMPARE THE RELATIONSHIP OF A PLATE HAPTIC SILICONE AND A HYDROPHOBIC ACRYLIC INTRAOCULAR LENS TO THE POSTERIOR CAPSULE: A PILOT RANDOMISED CLINICAL TRIAL

3.1 INTRODUCTION

3.1.1 Optical coherence tomography

Optical coherence tomography (OCT) (Huang et al., 1991; Fujimoto et al., 2004; Schmitt J.M., 1999) (Figure 3-1) is an imaging technology that is based on modification of the Michelson’s interferometer. The latter has been used to measure distances accurately by using a split light beam; a reference and a sample beam, each traverses a different path and then are recombined at a photo-detector that captures all the light to form an interference fringe. Depending on the length of the two paths, constructive or destructive fringes are formed and hence the centre of the fringe can be bright or less so by an amount proportional to the path difference.

3.1.2 Light source in OCT

In optical coherence tomography (Huang et al., 1991; Fujimoto et al., 2004), the light source is a super-luminant diode laser, which has a wave-length of 800 to 1300 nm and an emission power of 1-10 mW. This has low coherence (15-30 μm), which helps produce interference patterns of short temporal and spatial extent.
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

![Diagram of OCT principle and components]

Figure 3-1. Optical coherence tomography: principle and components (Reproduced from Schmitt J. 1999 & Huang D. et al 1991)
3.1.3 The beam splitter

The beam of light is split into two separate, mutually coherent beams by means of two isosceles prisms with their bases apposed with an intervening layer of partial silvering.

3.1.4 Scanning and scan images

The OCT relies on mechanical scanning mechanisms based on translation of a reference mirror mounted on a stage driven by a motor. A constant excursion of about 2.72 mm/s and a repetition rate of 55 Hz are maintained in the middle of the scan range by means of a feedback control.

The X-Y length of the scan can be varied from 2.5 to 19 mm in air at a working distance of 43 mm. This represents a scan angle of between 3° and 25°. The angular orientation of the scan can also be changed within X-Y plane within 360°.

The lateral resolution of the OCT image is limited by diffraction to a maximum of 25 μm (Chauhan & Marshall, 1999). However, lateral resolution depends also on the scan length as each image is composed of 100 scans regardless of scan length. The longer scan, therefore, has a lower lateral resolution. Also, because the image acquisition time is approximately 1 sec with no compensation for drifts in patient fixation, the lateral resolution can also be compromised.

The device has an internal fixation light visible to the patient but not on the operators viewing screen. A second light, generated by HeNe laser, is seen on the viewing screen and could be moved under the control of the operator to fall on any given tissues. The acquisition time for each composite OCT image is about 0.9s, independent of scan length and orientation.

The light reflected from the tissues is processed and a transducer is used to convert the light signal into pseudochromatic real-time image based on the reflectance of the light from the different tissues. The arbitrary pseudo-colour scale is logarithmic and had the effect of grouping a range of signal intensity into one colour. The image is displayed on a computer screen and the setting for each scan is stored on the computer for repeated measurement.
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

3.1.5 Use of the Optical coherence tomography for anterior segment examination

The OCT has been used before to examine the anterior segment structures. Because of the transparency of these structures, the only parts that are likely to result in significant OCT signals are the interfaces between different media. Hoerauf H (Hoerauf et al, 2000) used a slit-lamp adapted OCT and Radhakrishnan S et al (Radhakrishnan et al, 2001) used a high speed OCT (at 1310 nm wavelength) for in vivo imaging of the anterior segment structures, including the cornea, the chamber angle, the iris and the crystalline lens. Also, Hirano et al (Hirano et al, 2001) used the OCT 2000 (Zeiss-Humphrey) to study the different pathologies of the cornea. They demonstrated that the OCT was able to obtain reflection signals at the interface of the different corneal layers. Also, in a non-published in vitro and in vivo studies by Chauhan et al (Chauhan DS et al, 2000), the intraocular lens surfaces and posterior capsule opacification were clearly identified and characterised using the OCT.

It is known that IOL material and design influence the rate of PCO development. Acrylic implants have been found to be associated with lower rates than silicone implants (Hollick et al, 1999c), plano-convex (Nagamoto & Eguchi, 1997), and square edged implants (Nishi et al, 2000) with lower rates than other IOL profiles. In 1992, Apple and coauthors (Apple et al, 1992) proposed that the absence of space between the IOL and posterior capsule prevents LECs from migrating centripetally onto the posterior capsule and producing PCO: the ‘no space, no cells’ theory, which has not, hitherto, been demonstrated in vivo.

3.2 AIMS

In the previous study, it was shown that the plate-haptic silicone IOL (Chiron C11 UB; Bausch & Lomb) had a higher PCO rate than the hydrophobic acrylic IOL (Acrysof; Alcon Inc.). The aims of this study were to demonstrate the ability of the OCT scan to obtain in vivo images of the two IOLs; and to describe the characteristic relationships of their optics to the posterior capsule that can be related to the known difference in their PCO rates.
3.3 PATIENTS AND METHODS

3.3.1 Inclusion & exclusion criteria

Twenty-six patients were recruited consecutively between September 2001 and March 2002 from those who had uneventful phacoemulsification and IOL implantation of either plate-haptic silicone (Chiron C11UB) or hydrophobic acrylic (AcrySof) IOLs and gave consent to be included in the study. Twelve of the patients (46%) were recruited prospectively after they had been randomised to be given either of the above two implants. The rest of the patients (n=14, 54%) were recruited retrospectively.

Exclusion criteria were history of uveitis or other intraocular surgery, systemic steroids or other immunosuppressive therapy, the presence of corneal opacity, the development of postoperative uveitis that required additional steroid treatment, poor mydriasis, or refusal to be included in the study.

3.3.2 Surgical technique

One surgeon performed 81% of operations, including all those in the randomised group. All patients underwent a standard phacoemulsification through a superotemporal corneal incision. Subconjunctival antibiotic (Cefuroxime) and steroids (Betamethasone) were injected at the conclusion of the procedure. Patients were reviewed within 24 hours after surgery and prescribed G Chloramphenicol 0.1% to be used QDS for 2 weeks and Dexamethasone 0.1% QDS for 2 weeks than BID for 2 weeks.

3.3.3 OCT image acquisition

OCT scan was performed within 48 hours and 4 to 6 weeks later in the randomised group but only once in the retrospective group, except in one of the patients who needed Nd:YAG capsulotomy that had a follow-up scan after the laser. The scans were performed following pupillary dilatation with G. tropicamide 1% and G. phenylephrine 2.5% using a Humphery OCT scanner (Humphrey Inst., San Leonardo, CA). Patients were asked to fixate straight ahead with the other eye on the
instrument’s external target because the internal fixation light was not visible when scanning the anterior segment. Linear scans, which take approximately 0.9s to acquire regardless of their length and angular orientation, were obtained. A vertical and a horizontal scans of 4-6mm across the pupillary area were taken for all the patients. Because short scans provided better resolution, 4 scans of 1.5-3mm were added, when necessary, astride the pupillary margin at 12, 3, 6 & 9 o’clock positions for detailed study of the peripheral part of the optic. (Figures 3-2, 3-3 & 3-4).

Figure 3-2. Diagram showing the positions of the long scans across the pupillary area (interrupted lines) and short scans astride the pupillary margin (continuous lines)
Figure 3-3. An example of the video photographs and OCT scan images of a patient with a hydrophobic acrylic IOL. Top 2 panels: horizontal and vertical long scans, bottom 2 panels: short scans at 12 and 3 o’clock positions. Top panel OCT scan shows: pupillary margin (thin horizontal arrow), anterior capsule (thick horizontal arrows), anterior lens surface (thin vertical arrow), posterior lens surface (thick vertical arrow) and posterior capsule (curved arrow).
Figure 3-4. Video photograph and OCT scan of a patient with plate-haptic silicone IOL. Top 2 panels: vertical and horizontal long scans; bottom 2 panels: short scans at 6 and 9 o’clock positions. Top panel OCT scan shows: pupillary margin (thin horizontal arrow), anterior capsule (thick horizontal arrows), posterior lens surface (thin vertical arrow) and posterior capsule (thick vertical arrows).
3.3.4 Outcome measures and statistical analysis

The outcome of interest was the ability of the OCT to capture the outline of the IOL optic and the appositional relationship of the lens optic to the posterior capsule. An implant outline was classified ‘well-defined’ if clearly distinguishable signals were obtained from the anterior and posterior surfaces. Conversely, if either of the surfaces was partially or not at all distinguishable on all the scans, the outline was classified ‘partially defined’ or ‘ill-defined’.

When at least the posterior surface of the optic of the IOL and the posterior capsule were distinguishable, the pattern of apposition between them was examined. A ‘close apposition’ pattern described the absence of any discernible optical space i.e. a single signal is obtainable from both of them (Figure 3-3 & 3-4). The posterior capsule was distinguished from the anterior hyaloid, if visible, by its relative proximity to and conformity with the posterior surface of the IOL optic, the higher intensity of its signal, and by the absence of undulating movements with the saccadic eye movements that are characteristic of the anterior hyaloid face (Chauhan et al, 2000).

Binary variables were created for the presence of a ‘well-defined’ outline and for the presence of ‘close apposition’ between the IOL optic and the posterior capsule. Fisher’s exact test was used to compare the proportions of these binary variables in the two IOL groups. Multivariate logistic regression analysis was used to test the likelihood of having ‘well-defined’ outline as well as the association between the IOL type and the presence of ‘close apposition’ of its posterior surface to the capsule after controlling for possible confounders. A p value of < 0.05 was considered statistically significant.

3.4 RESULTS

3.4.1 Patient characteristics

Twenty-six patients were examined, 16 (63%) had plate-haptic silicone and 10 (37%) acrylic IOLs. The demographic data of the two groups of patients are shown in Table 3-1. The patients’ age ranged between 44 and 84 (median=67). Fifteen (57.7%) of the patients were male and 15 (57.7%) were diabetics, 10 of them were in the plate-
haptic silicone group. There was no significant difference in age, sex distribution or the proportion of diabetic patients between the two groups.

**Table 3-1. Patient characteristics**

<table>
<thead>
<tr>
<th></th>
<th>PH silicone (N=16)</th>
<th>Hydrophobic acrylic (N=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (Years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>66</td>
<td>67</td>
</tr>
<tr>
<td>IQR</td>
<td>59.8-76.3</td>
<td>58.3-73.5</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M:F</td>
<td>9:7</td>
<td>7:3</td>
</tr>
<tr>
<td><strong>Ethnic origin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian: Asian</td>
<td>8:8</td>
<td>4:6</td>
</tr>
<tr>
<td><strong>Follow-up</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>10.5</td>
<td>0.5</td>
</tr>
<tr>
<td>IQR</td>
<td>3.8 days to 22.2 months</td>
<td>1 day to 5.5 months</td>
</tr>
</tbody>
</table>

PH=plate-haptic; IQR=interquartile range

**3.4.2 Delineation of IOLs on the OCT scans**

In the randomised group, all the acrylic implants (n=6) had a ‘well-defined’ outline whereas all the plate-haptic silicone implants (n=6) had either of their surfaces ‘ill-defined’ or ‘partially defined’.

In the whole group, significantly more patients in the acrylic group had a ‘well-defined’ outline than in the plate-haptic silicone group (9/10 vs. 1/15) \( p<0.001 \).

There was no significant difference between diabetic and non-diabetic patients in the proportions with ‘well-defined’ IOL outline. After controlling for the length of follow-up and the presence of diabetes mellitus, the hydrophobic acrylic IOL was found to be more likely to have a ‘well-defined’ outline on the OCT scan \[\text{Odds Ratio}=134.9; 95\% \text{ Confidence Interval (7.5; 2433.2); } p=0.0009\].
3.4.3 Appositional relationship between the intraocular lenses and the posterior capsule

In the randomised group, 9 patients had distinguishable signals from the peripheral part of the optic i.e. the part subjacent to the pupillary margin and the posterior capsule. All the acrylic IOLs (n=5) showed ‘close apposition’ between the optic and the mid-peripheral part of the posterior capsule and an optically empty space centrally (Figure 3-5), whereas all the plate-haptic silicone implants (n=4) showed a distinct optically empty space between the peripheral parts of their optics and the capsule (Figure 3-6) but their central parts of the optics were difficult to discern from the capsule.

In the whole group, 20 IOLs (76.9%) had ‘well-defined’ posterior surfaces. The appositional pattern between the IOL and the posterior capsule varied. A ‘close apposition’ pattern existed in 7/8 (88%) of the patients with acrylic IOLs and in 1/12 (8%) of those with plate-haptic silicone IOLs (p<0.001). No significant difference was found between non-diabetic and diabetic patients in the presence of IOL-capsular apposition (4/9 vs. 4/11). After controlling for the length of follow-up and the presence of diabetes mellitus, the optics of acrylic IOLs were more likely to have ‘close apposition’ with the posterior capsule on OCT [Odds Ratio=480.3; 95% Confidence Interval (1.62, 142460.8); p=0.03].

3.4.4 Follow-up scans

In 8 patients in the randomised group (4 in each group), where the first and follow-up scan showed distinguishable signals from both the optic and the capsule, the central part of the optic was distinguishable only on all the patients with acrylic implants. In these patients, a central optically empty space was identified on their first scans (Figures 3-a & 4-a top panels). This was either shallow or completely obliterated on the follow-up scans at 4 to 6 weeks (Figure 3-7).

3.4.5 Posterior capsular opacification and IOL outline

Four patients had PCO and 3, all with plate-haptic silicone IOLs (16%), underwent Nd:YAG laser capsulotomy. The reflective substances on the posterior capsule on
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

the scan corresponded to the lens epithelial pearls seen in the colour photograph, which enhanced the outline of the posterior surface of the optic (Figure 3-8 & 3-9). Notably, however, the posterior optic surface outline was no longer discernible after Nd:YAG laser capsulotomy.

3.5 DISCUSSION

In this pilot study, OCT enabled us to examine in vivo features of two IOLs that are different in material and design and were shown to be different in their PCO rate in our previous study as well as in a recent study by Abhilakh Missier et al (Abhilakh Missier et al, 2003).

3.5.1 Delineation of the IOLs

The first feature studied here was the difference in the ability of the OCT to delineate the outline of the two IOLs. The outlines of the hydrophobic acrylic IOLs were better defined than those of the plate-haptic silicone IOLs (Figures 3-3 & 3-4). In latter group of patients, the outline of the peripheral part of the posterior surface of the optic was the only discernible part rather than their central part. This could be related to accumulation of extracellular substance and LECs on that part because of its proximity to the highly proliferative equatorial LECs. In patients with PCO, the posterior surface outline was enhanced by the presence of LECs and extracellular substance on the posterior capsule (Figure 3-7 & 3-8). This feature was lost following Nd:YAG posterior capsulotomy.

The ability of the OCT to delineate the outline of the hydrophobic acrylic IOLs better than that of the plate-haptic silicone IOLs can be related to the principle of the OCT and the reflective characteristics of the IOLs. The definition of tissues on the OCT relies on the formation of constructive interference fringes from the interaction between the reference light and that reflected from the target tissue, with more reflections leading to enhancement of the interference fringe signal. In an experimental study by Erie et al, 2003 (Erie et al, 2001) more external reflections were found with hydrophobic acrylic IOLs (AcrySof MA60) than with silicone IOLs (LI61U). They attributed that to the higher refractive index of the acrylic IOLs (1.55 vs. 1.43) and their optic design (an unequal biconvex vs. equiconvex). The latter features are similar to those of the plate-haptic silicone IOL’s, which has a refractive
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

index of 1.413 and an equiconvex optic. The deposition of a biofilm of extracellular substances such as fibronectin and vitronectin that was shown to occur more on the acrylic than on the silicone IOL surfaces (Kochounian et al, 1994) might perhaps have a role in rendering the surfaces of these implants more reflective or light-scattering.

Figure 3-5. Video photographs and OCT scan of two patients with hydrophobic acrylic IOLs within 2 days (top panel) and 9 months after surgery (bottom panel). Note the clear delineation of the IOL outline. The OCT scans show the anterior capsular leaflet (thin vertical arrows), the haptic (thin horizontal arrows) and the posterior capsule (thick vertical arrow). The mid-peripheral part of the latter (thick horizontal arrows) is in close apposition to the optic.
Figure 3-6. Video photographs and OCT scans of two patients with plate-haptic silicone IOLs within 2 days (top panel) and 14 months after surgery (bottom panel). The OCT scan shows that the implant surfaces are poorly delineated in both panels. The peripheral part of the optics are visible though (horizontal arrows) and there is absence of the close apposition pattern demonstrated in 3-a. Instead there is an optically empty space between the optic (horizontal arrows) and the posterior capsule (vertical arrows).
3.5.2 Appositional relationship of the posterior capsule to the IOLs

In the 20 patients where the posterior surface of the optic and the posterior capsule were identifiable, the most distinctive feature was the presence of 'close apposition' between the peripheral part of the optic of the acrylic IOL and the posterior capsule (Figures 3-7 & 3-8). On the other hand, an optically empty space was identifiable between the optic of the plate-haptic silicone IOLs (Figures 3-3, 3-6 and 3-8 upper panel) and the mid-peripheral part of the capsule that was filled with material of high reflectance, presumably LECs and extracellular substance, (Figures 3-6, 3-8 & 3-9).

Figure 3-10 depicts the relationship and the proposed appositional patterns between the posterior capsule and the two implants once in the capsular bag. The close apposition of the optic of the hydrophobic acrylic implant to the posterior capsule is evidently the result of its design and the interaction between its material and the capsule and concurs with the findings of other studies. The angulation between the haptic and the optic (10°) of the hydrophobic acrylic implants, which is lacking in the plate-haptic silicone IOL design, as well as their larger overall diameter (13 vs. 10.5 mm) presumably lead to posterior vaulting of the optic once they are in the capsular bag. It is conceivable that this increases as the capsular bag circumferentially contracts, increasing the appositional force between the optic and the posterior capsule. This could explain the disappearance of the central space in patients examined later after surgery (Figures 3-4 & 3-7). The sharp square edge of the lens optic is another attribute of the acrylic lens and perhaps the most important in producing this characteristic appositional relationship. Nishi and coauthors (Nishi et al, 2002) showed that capsular bend formation around the IOL implant occurs earlier with hydrophobic acrylic IOL than with silicone and PMMA IOL. Boyce et al, using a mathematical model, found that square-edged optic profiles exert a higher pressure on the posterior capsule than IOLs with round-edged optic profiles (Boyce et al, 2002). Also, in the study by Nagata et al, 1998 (Nagata et al, 1998), and another by Oshika et al, 1998 (Oshika et al, 1998b), the adherence force between the IOL and the capsule, attributable to integrins and cadherin adhesion molecules expressed by the LECs (Birk et al, 1994), was found to be greater with acrylic than...
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

with silicone IOLs. This adherence was found to occur even faster with the acrylic than with silicone and PMMA IOLs (Nishi et al, 2002).

In a study by Hollick et al (Hollick et al, 1998), LECs that migrated behind hydrophobic acrylic IOL optic were found to disappear. Our finding that the central optically empty space between the hydrophobic acrylic implant and the posterior capsule disappeared within few weeks after surgery corroborates the authors’ hypothesis that related the disappearance of cells to their demise as a result of posterior vaulting and mechanical compression of the cells by the optic.

The demonstrable appositional differences between the two implants are in keeping with experimental (Nishi et al, 1998c;Nishi et al, 2000) and clinical studies (Beltrame et al, 2002;Hayashi et al, 1998c;Hollick et al, 1999c) that have shown that square-edged acrylic implants prevent lens epithelial cell migration onto the posterior capsule and hence had lower PCO rate. All, also, is consistent with the time-honoured concept of 'no space, no cells, no PCO' (Apple et al, 1992).
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

Figure 3-7. Video photographs and OCT scans of a patient with a hydrophobic acrylic IOL. It shows a close mid-peripheral apposition between the posterior capsule and the optic 2 days (top panel: thin arrows) and total apposition 4 weeks after surgery (Bottom panel: thick arrow)
Figure 3-8. Video photographs and OCT scan of 2 patients with plate-haptic IOLs 2 years after surgery. There is lack of apposition between the implant and the mid-peripheral part of the capsule (thin arrows). A high-reflectance material is present between the capsule and the posterior lens surface (vertical arrows)(presumably of LECs and extracellular substance) and an optically similar substance underneath the anterior capsular leaflet (thick arrows), corresponding to the anterior capsular fibrosis showing in the video photograph.
Figure 3-9. A colour photograph and OCT scan of a patient with plate-haptic silicone IOL and PCO. The colour photograph shows abundant LECs forming Elshnig’s pearls on the posterior capsule. The OCT scans shows better definition of the posterior surface of the optic (top panel: thin arrow), the central part of which became indiscernible after Nd:YAG capsulotomy (bottom panel: thick arrow), indicating that the reflections were predominantly from the posterior capsule rather than the optic of the implant.
Chapter 3. OCT of the Relationship between the IOL Optic and the Posterior Capsule

Figure 3-10. A diagram of the proposed appositional patterns that develop between hydrophobic acrylic and plate-haptic silicone implants, and the posterior capsule. Once in the capsule bag, early close apposition of the edge of the hydrophobic acrylic IOL optic to the posterior capsule occurs due to the posterior vaulting that result from their larger overall diameter (13mm vs. 10 mm) and the angulation between the optic and the haptic (10°) that supposedly increases as the capsular bag contracts. The square edge and the acrylic material create a tighter adherence force between the capsule and the IOL optic. This close apposition with the posterior capsule helps prevent LEC migration (straight arrows), whereas the lack of similar apposition with the plate-haptic silicone IOLs allows early migration and proliferation of the LECs on the posterior capsule (curved arrows)
3.6 LIMITATIONS

The apparent limitation of the OCT is the dependency on pupillary dilation and medial clarity. This, however, is a uniform requirement for all currently used posterior capsule-imaging systems. Furthermore, the ability of the machine to delineate the outline of an IOL varies with the IOL material because of the differences in refractive indices that in turn affect light reflectance. It is not known, however, if this is true for all IOLs with a refractive index similar to that of the plate-haptic silicone IOL and if the IOL design had contributed to producing the difference in IOL surface reflectivity.

3.7 CONCLUSION

This is the first study to demonstrate in vivo the relationship between the optic of the IOL and the posterior capsule using OCT. We have shown that OCT can be used to demonstrate the appositional relationship between the IOL and the lens capsule. We have also shown that the optic of hydrophobic acrylic IOLs, in addition to being more reflective and thus better delineated on the OCT scan than plate-haptic silicone IOL, maintains a close appositional relationship with the posterior capsule that appears lacking with the plate-haptic silicone. These features are consistent with the ‘no-space; no-cell; no PCO’ concept.

The recent generations of OCT and their higher resolution may be able to overcome the above limitations and provide a potentially useful tool for in vivo examination of the IOL-capsule relationship. This should help to identify important design features in preventing PCO development.
CHAPTER 4

POSTERIOR CAPSULAR OPACIFICATION IN PATIENTS WITH UVEITIS
4 INCIDENCE AND RISK FACTORS OF POSTERIOR CAPSULAR OPAFICATION IN UVEITIS PATIENTS FOLLOWING PHACOEMULSIFICATION AND EXTRACAPSULAR CATARACT EXTRACTION

4.1 INTRODUCTION

Similar to diabetic patients, posterior capsule opacification in uveitis patients carries the risk of obscuring the fundus view and hence the timely diagnosis and treatment of posterior segment complications such as macular oedema. Moreover, performing Nd:YAG capsulotomy can potentially excite the dormant uveal inflammation and can itself cause macular oedema or other posterior segment complications such as retinal detachment. According to Dana et al, 1997 (Dana et al, 1997), the incidence of PCO in uveitis patients can be higher than in patients without uveitis and has been estimated to be 38.5% at 1 year and 56% at 3 years. In that study, the relatively young age of the patients was considered the most important risk factor that led to increased PCO in uveitis patients.

Dana’s study, however, included patients who underwent phacoemulsification as well as ECCE. Also, no study to date has investigated other factors that can potentially affect the rate of PCO in uveitis patients, including the surgical technique, prophylactic steroids, the development of postoperative inflammation, gender, type of IOL and ethnic origin.

4.2 AIMS

In the following two studies, we aimed at:

1. Estimating the incidence and identifying the factors that could potentially affect the rate of PCO in patients with uveitis.

2. Estimating and comparing the incidence of PCO in uveitis patients after phacoemulsification and ECCE
Chapter 4: Posterior capsular opacification in uveitis

4.3 STUDY OF THE INCIDENCE AND RISK FACTORS OF ND:YAG CAPSULOTOMY AFTER PHACOEMULSIFICATION IN PATIENTS WITH UVEITIS

For the purpose of this study two groups of patients were examined. The ‘Uveitis group’ refers to a consecutive series of patients that were recruited from 3 tertiary referral centres. The ‘Non-uveitic and uveitic group’ refers to a comparative series that was derived from the same centre.

4.3.1 Material and Methods

4.3.1.1 Uveitis group

4.3.1.1.1 Design and study population

This is a retrospective case-note review of a consecutive series of 156 uveitis patients who underwent phacoemulsification and intraocular lens implantation between 1996 and 2001 under the care of 3 consultants at Moorfields Eye Hospital and Whipps’ Cross University Hospital, London, UK; and at the Royal Prince Alfred Hospital and St Vincent’s Hospital, Sydney, Australia.

There were 57 patients with anterior uveitis (56%), comprising three subgroups: recurrent acute anterior uveitis (RAAU)(n=25, 43.9%), chronic anterior uveitis (CAU)(n=22, 38.6%), and Fuchs’ heterochromic cyclitis (FHC)(n=10, 17.5%). The posterior uveitis group comprised 44 patients (44%) consisting of intermediate uveitis (IU)(n=17, 39%) and posterior uveitis, retinal vasculitis and panuveitis (PU)(n=27, 61%).

A systemic disease associated with the uveitis was found in 25 (25%) of the patients. These included sarcoidosis (n=6, 24%), toxoplasmosis (n=5, 20%), Vogt-Koyanagi-Harada disease (n=3, 12%), ankylosing spondylitis (n=3, 12%), Crohn’s disease (n=2, 8%), ulcerative colitis (n=1, 4%), Reiter’s disease (n=2, 8%), Behçet’s disease (n=2, 8%) and tuberculosis (n=1, 4%). Eight patients had diabetes mellitus but none of them had clinically significant retinopathy requiring treatment. One of the patients had undergone a trabeculectomy operation for chronic glaucoma 5 years preoperatively and another pars plana vitrectomy for rhegmatogenous retinal
4.3.1.1.2 Inclusion & exclusion criteria

We included patients with a minimum postoperative follow-up of 3 months (n=151 eyes) and only the first eye of patients who had bilateral surgeries (n=36). Patients with juvenile idiopathic arthritis (n=2), herpetic kerato-uveitis (n=4) and lymphoma-associated uveitis (n=2) and patients who underwent phaco-trabeculectomy (n=6) were excluded. This left 101 patients whose details are shown in Table 1.

4.3.1.1.3 Data collection

The collected data, included age at surgery, gender, type of uveitis, the presence of systemic disease, the occurrence of uveitis episodes within the preoperative year and preoperative ocular findings, preoperative best-corrected visual acuity (BCVA), operative details, postoperative and final BCVA and postoperative complication, including early rise of intraocular pressure, uveitis or macular oedema requiring additional treatment.

4.3.1.1.4 Preoperative management

According to the uveitis service protocol in the 3 hospitals, all the patients had to have good control of ocular inflammation for a minimum of 3 months preoperatively, except in patients with chronic anterior uveitis or pan-uveitis, in whom the surgery had to be undertaken when the AC activity had been reduced to the lowest possible level.

Patients with disease activity within 3 months prior to surgery and those with previously documented posterior uveitis or macular oedema were given prophylactic systemic steroids (58, 57%). These were given either orally (50, 86%) as 40mg of prednisolone for 2 weeks prior to surgery or intravenously (4, 7%) as methylprednisolone 500mg on the day of surgery.

4.3.1.1.5 Surgery

Phacoemulsification was performed via a corneal or scleral tunnel incision using a standard technique. Pupillary dilation using iris hooks was carried out in 6 patients and iris sphincterotomy in another patient for poor dilation due to posterior synechiae.
One of 5 types of IOL was implanted in the capsular bag: silicone either plate-haptic (C10/11UB; Chiron, Bausch& Lomb) (32, 31.7%) or 3-piece (SI30 or SA40; Allergan Medical Optics or LI41U; Iolab) (15, 14.8%), hydrophobic acrylic (AcrySof MA60U, Alcon Lab Inc.) (24, 23.8%), polymethylmethacrylate (MC550, Bausch & Lomb Surgical) (21, 20.8%) or hydrogel (Hydroview, H60M) (Bausch & Lomb Surgical) (9, 9%)*.

Twenty-three patients (23%) required corneal sutures, 2 of them for poorly sealing wounds and the rest for larger incision size in those who had PMMA implants.

There were no major operative complications. Three patients with FHC and one who required sphincterotomy developed intraoperative hyphema. In one patient with chronic anterior uveitis, posterior capsular rupture occurred requiring anterior vitrectomy but an acrylic IOL was successfully placed in the bag. Corneal suturing was needed for the patients who had PMMA IOLs (21, 20.8%) in addition to 2 other patients who had leaky wounds at the end of the operation. Subconjunctival injection of antibiotics and steroids was performed in all patients at the conclusion of the procedure.

Two of the patients with sarcoidosis-related posterior uveitis required vitrectomy for persistent floaters and retinal detachment almost 1 and 4 years after surgery.

4.3.1.6 Postoperative management

Patients were discharged on the day of surgery and all but two, were reviewed within 48 hours. The frequency of subsequent clinic visits were determined by the treating clinician according to clinical findings and patients were advised to present to casualty should they have symptoms of uveal inflammation.

* The percentages do not add up to 100% because of the rounding.
Chapter 4: Posterior capsular opacification in uveitis

4.3.1.2 Non-uveitic and uveitic group

4.3.1.2.1 Design and study population

We reviewed the case-notes of 251 patients, 53 had established diagnoses of uveitis (10 (18.9%) recurrent acute anterior uveitis, 6 (11.3%) chronic anterior uveitis, 14 (26.4%) intermediate uveitis, 6 (11.3%) posterior uveitis and 17 (32.1%) pan-uveitis) and 198 contemporary random controls. Both groups underwent uneventful phacoemulsification cataract surgery and in-the-bag IOL implantation at Moorfields Eye Hospital between 1995 and 2001.

4.3.1.2.2 Inclusion and exclusion criteria

Only the first eye of those who underwent bilateral surgery was randomly included. Also, only non-diabetic patients and patients who had not undergone other intraocular surgery (e.g. penetrating keratoplasty, vitrectomy and trabeculectomy) were included. Also, in the uveitic group, patients with juvenile idiopathic arthritis, herpetic kerato-uveitis, lymphoma-associated uveitis and patients who underwent phaco-trabeculectomy were excluded.

The relevant preoperative, operative and postoperative data were collected, including gender, age at surgery, type of IOL, surgeon’s grade, the development of postoperative inflammation (within 3 months), the performance of Nd:YAG capsulotomy and best-corrected visual acuity at the final visit.

4.3.1.2.3 Preoperative management

Preoperatively, in the uveitis group the inflammation had to be controlled for a minimum of 3 months, except in patients with chronic anterior uveitis and 3 of those with posterior uveitis. In these patients, the surgery was undertaken when AC activity had been reduced to the lowest possible level. Patients with previously documented macular edema, disease activity within 3 months preoperatively or those with a poor outcome in the first eye due to macular edema or postoperative uveitis had been given prophylactic systemic corticosteroid treatment.

4.3.1.2.4 Postoperative management

After surgery, patients were reviewed within 48 hours and subsequent visits were determined according to clinical findings. Oral corticosteroids were withdrawn
gradually over 8 weeks. Routine phacoemulsification was performed and subconjunctival injection of antibiotics and corticosteroids was given to all the patients at the conclusion of the procedure.

4.3.1.2.5 Outcome measures and statistical analysis

In the two study groups, the primary outcome of interest was the performance of Nd:YAG capsulotomy, which was used as a surrogate measure of clinically significant PCO. The indications for Nd:YAG capsulotomy in the two groups were the presence of an opacified capsule that caused reduction in visual acuity in comparison to that achieved in the immediate postoperative period especially in the presence of visual symptoms or that compromised posterior segment visualisation even in the absence of visual symptoms.

Statistical analysis was undertaken using version 9 of Statistical Package for Social Science (SPSS) for Windows software. The distribution of continuous variables was expressed as the mean, standard deviation and inter-quartile range (IQR). Survival table analysis was used to derive the cumulative incidences as previously described (in 2.1.3.4) and Wilson's method to calculate their 95% confidence intervals (CI). Univariate and Cox multivariate survival analysis were used to identify risk factors associated with Nd:YAG capsulotomy. All variables that could possibly affect the development of PCO were included in the regression model especially if it had been shown to be associated with PCO in previous studies or if it had a $p$ value of less than 0.2 in the univariate analysis. The backward stepwise method was used and the strength of association as a hazard ratio (HR) and the 95% confidence interval (CI) was calculated for both ratios. A $p$ value of $<0.05$ was considered significant. Post-hoc assessment showed that the study had more than 90% power to detect the difference in median survival time and to identify a 10% difference in the hazard ratio between the different study groups.
4.3.2 Results

4.3.2.1 Uveitis group

4.3.2.1.1 Patient characteristics

Table 4-1 shows the demographic and different clinical features of the patients. One hundred and one eyes of 101 patients were included, 43 (43%) of them were male. The mean age was 52.8 years (range= 14.1 to 88.2 years) and the mean follow-up time was 23.3 years (range= 3 to 79.5 months).

Postoperatively, 76 patients (75%) had one or more Snellen’s lines of visual improvement (median=3 lines), with 65 (64%) having 2 or more lines. Fifty-eight (57%) of the patients had 6/12 or better and 32 (32%) 6/9 or better. At the final visit, 82 (81%) had 1 to 9 lines of visual improvement (median=4), with 72 (71%) having 2 or more lines. Seventy-eight (77%) had 6/12 or better and 57 (56%) 6/9 or better.

4.3.2.1.2 Postoperative complications

Raised intraocular pressure (IOP) requiring treatment occurred within the first 2 days in 6 patients (6%). During the postoperative follow-up, recurrence of uveitis occurred in 22 patients (22%) and macular oedema in 21 patients (21%).

Clinically significant deposits on the anterior lens surface were formed in 3 patients with plate-haptic silicone IOLs. They were dispersed using low-energy Nd:YAG laser applications. The procedures were uneventful and resulted in visual improvement in 2 of them.
Table 4-1. Patient characteristics in the uveitis group

<table>
<thead>
<tr>
<th>No</th>
<th>101</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age at surgery (in years)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>52.8(15.6)</td>
</tr>
<tr>
<td>Median</td>
<td>51.5</td>
</tr>
<tr>
<td>IQR</td>
<td>42.7-65.2</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Male: Female</td>
<td>43: 58</td>
</tr>
<tr>
<td><strong>Ethnic Origin</strong></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>67(66%)</td>
</tr>
<tr>
<td>Asian</td>
<td>13(13%)</td>
</tr>
<tr>
<td>Afro-Caribbean</td>
<td>10(10%)</td>
</tr>
<tr>
<td>Others</td>
<td>11(11%)</td>
</tr>
<tr>
<td><strong>Uveitis type</strong></td>
<td></td>
</tr>
<tr>
<td>Anterior</td>
<td>57(56%)</td>
</tr>
<tr>
<td>Posterior uveitis</td>
<td>44(44%)</td>
</tr>
<tr>
<td><strong>Systemic diseases associated with uveitis</strong></td>
<td></td>
</tr>
<tr>
<td>25(25%)</td>
<td></td>
</tr>
<tr>
<td><strong>IOL types</strong></td>
<td></td>
</tr>
<tr>
<td>PH silicone</td>
<td>32(32%)</td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>15(15%)</td>
</tr>
<tr>
<td>Acrylic</td>
<td>24(24%)</td>
</tr>
<tr>
<td>Hydrogel</td>
<td>9(9%)</td>
</tr>
<tr>
<td>PMMA</td>
<td>21(21%)</td>
</tr>
<tr>
<td><strong>Surgeon’s grade</strong></td>
<td></td>
</tr>
<tr>
<td>Resident</td>
<td>20 (20%)</td>
</tr>
<tr>
<td>Fellow or consultant</td>
<td>81(80%)</td>
</tr>
<tr>
<td><strong>Follow-up (in months)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>23.3(18)</td>
</tr>
<tr>
<td>Median</td>
<td>18.1</td>
</tr>
<tr>
<td>IQR</td>
<td>8.5-31.4</td>
</tr>
</tbody>
</table>

SD=standard deviation, IQR=interquartile range, BCVA=best-corrected visual acuity (Snellen’s), CF=count fingers, PL=perception of light, PH=plate-haptic, PMMA=poly-methylmethacrylate
4.3.2.1.3 PCO and Nd:YAG Capsulotomy

4.3.2.1.3.1 Incidence

The crude incidences of PCO and Nd:YAG capsulotomy were 39 (39%) and 33 (33%), respectively, over the follow-up period. As such, PCO was the most common postoperative complication. The median time to Nd:YAG capsulotomy was 10.8 months (range=1.5 to 42.3 months).

Survival table analysis showed that the incidences of Nd:YAG capsulotomy were 19.2% [95% CI (12.4, 28.6)], 19% [95% CI (10.3, 32.2)], 27.9% [95% CI (13.5, 49)] and 15.4% [95% CI (2.8, 53.7)] after 1, 2, 3 and 4 years, respectively (Table 4-2).
### Table 4-2. Incidences of Nd:YAG capsulotomy in the uveitic group

<table>
<thead>
<tr>
<th>No. of Patients Entering the Period:</th>
<th>No. of Nd:YAG Capsulotomy</th>
<th>% Incidence</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 1 year</td>
<td>101:25</td>
<td>17</td>
<td>19.2</td>
</tr>
<tr>
<td>&gt;1 year-2 years</td>
<td>59:23</td>
<td>9</td>
<td>19</td>
</tr>
<tr>
<td>&gt;2 years-3 years</td>
<td>27:11</td>
<td>6</td>
<td>27.9</td>
</tr>
<tr>
<td>&gt;3 years-4 years</td>
<td>10:7</td>
<td>1</td>
<td>15.4</td>
</tr>
<tr>
<td>&gt;4 years-5 years</td>
<td>2:0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

PCO = posterior capsular opacification
4.3.2.1.3.2 Risk factors

In order to identify the independent risk factors for Nd:YAG capsulotomy, a Cox regression model was constructed and included the patient’s age (>55 years vs. <=55 years), gender, ethnic origin, the uveitis type (anterior vs. posterior), the use of prophylactic steroids, the presence of a uveitis-associated systemic disease, the surgeon’s grade, the presence of significant posterior synechiae and the type of the IOL as covariates. The model revealed that Nd:YAG capsulotomy was more likely in patients of 55 years or younger and with the use of hydrogel IOLs [HR=3.74; 95% CI (1.05, 13.33)] and was lower with the use of plate-haptic silicone [HR=0.23; 95% CI (0.08, 0.62)] and 3-piece silicone [HR=0.18; 95% CI (0.05, 0.71)] in comparison with PMMA IOL and in patients who had prophylactic steroids [HR=0.24; 95% CI (0.11, 0.60)] (Table 4-3 & Figure 4-1).

Table 4-3. Cox regression analysis of the factors affecting the rate of Nd:YAG capsulotomy

<table>
<thead>
<tr>
<th></th>
<th>HR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;55 years</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;=55 years</td>
<td>2.28</td>
<td>1.06, 4.93</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Prophylactic steroids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.25</td>
<td>0.11, 0.59</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>IOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PH silicone</td>
<td>0.23</td>
<td>0.08, 0.64</td>
<td>0.005</td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>0.19</td>
<td>0.05, 0.74</td>
<td>0.02</td>
</tr>
<tr>
<td>Hydrophobic acrylic</td>
<td>0.74</td>
<td>0.25, 2.23</td>
<td>0.60</td>
</tr>
<tr>
<td>Hydrogel</td>
<td>3.71</td>
<td>1.04, 13.20</td>
<td>0.04</td>
</tr>
</tbody>
</table>

HR=Hazard ratio ; CI=confidence interval, IOP=intraocular pressure, PH=plate-haptic
Chapter 4: Posterior capsular opacification in uveitis

![Graph a](Image)

- **Cumulative Survival:**
  - Time (months)
  - Age:
    - >55 years
    - >55 years-censored
    - <=55 years
    - <=55 years-censored

![Graph b](Image)

- **Steroid Prophylaxis:**
  - Yes
  - Yes-censored
  - No
  - No-censored

Figure 4.1: Kaplan-Meier curves of Scheie AG capsulotomy. It shows that increased rate of complications with age of 55 or younger (a) and decreased rate with steroid prophylaxis (b). In comparison with NMA 431, phakic and aphakic eyes showed to have capsulotomy rates whereas hydroxyapatite had higher reoperation rates. It is noted that those who follow-up closely had more successful outcomes.
Figure 4-1. Kaplan Meier curves of Nd:YAG capsulotomy. It shows that increased rate was associated with age of 55 or younger (a) and decreased rate with the use of prophylactic steroids (b). In comparison with PMMA IOL, plate-haptic and 3-piece silicone had lower capsulotomy rates whereas Hydrogel had higher capsulotomy rate (c). Censored data are that of patients whose follow-up ended before they need Nd:YAG capsulotomy.
4.3.2.1.4 Post-Nd:YAG uveitis or macular oedema

After the procedure, 3 (7.7%) of the patients needed treatment for macular oedema or uveitis. One of the patients with sarcoidosis-related posterior uveitis was diagnosed with macular oedema immediately after the procedure and was given peri-ocular steroids. Another patient (3%) with posterior uveitis developed macular oedema at 8 weeks and was treated with peri-ocular steroid injection. The same patient developed uveitis within 3 months and was treated with topical steroids.

4.3.2.1.5 Post-Nd:YAG visual improvement

Visual improvement of 1 or more Snellen’s lines occurred in 22 patients (67%).

4.3.2.2 Non-uveitic and uveitic group

4.3.2.2.1 Incidence

Table 4-4 lists the demographic and different clinical features of the patients. There was a significant difference between the two groups in their Table 4-5 shows the incidence of PCO that required Nd:YAG capsulotomy in the two patient groups over the follow-up period.

4.3.2.2.2 Risk factors

Survival analysis showed that there was no statistically significant difference between the rate of Nd:YAG capsulotomy between the two groups (Figure . On Cox multivariate regression analysis, no significant association was found between the presence of uveitis, type of IOL, surgeon’s grade, young age, the devotion of postoperative inflammation and the need for Nd:YAG capsulotomy.
### Chapter 4: Posterior capsular opacification in uveitis

#### Table 4-4. Patient characteristic in the Non-uveitic and Uveitic group

<table>
<thead>
<tr>
<th></th>
<th>Non-uveitis (n=198)</th>
<th>Uveitis (n=53)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male:Female</strong></td>
<td>76:122</td>
<td>27:26</td>
<td></td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>73.5</td>
<td>55.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IQR</td>
<td>65-80</td>
<td>45.3-69</td>
<td></td>
</tr>
<tr>
<td>&lt;=55</td>
<td>22 (11.1%)</td>
<td>26 (49.1%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&gt;55</td>
<td>176 (88.9%)</td>
<td>27 (50.9%)</td>
<td></td>
</tr>
<tr>
<td><strong>Ethnic origin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>90 (45.5%)</td>
<td>27 (50.9%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asian</td>
<td>20 (10.1%)</td>
<td>12 (22.6%)</td>
<td></td>
</tr>
<tr>
<td>Afro-Caribbean</td>
<td>8 (4%)</td>
<td>6 (11.3%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>17 (8.6%)</td>
<td>8 (15.1%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>63 (31.8%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Surgeon’s grade</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resident</td>
<td>118 (59.6%)</td>
<td>4 (7.5%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fellow/consultant</td>
<td>64 (32.3%)</td>
<td>10 (18.9%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>16 (8.1%)</td>
<td>39 (73.9%)</td>
<td></td>
</tr>
<tr>
<td><strong>IOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA</td>
<td>28 (14.1%)</td>
<td>0 (0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Plate-haptic silicone</td>
<td>158 (79.8%)</td>
<td>31 (58.5%)</td>
<td></td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>12 (6.1%)</td>
<td>7 (13.2%)</td>
<td></td>
</tr>
<tr>
<td>Hydrophobic acrylic</td>
<td>0 (0%)</td>
<td>15 (28.3%)</td>
<td></td>
</tr>
<tr>
<td><strong>Postop. Inflammation</strong></td>
<td>20 (10.1%)</td>
<td>15 (28.3%)</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>Nd:YAG</strong></td>
<td>30 (15.2%)</td>
<td>12 (22.6%)</td>
<td></td>
</tr>
<tr>
<td><strong>Follow-up (months)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>13</td>
<td>18.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IQR</td>
<td>6.4-18.6</td>
<td>11.7-29.5</td>
<td></td>
</tr>
</tbody>
</table>
### Table 4-5. The incidence of Nd:YAG capsulotomy in the non-uveitic and uveitic group

<table>
<thead>
<tr>
<th></th>
<th>Non-uveitic (n=198)</th>
<th>Uveitic (n=53)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients :</td>
<td>No. of Patients :</td>
</tr>
<tr>
<td></td>
<td>No. lost to follow-up</td>
<td>No. lost to follow-up</td>
</tr>
<tr>
<td></td>
<td>No of YAG capsulotomy</td>
<td>No of YAG Capsulotomy</td>
</tr>
<tr>
<td></td>
<td>% Incidence</td>
<td>% Incidence</td>
</tr>
<tr>
<td></td>
<td>95% Confidence Interval</td>
<td>95% Confidence Interval</td>
</tr>
<tr>
<td>Up to 6 months</td>
<td>198:40</td>
<td>53:2</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>7.6</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>4.4:12.8</td>
<td>0</td>
</tr>
<tr>
<td>&gt;6 months-12 months</td>
<td>146:38</td>
<td>51:10</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>4.6</td>
<td>12.2</td>
</tr>
<tr>
<td></td>
<td>2:10.4</td>
<td>5.3:25.5</td>
</tr>
<tr>
<td>&gt;12 months-18 months</td>
<td>103:49</td>
<td>36:13</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>5.6</td>
<td>8.7</td>
</tr>
<tr>
<td></td>
<td>1.9:15.1</td>
<td>2.4:26.8</td>
</tr>
<tr>
<td>&gt;18 months-24 months</td>
<td>51:20</td>
<td>21:5</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>9.7</td>
<td>12.5</td>
</tr>
<tr>
<td></td>
<td>3.4:24.9</td>
<td>3.5:36</td>
</tr>
<tr>
<td>&gt;24 months-30 months</td>
<td>28:11</td>
<td>14:4</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>10.8:60.3</td>
</tr>
<tr>
<td>&gt;30 months-36 months</td>
<td>17:5</td>
<td>7:1</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>41.7</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>19.3:68.1</td>
<td>0</td>
</tr>
<tr>
<td>&gt;36 months-42 months</td>
<td>7:2</td>
<td>6:5</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3.6:62.5</td>
<td>0</td>
</tr>
<tr>
<td>&gt;42 months-48 months</td>
<td>4:0</td>
<td>1:1</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
Figure 4-2. Kaplan Meier curves of Nd:YAG capsulotomy. It shows no significant difference in the rate of Nd:YAG capsulotomy between non-uveitic and uveitic patients. Censored data are that of patients whose follow-up ended before they need Nd:YAG capsulotomy.
### 4.3.3 Discussion

#### 4.3.3.1 Incidences of Nd:YAG capsulotomy

In the uveitis group, PCO occurred in 39%, and Nd:YAG capsulotomy was performed on 33%. In the non-uveitic and uveitic group, the incidences were 15.2% and 22.6%, respectively. Table 4-6 shows the reported crude incidence of PCO in other studies of phacoemulsification in uveitis patients with a similar length of follow-up. Notably, the study by Dana et al reported a higher incidence, which was probably because some of their patients did not have IOL implantation. The variation in the reported percentages can also be attributed to differences in patient clinical and demographic features in addition to the variations in deciding on the indications and timing of Nd:YAG capsulotomy that in relation to the variability of disease activity.

In the uveitis group, the incidences of Nd:YAG capsulotomy were 19.2%, 19%, 27.9% and 15.4% after 1, 2, 3 and 4 years, respectively. The fourth year drop in Nd:YAG capsulotomy rate has not been shown before in uveitis patients. This is consistent with our previous observation in non-diabetic and diabetic patients study and can be related to the limited survival and proliferative capacity of the LECs shown in experimental studies (Kato et al, 1997b; Saika et al, 2002). The incidences, however, especially within the first 2 years, were higher than those reported before in patient without uveitis (Table 4-5). This was also the case in the non-uveitic and uveitic group, where the incidences were consistently higher in patients with uveitis over the first 2 years.

Although, we could not establish an independent risk associated with the presence of uveitis for an overall increase in the rate of Nd:YAG capsulotomy, the increased incidence within the first 2 years after surgery is in agreement with other studies. Abela Formanek et al (Abela-Formanek et al, 2002d) found that uveitis patients had a denser PCO at 6 months after surgery. Also, Dana et al suggested an increased incidence of PCO in patients with uveitis that is related to their younger age at the time of surgery (Dana et al, 1997).
Table 4-6. Demographic features and prevalence of PCO after phacoemulsification in uveitis patients in recent studies of similar follow-up.

<table>
<thead>
<tr>
<th>Study type</th>
<th>Dana et al, 1997 (N=78 (108 eyes)*</th>
<th>Rauz et al, 2000 (N=49 (60 eyes))</th>
<th>Estefanous et al, 2001 (N=32 (39 eyes))</th>
<th>Suresh et al, 2001 (N=75 (86 eyes))</th>
<th>This study (N=101 (101 eyes))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>6-81</td>
<td>9-83</td>
<td>21-73</td>
<td>19-89</td>
<td>14.1-88.2</td>
</tr>
<tr>
<td>Mean</td>
<td>68.5†</td>
<td>48.2</td>
<td>50</td>
<td>43.8</td>
<td>52.8</td>
</tr>
<tr>
<td>Follow-up (months)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>-</td>
<td>1-33</td>
<td>3-63</td>
<td>4-63</td>
<td>3-79.5</td>
</tr>
<tr>
<td>Mean</td>
<td>51.6</td>
<td>17.03</td>
<td>20</td>
<td>24.1</td>
<td>23.3</td>
</tr>
<tr>
<td>PCO</td>
<td>-</td>
<td>49(81.7%)</td>
<td>24(62%)</td>
<td>36(42%)</td>
<td>39(38.6%)</td>
</tr>
<tr>
<td>Nd:YAG capsulotomy</td>
<td>58(54%)</td>
<td>5(8.3%)</td>
<td>12(31%)</td>
<td>18(21%)</td>
<td>33(32.7%)</td>
</tr>
<tr>
<td>IOL deposits</td>
<td>-</td>
<td>19(31.7%)</td>
<td>-</td>
<td>17(19.7%)</td>
<td>3(3%)</td>
</tr>
<tr>
<td>Treatment of deposits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Nd:YAG or steroids)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†Median, *80% had a posterior chamber IOL.
Table 4-7. Comparison of the incidences of Nd:YAG capsulotomy in previous studies of non-uveitic and uveitic patients

<table>
<thead>
<tr>
<th></th>
<th>Non-uveitic</th>
<th></th>
<th>Uveitic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dana et al, 1997*</td>
<td>Baratz et al, 2001</td>
<td>Ando et al, 2003</td>
<td>Dana et al, 1997**</td>
</tr>
<tr>
<td>Type of study</td>
<td>Retrospective</td>
<td>Retrospective</td>
<td>Retrospective</td>
<td>Retrospective</td>
</tr>
<tr>
<td>No.</td>
<td>106(122 eyes)</td>
<td>2718</td>
<td>3997</td>
<td>78(108 eyes)</td>
</tr>
<tr>
<td>M:F (%)</td>
<td>-</td>
<td>33:67</td>
<td>34.8:65.2</td>
<td>-</td>
</tr>
<tr>
<td>Average age in years (Range)</td>
<td>68.5†(27-96)</td>
<td>74‡(1-103)</td>
<td>-</td>
<td>44.5†(6-81)</td>
</tr>
<tr>
<td>Average follow-up in months (Range or SD)</td>
<td>46.8</td>
<td>44.4‡(0-116.4)</td>
<td>17.8‡(17.1 SD)</td>
<td>51.6</td>
</tr>
<tr>
<td>% Incidence (95% confidence interval)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Up to 1 year</td>
<td>11.5 (6.2, 16.8)</td>
<td>6 (5, 7)</td>
<td>1.95 (1.43, 2.47)</td>
<td>38.5 (28.9, 48.2)</td>
</tr>
<tr>
<td>&gt;1 year-2 years</td>
<td>-</td>
<td>15 (14, 17)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>&gt;2 years-3 years</td>
<td>38.4 (29, 47.8)</td>
<td>23 (20, 25)</td>
<td>18.5 (16.1, 20.9)</td>
<td>56 (45.8, 66.3)</td>
</tr>
<tr>
<td>&gt;3 years-4 years</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>&gt;4 years-5 years</td>
<td>-</td>
<td>33 (31, 35)</td>
<td>32.7 (28.7, 36.7)</td>
<td>-</td>
</tr>
<tr>
<td>&gt;5 years-6 years</td>
<td>-</td>
<td>38 (35, 40)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

SD=Standard deviation, † Median, ‡ Mean, * 98% had a posterior chamber IOL, **80% had a posterior chamber IOL.
4.3.3.2 Risk factors for Nd:YAG capsulotomy

In the uveitis group, an increased Nd:YAG capsulotomy rate was associated with hydrogel IOLs, while a decreased rate was associated with plate-haptic and 3-piece silicone IOLs, in comparison to PMMA IOLs, and with the use of prophylactic steroids. There was no significant difference in the rate of Nd:YAG capsulotomy between patients with anterior and posterior uveitis nor between those who developed postoperative inflammation and those who did not. Also, neither ethnic origin nor gender affected the rate of Nd:YAG capsulotomy. In the non-uveitic and uveitic group, there was no association between increased risk of Nd:YAG capsulotomy over the follow-up period and the presence of uveitis, gender, ethnic origin, younger age, surgeon’s grade or the type of IOL. In the study by Dana et al, 1997 (Dana et al, 1997), increased PCO rate in uveitis patients and was attributed mainly to the patients’ younger age at surgery rather than to the presence of uveitis. Increased PCO rate with hydrogel implants has been shown before in uveitis (Abela-Formanek et al, 2002a) and non-uveitis patients (Abela-Formanek et al, 2002a; Hollick et al, 2000) and was ascribed to its increased water content in comparison with other implants, which encourages the proliferation of LECs.

To our knowledge, the effect of prophylactic steroids on lowering PCO rate in these patients has not been shown previously and may be related to inhibition of the lens epithelial cell proliferation as has been demonstrated in vitro studies with dexamethasone (McDonnell et al, 1988) and cyclosporin (Cortina et al, 1997). A possible indirect effect through inhibition of uveal inflammatory response cannot be excluded, however.

In the majority of patients, Nd:YAG capsulotomy was a relatively safe procedure and resulted in improvement of visual acuity in the majority of patients. The development of postoperative inflammation and CMO in 3 patients of those who needed the procedure (7.7%) seemed to be related to the natural course of the uveitis rather than to the procedure and its treatment was satisfactory.

There is lack of consensus regarding the most suitable type of IOLs to use in patients with uveitis (Rauz et al, 2000). In the current study, 3 patients with plate-haptic silicone IOLs developed clinically significant deposits on the anterior lens surface that required Nd:YAG laser treatment. Also, an increased rate of Nd:YAG laser
capsulotomy was found with the hydrogel implants. Both findings suggest that these two lenses should be better avoided in patients with uveitis.

4.3.4 Limitations

One caveat of this study seems to be its retrospective nature. We have tried to avoid bias in patient selection by including a continuous series. We also collected data about the possible surgery and uveitis-related potential confounders and used Cox multivariate analysis to account for differences in patient follow-up and to isolate independent factors associated with Nd:YAG capsulotomy. The lack of information on factors such as uveitis duration and the biochemical profile for all the patients, however, precluded their use in the multivariate analysis and their possible influence could not be rule out.

4.3.5 Conclusion

Posterior capsular opacification is the most frequent complication after phacoemulsification in uveitis patients. The incidence appears to be higher within the first two postoperative years than those reported in non-uveitic patients, although the presence of uveitis does not seem to be independently associated with an overall increased risk of PCO. Hydrophilic acrylic IOLs (in comparison to PMMA IOLs) and an age of 55 years or younger can be associated with an increased risk, while the use of prophylactic steroids and silicone IOLs (in comparison to PMMA IOLs) with a decreased risk of PCO. Nd:YAG capsulotomy is a relatively safe procedure and results in improvement of visual acuity in the majority of uveitis patients.
4.4 STUDY OF THE INCIDENCE AND RISK FACTORS OF ND:YAG CAPSULOTOMY IN UVEITIS PATIENTS: PHACOEMULSIFICATION VERSUS EXTRACAPSULAR CATARACT EXTRACTION

4.4.1 Patients and methods

4.4.1.1 Design

This is a retrospective study. The dataset of a previous study of ECCE in uveitis that was conducted at one of the study centres (Okhravi et al, 1999) was retrieved and added to dataset of the previous study. The variables common to both datasets were collated and a new dataset was created.

4.4.1.2 Inclusion and exclusion criteria

In order to match the two groups of patients, only patients who were followed up for at least 3 months and who had preoperative visual acuity of <6/18 were included. Both subgroups were managed using the same preoperative and postoperative protocols. The exclusion criteria were similar to those in the previous study.

4.4.2 Results

4.4.2.1 Patient Characteristics

Table 4-8 details the demographic and clinical features of the two groups of patients. There were 71 patients in the phacoemulsification group, 41 with anterior uveitis (57.7%) and 30 with posterior uveitis (42.3%) and 63 in the ECCE group, 38 (60.3%) with anterior uveitis and 25 (39.7%) with posterior uveitis. Prophylactic systemic steroids were used in 29 (41%) of phacoemulsification group and in 27 (43%) in the ECCE group.
### Table 4-8. Demographic and clinical features of patients in the phacoemulsification and ECCE groups

<table>
<thead>
<tr>
<th></th>
<th>Phacoemulsification (N=71)</th>
<th>ECCE (N=63)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>**Age (years) * **</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>52.4(15.4)</td>
<td>52(16.3)</td>
<td>0.92</td>
</tr>
<tr>
<td>Median</td>
<td>51.9</td>
<td>52.9</td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>41.9-64.5</td>
<td>37.8-66</td>
<td></td>
</tr>
<tr>
<td>Male: Female</td>
<td>30:41</td>
<td>30:33</td>
<td>0.53</td>
</tr>
<tr>
<td>**Ethnic origin (%) **</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>46(65%)</td>
<td>40(64%)</td>
<td>0.88</td>
</tr>
<tr>
<td>Asian</td>
<td>7(10%)</td>
<td>7(11%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Afro-Caribbean</td>
<td>8(11%)</td>
<td>16(25%)</td>
<td>0.81</td>
</tr>
<tr>
<td>**Uveitis diagnosis **</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior: posterior</td>
<td>30:41</td>
<td>38:25</td>
<td>0.76</td>
</tr>
<tr>
<td>**Systemic disease associated with the uveitis (%) **</td>
<td>16(23%)</td>
<td>13(21%)</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Preoperative Steroids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IOL†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA</td>
<td>19(26.8)</td>
<td>63(100)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PH silicone</td>
<td>18(25.4)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>12(16.9)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hydrophobic acrylic</td>
<td>14(19.7)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hydrophilic acrylic</td>
<td>8(11.3)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>**Time to Nd:YAG **</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>13</td>
<td>12.6</td>
<td>0.9</td>
</tr>
<tr>
<td>Median</td>
<td>10.8</td>
<td>11.9</td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>4.2-19.1</td>
<td>6.7-19.1</td>
<td></td>
</tr>
<tr>
<td><strong>Follow-up‡</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>23.1(19.4)</td>
<td>11.5(5.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median</td>
<td>15.9</td>
<td>11.3</td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>8.4-29.5</td>
<td>7.3-14.1</td>
<td></td>
</tr>
</tbody>
</table>

ECCE=extracapsular cataract extraction, IQR=interquartile range; PH=plate-haptic

*Independent t-test
† Chi-squared
‡ Mann-Whitney test
Chapter 4: Posterior capsular opacification in uveitis

The two groups had similar age, gender distribution, uveitis diagnoses and preoperative acuity. No significant difference was found in the proportion who had systemic diseases in association with uveitis or those who had preoperative prophylactic corticosteroids. The number of Asians in the ECCE group was significantly larger (16/63 vs. 8/71; \( p=0.03 \)) and the phacoemulsification group had a significantly longer follow-up (median=16.9 vs. 11.3, \( p<0.001 \)).

4.4.2.2 Postoperative findings

Postoperative visual improvement occurred in 66 (93%) and 64 (90%) of the phacoemulsification group and in 61 (96.8%) and 59 (93.7%) of the ECCE subgroup. Immediate postoperative BCVA was significantly better in the phacoemulsification group than in the ECCE group (\( p=0.015 \)).

Postoperative uveitis occurred in 14 patients (19.7%) in the phacoemulsification group and 19 patients (30.2%) in the ECCE subgroup. Macular oedema occurred in 14 (19.7%) and 13 (20.6%) in the phacoemulsification and ECCE subgroups, respectively.

4.4.2.3 Incidence of Nd:YAG capsulotomy

Nd:YAG capsulotomy was carried out on 22 patients in the phacoemulsification group and on 21 in the ECCE subgroup. The median time to Nd:YAG capsulotomy was 10.8 months in the phacoemulsification group (range=1.5-30.5 months) and 11.9 (range=3.3-26.9 months) in the ECCE subgroup. No postoperative complications were noted after Nd:YAG capsulotomy in either of the two subgroups.

Table 4-9 shows the incidences of Nd:YAG capsulotomy in the phacoemulsification and ECCE subgroups at each of the 6 monthly intervals following surgery. The incidences increased in the phacoemulsification group from 9% within the first 6 months to 20.2% within first half of the third year. In the ECCE subgroup, the incidences were 8.3% and 100% within the same periods. Notably, the incidences were consistently higher in the ECCE group after the first 6 months.
Table 4-9. Incidences of Nd:YAG capsulotomy in phacoemulsification and ECCE groups

<table>
<thead>
<tr>
<th></th>
<th>PE (n=71)</th>
<th></th>
<th></th>
<th>ECCE (n=63)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
<td>Entering the Period:</td>
<td>No of</td>
<td>Nd:YAG capsulotomy</td>
<td>% incidence</td>
</tr>
<tr>
<td></td>
<td>No. lost to follow-up</td>
<td>No. lost to follow-up</td>
<td>No of</td>
<td>Capsulotomy</td>
<td>% incidence</td>
</tr>
<tr>
<td>Up to 6 months</td>
<td>71:8</td>
<td>6</td>
<td>9</td>
<td>4.2, 18.2</td>
<td></td>
</tr>
<tr>
<td>&gt;6 months-12 months</td>
<td>57:11</td>
<td>6</td>
<td>11.7</td>
<td>5.5, 23.2</td>
<td></td>
</tr>
<tr>
<td>&gt;12 months-18 months</td>
<td>40:12</td>
<td>4</td>
<td>11.8</td>
<td>4.7, 26.6</td>
<td></td>
</tr>
<tr>
<td>&gt;18 months-24 months</td>
<td>24:5</td>
<td>2</td>
<td>9.3</td>
<td>2.6, 28.4</td>
<td></td>
</tr>
<tr>
<td>&gt;24 months-30 months</td>
<td>17:7</td>
<td>3</td>
<td>22.2</td>
<td>7.9, 48.9</td>
<td></td>
</tr>
<tr>
<td>&gt;30 months-36 months</td>
<td>7:0</td>
<td>1</td>
<td>14.3</td>
<td>2.6, 51.3</td>
<td></td>
</tr>
</tbody>
</table>

PCO = posterior capsular opacification
4.4.2.4 Factors affecting the rate of Nd:YAG capsulotomy

A Cox regression hazard model including the type of surgery in addition to the patients' age (<=55 years or > 55 years), gender, ethnic origin, uveitis type (anterior vs. posterior) the use of prophylactic steroids, the presence of a uveitis-associated systemic disease and the development of postoperative uveitis showed that ECCE was an independent risk factors for increased Nd:YAG capsulotomy rate (HR=2.02; 95% Confidence Interval (CI)=1.05, 3.89; \( p=0.03 \)) in comparison with PE, and so was age of 55 years or younger (HR=2.69; 95% CI=1.36, 5.30; \( p=0.004 \)) in comparison with those of older age. The use of prophylactic steroids reduced the risk for Nd:YAG capsulotomy (HR=0.52; 95% CI=0.27, 0.98; \( p=0.04 \)), Figures 4-2. The development of postoperative uveitis mildly increased the risk (HR=1.88; 95% CI=0.98, 3.58; \( p=0.06 \)).

Including the type of IOL in the regression model (Table 4-8) showed that surgery had no significant effect while age of 55 years or younger, the use of prophylactic steroid and the development of postoperative uveitis were associated with increased risk of Nd:YAG capsulotomy. On the other hand, in comparison with PMMA IOL, plate-haptic silicone and 3-piece silicone IOLs were associated with a decreased while hydrophilic acrylic IOL with an increased risk.

Nd:YAG capsulotomy was generally a safe procedure and none of the patients developed a clinically significant complication that required treatment.
### Table 4-10. Cox regression analysis of the factors affecting the rate of Nd:YAG capsulotomy

<table>
<thead>
<tr>
<th></th>
<th>HR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;55 years</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;=55 years</td>
<td>2.62</td>
<td>1.30, 5.30</td>
<td>0.007</td>
</tr>
<tr>
<td><strong>Prophylactic steroids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.27</td>
<td>0.13, 0.56</td>
<td>0.0005</td>
</tr>
<tr>
<td><strong>IOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PH silicone</td>
<td>0.09</td>
<td>0.02, 0.40</td>
<td>0.001</td>
</tr>
<tr>
<td>3-piece silicone</td>
<td>0.18</td>
<td>0.05, 0.68</td>
<td>0.01</td>
</tr>
<tr>
<td>Hydrophobic acrylic</td>
<td>0.93</td>
<td>0.28, 3.10</td>
<td>0.91</td>
</tr>
<tr>
<td>Hydrogel</td>
<td>5.81</td>
<td>1.57, 21.49</td>
<td>0.008</td>
</tr>
<tr>
<td><strong>Postop uveitis</strong></td>
<td>2.65</td>
<td>1.36, 5.18</td>
<td>0.004</td>
</tr>
</tbody>
</table>

HR=Hazard ratio; CI=confidence interval, IOP=intraocular pressure, PH=plate-haptic
Chapter 4: Posterior capsular opacification in uveitis

![Cumulative Survival Graph](image)

**Age**
- >55 years
- >55 years-censored
- <=55 years
- <=55 years-censored

**Systemic Steroids**
- Yes
- Yes-censored
- No
- No-censored

Time (months)
Chapter 4: Posterior capsular opacification in uveitis

4.4.3 Discussion

Figure 4-3. Kaplan-Meier curve of Nd:YAG capsulotomy rate of phacoemulsification and ECCE groups
4.4.3 Discussion

Posterior capsular opacification occurred in 22% and 21% in the phacoemulsification and ECCE groups after a median follow-up of 16.1 and 11.3 months respectively. PCO rate, albeit similar in the two groups within the first 6 months, was consistently higher following ECCE within the rest of the first year and second year (Table 4-7).

Extracapsular cataract extraction and age of 55 years or younger age were independent risk factors for the development of clinically significant PCO. A lower PCO rate following phacoemulsification was found in non-uveitis patients (Minassian et al, 2001; Ram et al, 2001). This is believed to be mainly due to the improved cortical clean up and modern lens material and design used in patients undergoing PE (Apple et al, 2001). This was further supported by the absence of an independent effect of the surgical procedure after including IOL type as a separate variable to the multivariate model.

Also, the relationship between younger age and increased PCO rate has been established before (Wormstone et al, 1997) and was explained in view of the better survival and proliferative capacity of the LECs (Oharazawa et al, 2001; Balaram et al, 2000). Less traumatic removal of the lens nucleus by and hence the lower magnitude of blood-aqueous barrier damage (Pande et al, 1996b; Chee et al, 1999) and inflammatory response (Oshika et al, 1992) could be contributory to lowering the PCO rate after PE.

The development of postoperative inflammation, the use of prophylactic steroids and IOL type independently affected the rate of PCO development. Increased PCO in uveitis patients and in patients who develop postoperative inflammation can be related to the stimulatory effect of the plasma-derived growth factors in the aqueous of these patients, as a result of blood-aqueous barrier breakdown, on LEC proliferation (The paracrine mechanism in 1.1.6.1.2.1.3). In a study by Wormstone et al, 1997 (Wormstone et al, 1997), the addition of serum to the growing LECs increased the rate of lens epithelial cell proliferation via increasing the amount of stimulating growth factors in the aqueous humour. The effect of prophylactic steroids and intraocular lenses has been discussed in the previous study.
4.4.4 Limitations

The comparability of the two subgroups in the known major sources of bias, such as age, preoperative acuity, use of prophylactic steroids and type of uveitis in addition to the standard protocol of management used in both groups must have limited that and yielded fairly reliable comparisons. It was not possible to include factors such as the preoperative course or severity of the disease because of the different length of time after the onset of the disease when the patients were referred to us and because of the lack of standardised system for clinically grading the severity of uveitis.

4.4.5 Conclusion

This study has shown that in patients with uveitis, the surgical technique affect the rate of Nd:YAG capsulotomy over the follow-up period. This appears to be related mainly to the type of the IOL rather than to the surgical technique per se. Other risk factors include younger age, the development of postoperative uveitis and hydrophilic acrylic IOL, in comparison to PMMA IOLs while the use of prophylactic steroid seems to have a protective effect against the development of PCO.
CHAPTER 5

POSTERIOR CAPSULAR OPACIFICATION AFTER MULTIFOCAL INTRAOCULAR LENS IMPLANTATION
5 POSTERIOR CAPSULAR OPACIFICATION AFTER MULTIFOCAL INTRAOCULAR LENS IMPLANTATION

5.1 STUDY OF THE INCIDENCE OF POSTERIOR CAPSULAR OPACIFICATION AND ND:YAG CAPSULOTOMY AFTER IMPLANTATION OF MULTIFOCAL INTRAOCULAR LENS IMPLANTATION

5.1.1 Introduction

SA40N Array intraocular lens (Advanced Medical Optics, Inc. (AMO)) (Fine & Hoffman, 2000; Steinert, 2000; Avitabile & Marano, 2001) is a second-generation silicone refractive multifocal IOL that enables focusing for near as well as for intermediate and distant objects. The lens design was discussed in detail in 1.1.4.2.4. It has five aspheric concentric zones that incorporate an additional refractive power of 3.5 diopters (Figures 1-7 & 1-8). The design allows 50% of the light entering the eye to be dedicated to distance focusing, 13% to intermediate focusing and 37% to near focusing. Because of these features, the Array IOL is known to cause dysphotopic symptoms such as glare (Haring et al., 2001; Javitt & Steinert, 2000; Leyland et al., 2002; Leyland & Zinicola, 2003; Steinert et al., 1999) and to reduce contrast sensitivity (Gimbel et al., 1991; Leyland & Zinicola, 2003; Steinert et al., 1999).

Dysphotopic symptoms and reduced contrast sensitivity can be exacerbated by opacification of the posterior capsule, which often gives rise to similar symptoms (Magno et al., 1997; Tan et al., 1998; Meacock et al., 2003; Hayashi et al., 2003), and, therefore, could potentially increase Nd:YAG capsulotomy rate among patients with this implant. Also, it is not known if factors such increasing age (Schmitz et al., 2000) and the degree of corneal astigmatism, which were found to affect the degree of contrast sensitivity loss as well as patients' satisfaction with these lenses (Ravalico et al., 1999) (Hayashi et al., 2000), can similarly affect the rate of Nd:YAG capsulotomy.
Several reports have been published on the incidence of PCO with monofocal silicone IOLs, which ranged between 24% to 39% up to 3 years after surgery (Mamalis et al, 1996b; Milazzo et al, 1996). One previous study reported an incidence of 32.5% PCO within one year in patients with diffractive multifocal IOLs (Voigt & Strobel, 1999). No study to date, however, has reported the long-term incidence and potential risk factors of PCO development and Nd:YAG capsulotomy following implantation of refractive multifocal IOLs.

5.1.2 Aims

The purpose of this study was to report the incidence of PCO and Nd:YAG capsulotomy after implantation of multifocal AMO Array IOL. We also aimed to examine the potential risk factors associated with the development of PCO and the symptoms most frequently prompting Nd:YAG capsulotomy.

5.1.3 Patients and methods

5.1.3.1 Inclusion and exclusion criteria

All available clinical notes of consecutive patients who underwent phacoemulsification and implantation of AMO Array IOLs between January 1996 and September 2002 (n=181) were retrieved and reviewed. All those who had uneventful surgery were eligible for inclusion. Exclusion criteria included amblyopia (n=1), concurrent ocular pathology such as significant macular scars of age-related maculopathy (n=3), uveitis (n=2) and glaucoma (n=3), a systemic disease that could affect PCO development such as diabetes mellitus (n=3) and long-term use of systemic steroids or cytotoxic agents (n=8). One eye only was randomly chosen for those who had bilateral surgery (n=11), which left 150 eyes of 150 patients.

5.1.3.2 Surgical technique

All the patients were operated on by a single surgeon using a standard phacoemulsification technique involving a temporal corneal section, capsulorhexis, hydrodissection, washout of the cortical matter, and insertion of the IOL using an unfoldable (Advanced Medical Optics, Inc.). This was followed by subconjunctival injection of Cefuroxime 100mg and methylprednisolone acetate 40mg (Depo-Medrone, Pharmacia & Upjohn) at the conclusion of the procedure. Postoperative
treatment included G. Maxitrol (Alcon) QDS for 2 weeks then BID for 2 weeks or G Chloramphenicol and Dexamethosone 1% in patient allergic to the preparation. Patients were reviewed at 1 day, 6 weeks and 3 months then discharged or further follow-up arranged should there be a clinical indication.

5.1.3.3 Data collection

A spreadsheet was used for entering all the relevant data including age at surgery (<75 years & &ge; 75 years), the medical and ocular history, Snellen’s best-corrected visual acuity (BCVA) preoperatively, postoperatively as well as pre and post Nd:YAG capsulotomy, the time to Nd:YAG capsulotomy and follow-up time. The occurrence of uveal inflammation that required steroid treatment within 3 months after surgery, the dioptric power of the IOL, postoperative refraction and visual symptoms that prompted capsulotomy were recorded. The spherical equivalent was categorised into: emmetropic, myopic or hyperopic, and the presence of astigmatism into <1 dioptre or &ge; 1 dioptre.

5.1.3.4 Outcome measure and statistical analysis

Two outcome measures were examined: the presence of PCO and the need for Nd:YAG capsulotomy. Patients were either self-referred or referred by a primary care unit if they had developed visual symptoms attributable to PCO i.e. blurred or double vision or increased glare or halos. Patients were offered Nd:YAG capsulotomy if they were found to have PCO in the presence of the above symptoms or impaired fundus visualization. Slitlamp grading of PCO was carried out by a single observer into: mild (faint opacity, clear fundus view, with or without minimal symptoms of reduced acuity or glare symptoms), moderate (moderate opacity, slightly hazy fundus view, and symptoms of glare or reduced acuity) or severe (severe opacity, blurred fundus view and symptoms of reduced acuity).

The Statistical Package for Social Science software for Windows (Release 9, SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis. Survival tables were used to derive the incidences of PCO and Nd:YAG capsulotomy. The incidence was calculated as the number of events (i.e. PCO or Nd:YAG) divided by the number of patients at risk at each of the time intervals (No. of patients entering the period-50% of those lost to follow-up). Confidence intervals for incidences were calculated using the Wilson score method. Log rank and the Median tests were used for comparisons.
and a p value of $<0.05$ was considered significant. The study had more than 90% power to detect a 10% difference in hazard ratio for the examined risk factors of PCO (age, refractive outcome, degree of astigmatism and postoperative inflammation).

5.1.4 Results

5.1.4.1 Patient characteristics

We included 150 patients, of whom 87 (58%) were female. The median age was 78 years (range=47-100) and the median follow-up 23.4 months (range=1.4-73.2).

Twenty-three patients (15.3%) were referred with PCO, 14 of whom (60.1%) were of grade 1 and 9 (39.1%) of grade 2. Nd:YAG capsulotomy was performed in 14 (9.3%) and the median time to Nd:YAG capsulotomy was 25.2 months (range=8.6 to 47.7 months).

5.1.4.2 Incidence of PCO and Nd:YAG capsulotomy

Survival tables (Table 5-1) and the survival curves (Figure 5-1) show the incidences of PCO and Nd:YAG capsulotomy within 6 years of follow-up. Both show that the majority of PCO and Nd:YAG capsulotomy occurred between two and four years after surgery and that no new cases of PCO or Nd:YAG capsulotomy were noted after the fourth year.
Table 5-1. Incidence of PCO and Nd:YAG capsulotomy

<table>
<thead>
<tr>
<th>PCO (n=23)</th>
<th>Nd:YAG capsulotomy (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
</tr>
<tr>
<td></td>
<td>Entering the Period:</td>
</tr>
<tr>
<td>Up to 1 year</td>
<td>150:27</td>
</tr>
<tr>
<td>&gt;1 year-2 years</td>
<td>121:47</td>
</tr>
<tr>
<td>&gt;2 years-3 years</td>
<td>69:26</td>
</tr>
<tr>
<td>&gt;3 years-4 years</td>
<td>34:16</td>
</tr>
<tr>
<td>&gt;4 years-5 years</td>
<td>11:8</td>
</tr>
<tr>
<td>&gt;5 years-6 years</td>
<td>3:3</td>
</tr>
</tbody>
</table>

PCO=posterior capsular opacification
Figure 5-1. Kaplan-Meier survival curve of PCO (a) and Nd:YAG capsulotomy (b) over the follow-up period. It shows that the majority of cases occurred between 2 to 4 years after surgery.
Table 5-2 shows that patients who developed PCO were younger (median=74.4 years) than those who did not (median=78.4) \((\text{Median test}; p=0.01)\). The difference was only of borderline significance between those who required Nd:YAG capsulotomy and those who did not (median=75.5 vs. 78.1); \((\text{Median test}; p=0.09)\).

Postoperative refraction was available on 122 and IOL power on 148 of the patients. No significant difference was found in postoperative spherical equivalence or in the power of the IOL given between patients who underwent Nd:YAG capsulotomy and those who did not. Kaplan-Meier survival analysis and Log-rank test showed that gender, postoperative inflammation, the refractive outcome (myopic, emmetropic & hyperopic) and the degree of astigmatism (<1 dioptre & >=1 dioptre) did not have a statistically significant effect on the rate of PCO or Nd:YAG capsulotomy.

PCO-related symptoms that prompted Nd:YAG capsulotomy included predominantly reduction of BCVA, which ranged between 1 to 5 Snellen’s lines (median=2.5 lines) \((n=12; \ 85.7\%)\) and, less frequently, glare or halos \((n=2, \ 14.3\%)\), which was not associated with reduced acuity in either of them.

| Table 5-2. Clinical features of patients who developed PCO and those who underwent Nd:YAG capsulotomy |
|---|---|---|---|
| | PCO | Nd:YAG capsulotomy |
| | Yes (n=23) | No (n=127) | Yes (n=14) | No (n=136) |
| Age (years) | | | | |
| Median | 74.4 | 78.4 | 75.5 | 78.1 |
| IQR | 66-79.6 | 72.9-83.1 | 68.2-80.7 | 72.3-82.9 |
| Sex | | | | |
| M:F | 12:11 | 51:76 | 9:5 | 54:82 |
| IOL power (dioptres) | | | | |
| Median | 21.5 | 21 | 21.3 | 21 |
| IQR | 19.5-22.5 | 20-22.5 | 19.4-22.6 | 19.9-22.5 |
| Postop sph. equivalent | | | | |
| Median | -0.25 | 0.13 | -0.25 | 0.13 |
| IQR | -0.50 to 0.50 | -0.50 to 0.50 | -0.88 to 0.43 | -0.5 to 0.50 |
| Postop inflammation | | | | |
| Yes/No | 4/19 | 8/119 | 2/12 | 10/126 |

PCO=posterior capsular opacification, M=male, F=female, IQR=interquartile range
5.1.5 Discussion

5.1.5.1 Incidences of PCO and Nd:YAG capsulotomy

This study is the first to report the long-term incidence of PCO with AMO ARRAY multifocal implants. The estimated annual incidences were based on the number of patients who were self-referred or were referred by primary care units for PCO-related symptoms. The assumption of the study was that the rest of the patients either had clinically insignificant PCO or did not require Nd:YAG capsulotomy for their vision was reduced because of other concomitant ocular pathology. As such, our estimated incidences should reflect those in the majority of secondary ophthalmic units. Sundelin and Sjostrand (Sundelin & Sjostrand, 1999) estimated that a ‘hidden’ group of patients that would have clinically significant PCO and benefit form Nd:YAG capsulotomy represents only 9% of patients within 5 years following cataract extraction.

In this study, the incidences of PCO were 1.5% (0.4, 5.2), 5.1% (2.2, 11.5), 16.1% (8.7, 27.8) and 26.9% (13.7, 46) and that of Nd:YAG capsulotomy were 1.5% (0.4, 5.2), 3.1% (1.1, 8.8), 9.2% (4, 19.9) and 16.7% (6.7, 35.9) after 1, 2, 3 and 4 years of follow-up. These progressively increasing incidences concur with the study by Ando et al, (Ando et al, 2003) who reported a cumulative probability of capsulotomy of 1.95%, 18.5% and 32.7% after 1, 3, and 5 years, respectively. The relatively higher percentage in their study could possibly be related to the variety of IOLs used, which included PMMA (43.6%), silicone (41.5%) and acrylic (12.6%) types, in addition to the inclusion in their series of patients with other systemic and ocular comorbidity such as diabetes mellitus (14%), diabetic retinopathy (5.2%) and retinitis pigmentosa (0.8%).

In our study, no cases were noted after the fourth year possibly because of the relatively small number of patients that were followed up more than 4 years. Baratz et al (Baratz et al, 2001) in a large retrospective series, reported a cumulative incidence of 23% at 3 years that increased to 33% at 5 years and only to 38% at 9 years. They suggested that the increase in PCO rate that occurs within the first 5 years might not continue after the sixth year. This could be related to a plausible temporal decline in the survival of LECs and their proliferative capacity.
The PCO incidence in this study is less than that reported after other multifocal IOLs. Negishi and associates (Negishi *et al*, 1996) reported 4.2% incidence of PCO after 6 months of follow-up of patients who had a five-zone refractive multifocal IOL made of PMMA. The incidences in our study are, however, comparable to those reported after other modern silicone and acrylic IOLs. Beltrame *et al* (Beltrame *et al*, 2002) found that two years after surgery 27.6% of patients with the SI-40 monofocal silicone lens had PCO and 9.7% had Nd:YAG laser capsulotomy. Oner *et al* (Oner *et al*, 2000) and Abhilakh *et al* (Abhilakh Missier *et al*, 2003) reported incidences of 14.3% and 8.5% of PCO after 18 months and 3 years of implantation of acrylic IOLs, respectively.

### 5.1.5.2 Risk factors for PCO and Nd:YAG capsulotomy

We found that patients who developed PCO were younger, but there was no significant age difference between those who had Nd:YAG capsulotomy and those who did not. The explanation could be that the need for Nd:YAG capsulotomy is perhaps more related to the magnitude of influence of PCO on visual function and visual demands dictated by patients' life style than their age. On the other hand, our sample size could have limited the ability to detect a difference in the age between patients who needed Nd:YAG capsulotomy and those who did not.

### 5.1.5.3 Symptoms associated with Nd:YAG capsulotomy

Patients required Nd:YAG capsulotomy predominantly for reduced vision (85.7%) rather than for glare symptoms (14.3%). This concurs with the findings by Hayashi *et al* (Hayashi *et al*, 2003) that PCO value in patients with monofocal IOLs correlates more strongly with visual acuity than with contrast sensitivity and glare sensitivity. Notably, however, none of our patients had PCO of more than grade 2 and it is not known if that is due to a tendency of these patients to present earlier due to the effect of PCO on other visual functions such as near acuity or contrast sensitivity.

### 5.1.6 Limitations

The limitation of this study is related to the retrospective design. Future prospective studies that will include a contemporary group of patients with monofocal implants will be able to avoid some of the inherent potential bias of the retrospective design and will help to directly compare the incidences as well as the differential effect of...
PCO on the different aspects of visual function between the two groups. It will also help to establish if that effect will rather vary the length of time to presentation and to requiring Nd:YAG capsulotomy than its incidence.

5.1.7 Conclusion

After phacoemulsification and AMO ARRAY IOL implantation, PCO and Nd:YAG capsulotomy incidences are similar to those reported after other modern foldable monofocal implants. The incidences steadily increase till the fourth year, with the majority of cases occurring after the first year. PCO tends to develop in younger patients and Nd:YAG capsulotomy, similar to the case with monofocal implants, appears to be largely prompted by reduced vision rather than glare symptoms.
5.2 STUDY OF THE EFFECT OF POSTERIOR CAPSULAR OPACIFICATION ON VISUAL FUNCTION IN PATIENTS WITH MONOFOCAL AND MULTIFOCAL INTRAOCULAR LENSES

5.2.1 Introduction

Posterior capsular opacification (PCO), by causing forward and backward light scattering, reduces visual acuity and contrast sensitivity (Cheng et al, 2001; Meacock et al, 2003; Hayashi et al, 2003; Magno et al, 1997; Tan et al, 1999). The magnitude of the effect of PCO on visual function was found to be related mainly to its location, density and type, with epithelial pearls having a more pronounced effect on visual acuity and contrast sensitivity (Cheng et al, 2001; Aslam et al, 2003a; Aslam & Patton, 2004).

All published studies of the effect of PCO on visual function have been conducted on patients with monofocal IOLs. Because multifocal intraocular lens design reduces contrast sensitivity (Haring et al, 2001; Leyland & Zinicola, 2003), it is not known if this can be exacerbated by the development of PCO, which could lead to an increased rate of Nd:YAG capsulotomy. We hypothesised that the magnitude of PCO-induced impairment of visual function when presenting for Nd:YAG capsulotomy might be different between patients with monofocal and multifocal IOLs.

5.2.2 Aim

The aim of this study was to compare the functional impairment in patients with monofocal and multifocal IOLs who presented for Nd:YAG capsulotomy. The results will help in understanding the relative effect of this complication on visual function in the two groups of patients and to assess whether functional loss can potentially be a risk factor for increased Nd:YAG capsulotomy rate.
5.2.3 Patients and method

This is a prospective non-randomised case-control study. The appropriate ethical approval was obtained for the study and all eligible patients were informed of the study design and its aims before they gave consent to be included.

5.2.3.1 Eligibility and inclusion criteria

Fifty-four patients were recruited consecutively from the outpatient clinic at Essex County Hospital, Colchester between April and November 2004. Only the first eye to develop the symptoms for patients who needed bilateral Nd:YAG capsulotomy was included. Patients were considered eligible for inclusion if they had undergone cataract extraction and implantation of either monofocal or multifocal IOLs and were referred because of visual symptoms attributable to PCO and had lost at least one line of Snellen’s visual acuity.

5.2.3.2 Exclusion criteria

Patients with a history suggestive of amblyopia (n=1) or colour blindness (n=1) and those who had glaucoma (n=6), diabetic retinopathy (n=4), neo-vascular or atrophic age-related maculopathy (n=6) or pupillary abnormality (n=3) were excluded, which left 33 patients.

5.2.3.3 Examination

5.2.3.3.1 Visual acuity

High-contrast (90%) distance and near best-corrected visual acuities (BCVA) were measured using logMAR charts at 3 meters and 40 cm, respectively. The charts were externally illuminated and illumination levels at the charts were 400 lux. The patients were encouraged to read as far down the charts as they can. The acuity was recorded as a logMAR score of the total number of letters that were identified correctly.

5.2.3.3.2 Contrast sensitivity

Pelli-Robson and low-contrast (10%) logMAR acuity charts were used to examine contrast sensitivity. Pelli-Robson chart has 8 lines of Sloan letters that subtend a visual angle of 3 degrees at a test distance of 1 meter. The letters are arranged in triplets, each progressively decrease in contrast from 96% to 1%. The 10% logMAR
acuity chart was tested at 3 meters. Both charts were externally illuminated and the illumination levels at their surfaces were approximately 400 and 300 lux, respectively.

5.2.3.3 Colour vision

All the patients underwent Ishihara test to identify those with congenital colour blindness. Colour vision was then tested using Lanthony desaturated D15 test that was conducted under an additional external illumination of 1000 lux produced by a fluorescent lamp placed at 35 cm from the colour chips. The Colour Vision Recorder software (v. 2.3; Optical Diagnostics, The Netherlands) was used to record the results and to calculate the colour confusion index (CCI). (Bowman, 1982) The latter indicates how much the patient's arrangement of the colour chips deviates from the perfect arrangement: an index of 1 indicates a perfect arrangement and a value larger than 1 indicates some colour confusion or error.

5.2.3.4 Slit lamp examination

This included anterior segment and fundus examination in addition to intraocular pressure measurement.

5.2.3.5 Determining type and grading of PCO

A single examiner determined the PCO type and grade. PCO was classified clinically into 'fibrotic' or 'cellular' according to the predominant feature (> 50%) within the retro-optic part of the posterior capsule. PCO grading was carried out after pupillary dilatation and was determined based on the visibility of the posterior segment structures on the slit lamp. A modification of the grading system used by several other authors (Aslam & Dhillon, 2002; Kucuksumer et al, 2000; Kruger et al, 2000; Sellman & Lindstrom, 1988) was adopted (Table 5-3).
Chapter 5. PCO after Multifocal IOL Implantation

Table 5-3. PCO grades

<table>
<thead>
<tr>
<th>Grade I (Mild)</th>
<th>The outlines of the optic nerve head and main retinal vessels (± retinal striations) are clearly distinguishable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade II (Moderate PCO)</td>
<td>The outlines of the optic nerve head or of the main retinal blood vessels are blurred</td>
</tr>
<tr>
<td>Grade III (Severe or Dense)</td>
<td>The optic nerve head and blood vessels are barely visible.</td>
</tr>
</tbody>
</table>

5.2.3.4 Questionnaire

A questionnaire (Table 5-4) was administered by the examiner during the consultation before and 2 to 6 weeks after capsulotomy. It included questions about different PCO-related visual symptoms, including blurred distance and near vision, colour vision, dysphotopic symptoms or diplopia. Patients were asked to rate the symptoms as mild, moderate or severe, depending on how much it affected their day-to-day activities. After capsulotomy, the questions were whether the symptoms have disappeared, improved or got worse and if new symptoms had developed.

5.2.3.5 Nd:YAG capsulotomy

Before capsulotomy, G. Tropicamide 1% was instilled in the eye to achieve 4 to 6mm of pupillary dilation. Also, G. Apraclonidine 0.1% (Iopidine) was used before and after the procedure to prevent rise of intraocular pressure. The procedure was preformed using Cooper Vision 2500 (Alcon) machine and 2 to 4mJ of energy per pulse that were increased as needed. The laser beam was posteriorly defocused in order to avoid pitting the lens.

5.2.3.6 After care

After capsulotomy, G. Dexamethasone 0.1% (Maxidex; Alcon Inc.) was prescribed QDS for 1 week and BID for one week. All the patients were reviewed 2 to 6 weeks when the same visual tests were carried out and a questionnaire regarding the change in visual symptoms was administered. Visual acuity, contrast sensitivity and colour vision were assessed as before and under the same conditions. The anterior and posterior segments were assessed for adequacy of the capsular opening, IOL position, clarity of the visual axis, signs of inflammation and macular oedema.
Table 5-4. The questionnaires administered before and after Nd:YAG capsulotomy

**Before capsulotomy**

**What is the main problem with the eye that needs laser treatment?**

Mild (can manage)/ Moderate (manage with difficulty)/ Severe (unable to manage)*

- Blurred distance vision (e.g. TV/reading signs or bus numbers)
- Blurred near vision (e.g. reading/needle work)
- Disturbed colour vision
- Glare
- Halos
- Streaks/stars/flare
- Double vision
- Other (please mention)

**After capsulotomy**

**How has the laser affected the symptoms you had?**

Disappeared, No change, Worse*

- Blurred distance vision (e.g. TV/reading signs or bus numbers)
- Blurred near vision (e.g. reading/needle work)
- Disturbed colour vision
- Glare
- Halo
- Streak/stars/flare
- Double vision
- Other (please mention)

* These were the choices for each of the questions.
5.2.3.7 Statistical Analysis

The primary outcome of the study was the difference in the presenting visual functions (distance and near visual acuity, contrast sensitivity and colour confusion index) at presentation between the two groups of patients. The secondary outcome was the difference in the proportion of patients with different PCO-related symptoms in the two groups.

We used the independent t-test or Mann-Whitney test (when the data were not normally distributed) for comparison of continuous data. Fisher's exact test was used for comparing proportions of patients with different PCO-related symptoms. The study had 90% power to detect a 0.2 log units (2 lines on the high and low contrast log MAR chart) in the mean preoperative acuity (SD 0.1), of 0.3 of log units of Pelli-Robson contrast sensitivity (1 line) and 0.25 in the mean colour confusion index (with a standard deviation of 0.15) at an alpha level of 0.05.

5.2.4 Results

5.2.4.1 Clinical features

Thirty-three patients were included in the study, 13 of them were males and the median age was 76.2 years (range 18 to 91). Thirty-two of the patients had undergone phacoemulsification and one extracapsular cataract extraction. Twenty-four patients (72.7%) had monofocal IOL, including PMMA: 95UV, Storz (Refractive index (RI)=1.49) (n=3, 12.6%); Silicone: SI30NB, SI40NB or Clariflex; Advanced Medical Optics, Inc. (RI=1.46) (n=15, 62.6%), Lenstec LH3000, Lenstec Inc. (RI=1.4585) (n=5, 25%) or Hydrogel: Li61U Soflex, Bausch & Lomb (RI=1.427) (n=1, 4.2%). Nine patients (27.3%) had silicone refractive multifocal IOL, Array SA40N, Advanced Medical Optics, Inc. (RI=1.46, n=9, 100%).

There was no significant difference in age, gender distribution, PCO type or grade, the time to presentation for capsulotomy or the spherical equivalent between the two groups (Table 5-5).
## Chapter 5. PCO after Multifocal IOL Implantation

### Table 5-5. Clinical features of patients in the two groups

<table>
<thead>
<tr>
<th></th>
<th>Monofocal</th>
<th>Multifocal</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>M:F</strong></td>
<td>12:12</td>
<td>1:8</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>75.1 (9.5)</td>
<td>67.01 (22.6)</td>
<td>0.48</td>
</tr>
<tr>
<td>Median</td>
<td>76.2</td>
<td>75.9</td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>71.4 to 82.6</td>
<td>54.4 to 83.1</td>
<td></td>
</tr>
<tr>
<td><strong>PCO type</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellular</td>
<td>10 (41.7%)</td>
<td>3 (33.3%)</td>
<td>0.25</td>
</tr>
<tr>
<td>Fibrotic</td>
<td>14 (58.3%)</td>
<td>6 (66.7%)</td>
<td></td>
</tr>
<tr>
<td><strong>PCO grade</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>5 (20.8%)</td>
<td>5 (55.6%)</td>
<td>0.15</td>
</tr>
<tr>
<td>Moderate</td>
<td>13 (54.2%)</td>
<td>3 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>6 (25%)</td>
<td>1 (11.1%)</td>
<td></td>
</tr>
<tr>
<td><strong>Time to Nd:YAG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>36.5 (34.6)</td>
<td>24.8 (18.3)</td>
<td>0.54</td>
</tr>
<tr>
<td>Median</td>
<td>28.9</td>
<td>16.5</td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>11.1 to 49.1</td>
<td>8.1 to 40.7</td>
<td></td>
</tr>
<tr>
<td><strong>Spherical equivalent</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>-0.31 (1.31)</td>
<td>-0.33 (0.56)</td>
<td>0.54</td>
</tr>
<tr>
<td>Median</td>
<td>0</td>
<td>-0.38</td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>-1.19 to 0.75</td>
<td>-0.69 to 0.06</td>
<td></td>
</tr>
</tbody>
</table>

M=male; F=female; SD=standard deviation; IQR=interquartile range

### 5.2.4.2 Visual function

At presentation, high- and low-contrast logMAR acuity were significantly better (smaller values) in the multifocal group (0.40 vs. 0.20; \(p=0.04\) & 0.34 vs. 0.98; \(p=0.006\)) (Table 5-6). On the other hand, near acuity, Pelli-Robson contrast sensitivity and CCI were not significantly different between the two groups. After capsulotomy, high- and low contrast distance and near visual acuity, Pelli-Robson contrast sensitivity and CCI were not significantly different between the two groups (Table 5-6).
Table 5-6. Visual function in the two groups of patients

<table>
<thead>
<tr>
<th></th>
<th>Monofocal (n=24; 72.7%)</th>
<th></th>
<th>Multifocal (n=9; 27.3%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Nd:YAG</td>
<td>Post-Nd:YAG</td>
<td>Difference</td>
</tr>
<tr>
<td>Distance BCVA (logMAR)</td>
<td>0.40 (0.58)*</td>
<td>-0.13(0.17)</td>
<td>0.54(0.64)</td>
</tr>
<tr>
<td>Near BCVA (logMAR)</td>
<td>0.68 (0.36)</td>
<td>0.19(0.17)</td>
<td>0.47(0.39)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.15 (0.39)</td>
<td>1.66(0.08)</td>
<td>0.48(0.39)</td>
</tr>
<tr>
<td>CS (Pelli-Robson)</td>
<td>0.98 (0.76)*</td>
<td>0.07(0.19)</td>
<td>0.88(0.79)†</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.31 (0.34)</td>
<td>1.23(0.41)</td>
<td>0.07(0.36) *</td>
</tr>
<tr>
<td>CCI</td>
<td>1.36 (0.48)</td>
<td>1.31(0.33)</td>
<td>0.09(0.36) *</td>
</tr>
</tbody>
</table>

BCVA=best-corrected visual acuity; logMAR=logarithm of minimum angle of resolution; SD=standard deviation; IQR=interquartile range; CS=contrast sensitivity; CCI=colour confusion index

*Mann-Whitney test
5.2.4.3 Questionnaire results

The presenting symptoms (Table 5-7 & Figure 5-2) in the majority of patients in the two groups were blurred distance or near vision (95.8% & 100% in the monofocal group and 88.9% and 66.7% in the multifocal group). Glare and halos affected 45.8% and 25% of patients in the monofocal group and each affected 44.4% of patients in the multifocal group. Other dysphotopic symptoms such as seeing stars/ streaks/ flare; and other symptoms such as double vision and floaters affected a smaller proportion of patients in the two groups. A significantly greater proportion of patients in the monofocal group had blurred near vision (24/24 vs. 6/9; Fisher’s exact; \( p=0.01 \)). There was no statistically significant difference between the proportions of patients affected by the other symptoms in the two groups. While the symptoms in the majority of patients in the monofocal group were moderate to severe, in the majority of patients in the multifocal group they were mild to moderate (Table 5-7).

After capsulotomy, Table 5-8 shows that all patients in the monofocal group experienced improvement or complete disappearance of their symptoms. One of the patients in the multifocal group (1/8, 12.5%) had persistent symptoms of blurred distance and near vision and another (1/8, 12.5%) had persistent glare and halos. Also, 19% and 25% of the monofocal and multifocal group, respectively, reported seeing floaters that was graded as mild by all the patients.
### Table 5-7. Questionnaire result before Nd:YAG capsulotomy

<table>
<thead>
<tr>
<th></th>
<th>Monofocal (n=24); n (%)</th>
<th></th>
<th>Multifocal (n=9); n (%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td><strong>Blurred distance vision</strong></td>
<td>1(4.2)</td>
<td>5(20.8)</td>
<td>9(37.5)</td>
<td>9(37.5)</td>
</tr>
<tr>
<td><strong>Blurred near vision</strong></td>
<td>0</td>
<td>4(16.7)</td>
<td>10(41.7)</td>
<td>10(41.7)</td>
</tr>
<tr>
<td><strong>Disturbed colour vision</strong></td>
<td>24(100)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Glare</strong></td>
<td>13(54.2)</td>
<td>2(8.3)</td>
<td>6(25)</td>
<td>3(12.5)</td>
</tr>
<tr>
<td><strong>Halos</strong></td>
<td>18(75)</td>
<td>2(8.3)</td>
<td>3(12.5)</td>
<td>1(4.2)</td>
</tr>
<tr>
<td><strong>Streaks/stars/flare</strong></td>
<td>20(83.3)</td>
<td>2(8.3)</td>
<td>1(4.2)</td>
<td>1(4.2)</td>
</tr>
<tr>
<td><strong>Double vision</strong></td>
<td>22(91.7)</td>
<td>2(8.3)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Floaters</strong></td>
<td>21(87.5)</td>
<td>3(12.5)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*<sup>p=0.01</sup>
Figure 5-2. Bar chart of the different presenting symptoms of PCO in the monofocal and multifocal IOL patients
Table 5-8. Questionnaire result after Nd:YAG capsulotomy

<table>
<thead>
<tr>
<th></th>
<th>Monofocal (n=21; 72.4%)</th>
<th></th>
<th>Multifocal (n=8; 27.6%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td></td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes (new cases)</td>
<td>The same</td>
<td>Less</td>
<td>Disappeared</td>
</tr>
<tr>
<td>Blurring of distance vision</td>
<td>0</td>
<td>0</td>
<td>5(23.8)</td>
<td>15(71.4)</td>
</tr>
<tr>
<td>Blurring of near vision</td>
<td>0</td>
<td>0</td>
<td>5(23.8)</td>
<td>16(76.2)</td>
</tr>
<tr>
<td>Disturbance of colour vision</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Glare</td>
<td>0</td>
<td>0</td>
<td>3(14.3)</td>
<td>7(33.3)</td>
</tr>
<tr>
<td>Halos</td>
<td>0</td>
<td>0</td>
<td>2(9.5)</td>
<td>4(19)</td>
</tr>
<tr>
<td>Streaks/stars/sunburst/flare</td>
<td>0</td>
<td>0</td>
<td>2(9.5)</td>
<td>2(9.5)</td>
</tr>
<tr>
<td>Double vision</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5(23.8)</td>
</tr>
<tr>
<td>Floaters</td>
<td>4(19)</td>
<td>3(14.3)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
5.2.5 Discussion

Several studies have shown that patients with monofocal and multifocal IOL have comparable visual functions and that the effect of the multifocal lens design on visual function is limited and clinically insignificant (Steinert et al, 1999; Vaquero et al, 1996; Arens et al, 1999; Elgohary & Beckingsale, 2004). In this study, we compared the presenting visual functions between two groups of patients who had either monofocal or multifocal IOLs and presented with PCO and needed Nd:YAG capsulotomy with view to relating that to a possible effect on Nd:YAG capsulotomy rate. We showed that while near BCVA, Pelli-Robson contrast sensitivity and colour confusion index were not significantly different at presentation in the two groups, high- and low-contrast acuity values were significantly greater in the multifocal group. After Nd:YAG capsulotomy, all visual functions were comparable in the two groups.

Hayashi et al (Hayashi et al, 2003) showed that visual acuity reflects most relevantly the degree of PCO. Other studies of the effect of PCO on contrast sensitivity (Meacock et al, 2003; Tan et al, 1999) have shown that patients suffer a predominantly global loss over all spatial frequencies and Cheng et al (Cheng et al, 2001) showed a preferential loss at low- to intermediate spatial frequency (6 cpd). Our finding suggest that logMAR acuity charts, perhaps by displaying a wide range of spatial frequencies (Adams, 1993) (Figure 5.3), are probably more sensitive in detecting PCO-related differences between the two groups than other charts.

There are two explanations for the difference between two groups: either that patients with multifocal IOLs were referred earlier for Nd:YAG capsulotomy or that these patients were less tolerant to PCO-induced functional loss. Against the first proposition is the fact that the two groups had comparable pre-capsulotomy features, including their PCO type (cellular or fibrotic) and grade. In support of the second proposition, is that in our multifocal group, the difference between pre-YAG and post-YAG mean functional loss was 0.33 log units for high contrast acuity, 0.24 log units for Pelli-Robson contrast sensitivity and 0.12 log units for low-contrast acuity. The respective values in the monofocal group were 0.54, 0.48 and 0.88 (Table 5-6). Moreover, the presenting symptoms in the multifocal group were predominantly mild or moderate while in the monofocal group moderate or severe. Also, although
Chapter 5. PCO after Multifocal IOL Implantation

symptoms in the two groups were generally comparable, more patients in the monofocal group had difficulty with reading than those in multifocal group. This, in addition to further confirming the earlier presentation of patients with multifocal IOLs, can be related to the enhancement of near vision performance achieved by the power incorporated within the multifocal IOL design.

Colour confusion index showed the least change of all the visual functions, indicating that colour vision is perhaps more resistant to PCO-induced blur. This is consistent with the evidence suggesting that colour vision is resistant to different forms of blur, including optical blur (Mantyjarvi & Tuppurainen, 1995; Degen et al., 1983) and that resulting from medial opacities such as cataract (Pinckers, 1980).

After capsulotomy, the majority of patients in the two groups experienced improvement or disappearance of their symptoms after capsulotomy. On the other hand, one patient (12.5%) with multifocal IOL experienced persistent glare or halos. In the other patient there was no explanation for the persistent blurring of vision. A small percentage in each group, (19% & 25%, respectively) developed floaters, but all patient reported that to be mild and not affecting their vision.

5.2.6 Limitations

It was not possible to compare the survival time between the two groups of patients nor between those in the subgroups with different PCO type and grade because of the small sample size and the absence of control groups who did not have PCO or require Nd:YAG capsulotomy. A similarly designed study with a larger sample size and a contemporary control group will enable further assessment of the incidences in patients with different types of PCO.

5.2.7 Conclusion

This study suggests that patients with multifocal IOLs present for Nd:YAG capsulotomy with a lesser magnitude of functional impairment, that mainly affects high- and low-contrast acuity. This perhaps reflects more vision-consciousness or sensitivity to early functional loss and could lead to a higher rate of Nd:YAG capsulotomy in these patients.
Chapter 5. PCO after Multifocal IOL Implantation

Contrast sensitivity

Figure 5-3. The relationship between different letter-based test charts and contrast sensitivity. (Courtesy of T. Adams) (Adams, 1993).
6 SUMMARY AND FUTURE DIRECTIONS

The ever-increasing drive to perfect the outcome of cataract extraction is a lasting motivation for researchers to explore the means by which the incidence of PCO can be reduced or even prevented. The latter, perhaps, would be the next revolutionary step in cataract surgery development.

From the previous studies, it is clear that clinically significant PCO—that requires Nd:YAG capsulotomy—still develops in a large proportion of all patient groups (Figure 6-1). The incidence, however, seems to have decreased in comparison to that reported in previous studies. This is mainly because of the improvement in surgical techniques, with the use of phacoemulsification and the development of new intraocular lenses with better designs and greater capsular biocompatibility.

We have shown that there is a tendency for diabetic patients to have a lower incidence of Nd:YAG capsulotomy than non-diabetic patients. Similarly, we have shown that in uveitic patients, there was a decrease in the incidence of Nd:YAG capsulotomy after the first three years, which showed consistently higher incidences than those reported in non-uveitic patients. In patients with multifocal IOLs, the capsulotomy incidence was not particularly higher than those reported with monofocal implants of similar designs and the incidence pattern was generally similar to the non-diabetic/non-uveitic group of patients (Figure 6-1), with gradual increase in incidence over the 4 postoperative years.

Several factors were found to affect the rate of Nd:YAG capsulotomy and PCO development (Table 6-1). The presence of diabetes mellitus was found to be associated with a lower risk of Nd:YAG capsulotomy over a 4-year postoperative period. Factors associated with increased risk of Nd:YAG capsulotomy included young age, postoperative inflammation, pars plana vitrectomy and polymethylmethacrylate and plate-haptic silicone IOL, as compared to 3-piece silicone IOLs. Also, in diabetic patients, plate-haptic silicone (Chiron C11UB) were associated with a higher PCO rate than hydrophobic acrylic IOLs (AcrySof) within 1 year after surgery. Optical coherence tomography showed that decreased PCO and Nd:YAG capsulotomy rates in patients with hydrophobic acrylic IOLs could be related to the development of a peripheral appositional contact between the IOL optic and the posterior capsule. This is consistent with the previously demonstrated
Summary and future directions

beneficial effect of the square-edge of these IOL optic, its stronger adherence to the capsule and the 'no-space, no cell, no PCO theory'.
Figure 6-1. Summary of the incidences of Nd:YAG laser capsulotomy in non-diabetic/non-uveitic patients, diabetic and uveitic. The incidences increased gradually over the 4 years (including in those with multifocal IOL). A drop in the incidence occurs after the third year in both diabetic and uveitic patients.
In uveitis patients, in addition to young age, postoperative uveitis and the use of hydrophilic acrylic implants were associated with a higher Nd:YAG capsulotomy rates over the follow-up period. The use of silicone IOLs and prophylactic systemic steroids were associated with a lower risk.

Young age was a risk factor for developing PCO in patients with multifocal IOLs. These patients presented for Nd:YAG capsulotomy with earlier loss of high and low-contrast acuity than those with monofocal IOLs. This suggests that functional loss can potentially increase the rate of Nd:YAG capsulotomy in these patients.
Table 6-1. Risk factors for PCO/Nd:YAG capsulotomy identified in the different studies

<table>
<thead>
<tr>
<th>Increased risk</th>
<th>Non-diabetic/Diabetic Studies</th>
<th>Uveitis Study</th>
<th>Multifocal IOL Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young age</td>
<td>Young age</td>
<td>Young age</td>
<td></td>
</tr>
<tr>
<td>PH silicone IOL*</td>
<td>Hydrophilic acrylic IOL†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMMA IOL**</td>
<td>Postoperative uveitis (within 3 months)</td>
<td>Postoperative uveitis (within 3 months)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pars plana vitrectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased risk</td>
<td>Diabetes mellitus</td>
<td>Prophylactic steroids</td>
<td></td>
</tr>
<tr>
<td>Hydrophobic acrylic IOL (AcrySof)‡</td>
<td>3-piece silicone IOL†</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PH silicone IOL†</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PH=plate-haptic, PMMA=poly methylmethacrylate

* Reference IOL was 3-piece silicone IOL & hydrophobic acrylic IOL

** Reference IOL was 3-piece silicone

†Reference IOL was polymethylmethacrylate (PMMA) IOL

‡The rate of PCO formation after 6 months and 1 year was compared to that of PH silicone IOL
From the previous studies, there are clearly still unresolved issues that should be addressed in future studies. Although we found a tendency for diabetic patients to have a lower incidence of Nd:YAG capsulotomy, the bias of the retrospective design have limited our conclusion from that finding. A prospective long-term case-control study of a single-surgeon, using a single-implant will be a pre-requisite to validly establish the relative incidences of this complication in diabetic and non-diabetic patients. Objective photographic assessment as well as functional and subjective assessment of PCO will perhaps be more clinically relevant than using either of them alone in such a study.

The development of postoperative inflammation is one of the modifiable risk factors that was identified in our studies to increase the risk for requiring Nd:YAG capsulotomy in diabetic and uveitic patient groups. Furthermore, in the latter group we found that the use of prophylactic systemic steroids preoperatively was associated with a lower risk for requiring Nd:YAG capsulotomy. Investigations are required of the possible causa-effect relationship between postoperative inflammation and PCO development. Also, the proposed beneficial effect of using peri-operative steroids in patients predisposed to postoperative inflammation or to increased rate of PCO such as those of a relatively young age and those who underwent vitrectomy will need further studies.

The use of the high-resolution OCT should enable us to study the relationship between the posterior capsule and the different IOL optics in vivo. This should help to establish the required enhancement and modification of the IOL designs to lower or prevent the PCO development. Correlating the different capsular features to the clinical and functional features may help to establish OCT as an additional beneficial PCO imaging technique.

Studies involving comparison of contemporary groups of patients with monofocal and multifocal IOLs will determine whether the latter group have a higher rate of Nd:YAG capsulotomy that could be attributed to IOL multifocal design alone and its effect on visual function. The purpose-designed questionnaire that was used in assessing the subjective effect of PCO on visual function of patients with multifocal IOLs will need validation by comparing it to other currently used and more established visual function questionnaires i.e. VF-14 in order to enable its use in future studies of PCO assessment.
7 PUBLICATIONS AND PRESENTATIONS
GENERATED FROM THIS THESIS

7.1 PUBLICATIONS

Elgohary MA, Chauhan DS, Dowler JFG. Optical Coherence tomography of the relationship between the posterior capsule and plate-haptic silicone and acrylic IOLs after phacoemulsification. Accepted by *Ophthalmic Research*

Elgohary MA, Hollick EJ, Dowler JFG, Bender L, Healy C, Wren S, Spalton D: Posterior capsular opacification after plate-haptic silicone and acrylic IOLs in diabetic patients. Accepted by *Journal of Cataract and Refractive Surgery*

Elgohary MA, Dowler JF. Incidence and risk factors of posterior capsular opacification in non-diabetic and diabetic patients. Accepted by *Journal of Clinical and Experimental Ophthalmology*

Elgohary MA, Beckingsale AB. Effect of illumination on visual function in patients with monofocal and multifocal intraocular lenses. Accepted by *Eye*


Elgohary MA, Saleh G, Beckingsale AA. Incidence of PCO after multifocal intraocular lens implantation. Submitted to *Ophthalmic Surgery, Laser and Imaging*

Elgohary MA, Beckingsale AB. Effect of posterior capsular opacification on visual function in patients with monofocal and multifocal intraocular lenses. Submitted to *Eye*
7.2 ORAL PRESENTATIONS

Outcome of phacoemulsification in patients with uveitis. European society of Vision and Eye Research (EVER), Sept 2004


7.3 POSTER PRESENTATIONS

Effect of posterior capsular opacification on visual function of patients with monofocal and multifocal intraocular lenses. Elgohary MA, Beckingsale AB. Royal College of Ophthalmologists Annual Congress, Birmingham, May 2005

Incidence of posterior capsular opacification after multifocal IOL implantation. Saleh G, Elgohary MA, Beckingsale AA, European Society of Cataract and Refractive Surgery (ESCRS) Meeting, Munich, Germany, Sept 2003

Comparison of posterior capsular opacification in diabetic eyes with either a silicone plate or acrylic lens. Wren SM, Heatley CJ, Bender L, Elgohary M, Hollick E, Dowler J, Spalton DJ. Royal College of Ophthalmologists Congress, Birmingham, UK, May 2003


Evaluation of the lens capsule with the optical coherence tomography. Elgohary MA, Chauhan DS, Dowler JF, International Congress of Ophthalmology (ICO) Sydney, Australia, Apr 2002

8 REFERENCES


References


Chauhan DS, Hollick EJ, El-Osta AR, Spalton DJ, & Marshal J. OCT of PCO. 28-12-2000. *Personal Communication*


References


References


References


References


References


References


References


References


Saika, S., Miyamoto, T., Tanaka, T., Ishida, I., Ohnishi, Y., & Ooshima, A. (2001)
Collagens XII and XIV (FACITs) in capsular opacification and in cultured

Saika, S., Miyamoto, T., Yamanaka, A., Kawashima, Y., Okada, Y., Tanaka, S.,
Immunohistochemical evaluation of cellular deposits on posterior chamber

Saika, S., Ohmi, S., Ooshima, A., Kimura, M., Tanaka, S., Okada, Y., Ohnishi, Y., &
Yamanaka, A. (1997) Deposition of extracellular matrix on silicone
517-522.

Phagocytosis and fibronectin of cells observed on intraocular lenses.


epithelium in human cataracts. (Abstract). *Nippon Ganka Gakkai Zasshi*, 94,
176-180.

on foldable intraocular lenses after combined cataract and glaucoma surgery.


Schauersberger, J., Kruger, A., Abela, C., Mullner-Eidenbock, A., Petternel, V.,


References


References


References


References


References


References


References


